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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder of the brain that presents as
progressive impairment across several cognitive domains. The biological mechanisms un-
derlying the development of AD remain unclear, with amyloid-beta plaques, neurofibril-
lary tangles, calcium dysregulation, and oxidative stress all contributing to neurodegener-
ation in AD. Vitamin D (VitD) deficiency, a common condition in the elderly, may modulate
these mechanisms and complicate the AD process. Due to this complicated pathogenesis,
the diagnosis of AD requires subjective clinical judgement, staging of AD is challenging,
and it remains difficult to predict when and who will progress to AD. The purpose of this
thesis was to study the metabolic and structural changes of specific brain regions as a con-
sequence of AD alone and under conditions of AD and VitD deprivation. Identification of
biological changes underlying the early symptoms of AD will help to identify and stage
individuals prior to symptom onset.
In one study, proton magnetic resonance spectroscopy (1H-MRS), diffusion tensor imag-
ing (DTI), and neurospychological testing was used to measure the metabolic and mi-
crostructural processes associated with episodic memory impairment. Individuals with
AD, mild cognitive impairment (MCI), and normal elderly controls (NEC) were stud-
ied. Left hippocampal glutamate and posterior cingulate N-acetyl aspartate concentrations
were reduced in MCI and AD compared to NEC. Differences in DTI metrics indicated vol-
ume and white matter loss along the cingulum in AD compared to NEC. Metabolic and
microstructural changes were also associated with episodic memory performance assessed
using Craft Story 21 Recall and Benson Complex Figure Copy. The results of this study sug-
gested that metabolite concentrations may provide insight into the underlying biological
processes of AD and increase the confidence of a clinical diagnosis of MCI or AD.
To improve glutamate measurement in future studies, the echo time (TE) for 1H-MRS
ii
measurement of glutamate at 7 T was optimized for signal strength and measurement pre-
cision in a second study. Time-domain simulations were performed and verified against in
vivo and in vitro measurements. The results of this study indicated that TE = 105 ms was
optimal for in vivo glutamate measurement at 7 T with the semi-LASER (localization by
adiabatic selective refocusing) sequence as this echo time produced the greatest glutamate
signal while also producing the lowest measurement coefficient of variation. Use of a long
TE will also decrease power deposition and minimize macromolecule contributions to the
spectrum.
In a third study, the role of VitD deficiency in AD was comprehensively evaluated in
the APPSwe/PS1∆E9 mouse model of mild AD using 1H-MRS, high-resolution MRI, and
spatial memory tasks. VitD deficiency did not change ventricle volume, an MRI marker
of neuronal loss, but did result in changes in metabolite concentrations consistent with
astrocytosis and gliosis. Overall, VitD deficient mice also performed better or improved
on measures of spatial memory than mice on a nutritionally sufficient control diet. The
results of this study suggested that VitD deficiency may improve memory by upregulating
beneficial reactive astrocytosis in the prodromal stages of AD.
Keywords: Alzheimer’s disease, high magnetic field, magnetic resonance spectroscopy,
diffusion tensor imaging, N-acetyl aspartate, glutamate, Vitamin D
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Lay Summary
Alzheimer’s disease (AD) is a brain disorder that causes a progressive decline in memory
and thinking. No one knows what gives rise to AD, but it includes abnormal deposits of
different proteins, irregular calcium levels, and changes in antioxidant defences. Vitamin
D (VitD) deficiency, a common condition in the elderly, could also play a role. Uncertainty
of the root cause makes it hard for physicians to diagnose and predict the progress of AD.
The purpose of this thesis was to study brain changes due to AD and VitD deficiency.
In one study, brain chemistry and structure in individuals with AD were studied using
magnetic resonance imaging (MRI) techniques. Compared to elderly individuals without
AD, individuals with AD had lower amounts of glutamate (the chemical responsible for
cell communication), which was associated with volume loss and deterioration of struc-
tural connections. Changes occurred in the brain circuit responsible for episodic memory,
the type of memory affected early in AD. As expected, changes were associated with per-
formance on tests of episodic memory. Therefore, measuring brain chemicals could pro-
vide insight into biological processes underlying AD symptoms and increase a physician’s
confidence in their diagnosis.
In a second study, computer simulations were used to determine the best settings for
glutamate measurement. The simulation results were verified against measurements made
in a model with a known amount of glutamate and in the human brain. The optimal set-
tings provided the greatest amount of glutamate signal, while also providing the best mea-
surement precision.
In a third study, the role of VitD deficiency was evaluated in mice genetically engi-
neered to reproduce aspects of the early stages of human AD. MRI was also used to mea-
sure brain chemistry. Over time, VitD deficiency resulted in brain chemical changes indica-
tive of increased numbers of astrocytes, special cells that support and protect nerve cells
in the brain. VitD deficient mice also performed better on tests of memory than mice that
iv
were not VitD deficient. The results of this study suggested that VitD deficiency may actu-
ally improve memory in the early stages of AD through a beneficial increase in astrocyte
numbers.
v
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1
Introduction
1.1 Overview of Thesis
The purpose of this thesis was to study the metabolic and structural changes of specific
brain regions as a consequence of Alzheimer’s disease (AD) and under conditions of Vita-
min D deprivation. The studies presented in this thesis applied techniques such as mag-
netic resonance spectroscopy, diffusion tensor imaging, and neuropsychological and be-
havioural testing to study the chemistry, structure, and function of the brain in both human
participants with AD and a pre-clinical mouse model of AD.
Sections 1.2.1 – 1.2.4 of this chapter provide a brief summary of the current understand-
ing of Alzheimer’s disease. Commonly used neuroimaging techniques, neuropsychologi-
cal testing, and pre-clinical mouse models of AD are summarized in Sections 1.2.1 – 1.2.4.
The remaining section (Section 1.3) briefly describes the physics of nuclear magnetic reso-
nance. These physical principles are the basis of the two main techniques used in this thesis
to study brain metabolism and structure: magnetic resonance spectroscopy and diffusion
tensor imaging.
The following three chapters of the thesis describe the scientific investigations that were
completed. The first study (Chapter 2) investigated the association between white matter
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structure in the cingulum and metabolism in the hippocampus and posterior cingulate cor-
tex, as such measurements could provide valuable information to support a clinical diag-
nosis of mild cognitive impairment or probable Alzheimer’s disease. It was hypothesized
that glutamate and N-acetyl aspartate concentrations as measured by magnetic resonance
spectroscopy would be lower in the posterior cingulate cortex and hippocampus of indi-
viduals with Alzheimer’s disease as compared to normal elderly controls and significantly
correlated with both measures of microstructural integrity in the cingulum and measures
of episodic memory. In line with this hypothesis, a relative reduction in hippocampal glu-
tamate was found in individuals with Alzheimer’s disease and was associated with de-
creased microstructural integrity and episodic memory performance.
With glutamate as a metabolite of interest, a second study was performed (Chapter 3)
to find the spectroscopy acquisition parameters that optimized future measurements of
glutamate concentration using proton magnetic resonance spectroscopy at a field strength
of 7 Tesla.
Finally, magnetic resonance spectroscopy was applied in the third study (Chapter 4) to
examine changes in brain metabolism in a pre-clinical mouse model of Alzheimer’s disease
after Vitamin D deficiency. It was hypothesized that Vitamin D deficiency would decrease
N-acetyl aspartate concentrations and worsen spatial memory performance, but the results
of this study did not support this hypothesis.
The last chapter (Chapter 5) summarizes the main scientific contributions of the thesis
and describes opportunities for future investigations.
1.2 Alzheimer’s Disease
1.2.1 Overview
Dementia, a decline in memory and thinking that interferes with activities of daily life, af-
fects over 47 million people worldwide of which over 550,000 are Canadians [1]. In Canada,
2
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dementia is already a major burden on the healthcare system, with the cost of care for pa-
tients with dementia being $10.4 billion in 2016 and expected to rise to $16.6 billion by
2031 [2]. The most common form of dementia is Alzheimer’s disease (AD), accounting for
60-80% of dementia cases [3].
AD is a neurodegenerative disorder of the brain that not only results in progressive
memory impairments, but also progressive language, visual, and executive function prob-
lems [4]. Patients with AD can also develop neuropsychiatric symptoms such as apathy,
depression, anxiety, and aggression [5] that can impact the quality of life of both patient
and caregiver [6]. The biological mechanisms of AD are complex and heterogeneous, with-
out a clear cause [4] or a clear chain of events that lead to symptoms and impairments [3].
This has resulted in a wide range of treatments that target different aspects of AD. There
are many different research tools developed to probe these different aspects, including a
variety of neuroimaging techniques, neuropsychiatric tests, and mouse models of AD.
1.2.2 Pathogenesis and Neuropathology of Alzheimer’s Disease
1.2.2.1 Familial and Sporadic Alzheimer’s Disease
There are two forms of Alzheimer’s disease: a rare form called familial AD that accounts for
about 5% of AD cases, and a more common form called sporadic AD [7]. The pathogenesis
of familial AD is better understood than the pathogenesis of sporadic AD.
Familial AD results from either a mutation in the presenilin 1 (PS1) gene on chromo-
some 14 [8], the presenilin 2 (PS2) gene on chromosome 1 [9, 10], or the amyloid-β pre-
cursor protein (APP) gene on chromosome 21 [11]. APP codes for the protein from which
amyloid-β (Aβ) is cleaved, while PS1 and PS2 code for the catalytic core of the γ-secretase
enzyme that cleaves APP [12, 13, 14]. Mutations in these genes cause abnormal Aβ produc-
tion, processing, and aggregation, which is thought to ultimately result in AD. Repetitions
of the APP located on chromosome 21 can also result in abnormal amyloid processing and
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AD, as is the case in trisomy 21 (Down syndrome). Although all mutations can occur, PS1
mutations are the most common, accounting for the majority of familial AD cases [7, 15].
Familial AD typically occurs in individuals aged 30-60 years of age.
In contrast, sporadic AD typically presents in individuals over 60 years of age. As in
familial AD, the same proteinopathies (Aβ and tau tangles, discussed below) are exhibited
in sporadic AD, but without APP, PS1, or PS2 mutations. Though no single gene has been
identified to cause sporadic AD, polymorphisms of the apolipoprotein E (ApoE) gene have
been identified to confer risk for sporadic AD [16]. Individuals who have inherited two
alleles of the ApoE-ε4 polymorphism increases the risk of developing AD by 15 times [17].
1.2.2.2 Amyloid and Tau Proteinopathies
The neuropathology of AD is characterized by the occurrence of two main molecular le-
sions: the aggregation of amyloid plaques and the formation of intraneuronal neurofibril-
lary tangles [3]. As the disease progresses, amyloid first deposits in the isocortex, followed
by the allocortex (i.e. the entorhinal cortex, hippocampal formation, amygdala, insular cor-
tex, and cingular cortex), and finally the subcortical nuclei [18]. Neurofibrillary tangles
(NFTs) begin forming in the entorhinal cortex and hippocampus, followed by the limbic
structures, and finally the isocortex, with the association areas being affected earlier and
more severely than the primary sensory, motor, and visual areas [19]. Importantly, depo-
sition of amyloid plaques and NFTs and the subsequent loss of neurons in the nucleus
basalis of Meynert is thought to be responsible for the widespread deficiency of cortical
acetylcholine observed in AD [20, 21].
Amyloid plaques are mainly composed of Aβ protein. Aβ peptides of either 40 or 42
amino acids long are formed from the sequential cleavage of APP by the β- and γ-secretases
[22, 23]. The peptides can then aggregate into different forms, such as the insoluble fibrils
of amyloid plaques. Aβ can also aggregate into soluble oligmers of 2 to 6 peptides [24], the
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concentration of which correlates better with synapse loss in AD than the concentration of
Aβ plaques in the brain [25].
Neurofibrillary tangles result from the misfolding and hyperphosphorylation of the
microtubule-associated tau protein. This abnormal form of tau is insoluble, aggregating as
a helical fibrils in the neuron [3]. The loss of normal tau and aggregation of abnormal tau
renders microtubules unstable, and is thought to cause the breakdown of dendrites and
axons of the neuron [23].
There is evidence that Aβ deposition precedes and drives NFT formation [26, 27], which
is in line with the current prevailing theory of AD pathogenesis: the “amyloid cascade”
hypothesis. This theory postulates that amyloid dyshomeostasis, either as a result of in-
creased relative Aβ production throughout life (as in familial AD) or a failure of Aβ clear-
ance mechanisms (as in sporadic AD), results in Aβ fibril and oligmer formation, which in
turn leads to NFT formation and neuronal death, ultimately causing dementia [28].
1.2.2.3 Calcium Dysregulation, Oxidative Stress, and Synaptic Dysfunction
NFT formation is only one of many downstream events that can occur as a result of Aβ
peptide formation and deposition. Another important result of Aβ peptide formation is
neuronal calcium dysregulation. Aβ peptides contribute to this directly by inserting into
the plasma membrane of the neuron, creating voltage-insensitive calcium pores, and in-
creasing the intracellular concentration of calcium [29].
Aβ peptides can also indirectly increase the intracellular concentration of calcium by
modulating the glutamatergic system. Aβ renders neurons vulnerable to excitotoxicity
mediated by the ionotropic N-methyl-D-aspartate receptors (NMDARs) [30], glutamate-
activated calcium channels, by direct assocation with the receptor subunuits [31, 32] and
by inhibiting glutamate reuptake from the synapse [33]. Aβ can also affect metabotropic
glutamate receptors (mGluRs). Specifically, Aβ binds prion protein (PrPC), activating the
metabotropic G-protein coupled glutamate receptor, inducing inositol triphosphate (InsP3)
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formation and InsP3 receptor activation, resulting in calcium release from the endoplasmic
reticulum [34]. Interestingly, PS1 and PS2 mutations responsible for familial AD can also
induce endoplasmic reticulum release via modulation of InsP3 receptor gating and other
cellular pathways, while ApoE-ε4 expression has been functionally linked to increased
intracellular calcium levels [35]. Observed reductions in the AD brain of both vesicular
glutamate transporters 1/2 (VGLUT1/2), proteins of the pre-synaptic neuron that main-
tain the storage of glutamate in vesicles, as well as excitatory amino acid transporters 1/2
(EAAT1/2), proteins of the astrocyte that clear glutamate from the synapse, also contribute
to increased glutamate in the synapse, resulting in overactivation of NMDARs and in-
creased calcium flux into the cell [36].
Increased intracellular calcium due to Aβ has consequences for the neuron. First, pos-
itive feedback loops can be activated to increase intracellular calcium levels further. Due
to calcium’s positive charge, membrane depolarization will result in the activation of L-
type voltage gated calcium channels (LVGCC) [31], which have increased activity and ex-
pression due to Aβ [37, 38, 39, 40]. Increased intracellular calcium can also stimulate the
cleavage of APP and the formation of more Aβ peptides [41], perpetuating the calcium
dysregulation. Second, cell metabolism is affected. Excessive intracellular calcium is taken
up by the mitochondria via the mitochondrial calcium uniporter, which results in increased
reactive oxygen species production, reduced energy metabolism, and mitochondrial dys-
function [32, 42]. Finally, increased intracellular calcium can activate pathways that induce
synaptic depression. Specifically, prolonged NMDAR activation can eventually result in
desensitization and internalization of the receptors. Coupled with the activation of extrasy-
naptic NMDARs and mGluRs due to the presence of glutamate outside of the synapse as a
result of impaired glutamate uptake, long-term synaptic depression is induced [43]. Long-
term synaptic depression with high levels of Aβ ultimately leads to dendritic spine shrink-
age, reduced glutamatergic transmission, and synaptic loss [44]. In fact, it is not neuronal
loss, but rather synaptic loss that is the best correlate to cognitive impairment in AD [45].
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These mechanisms offer many potential avenues for therapy. For example, increased re-
active oxygen species production could potentially be counteracted by Vitamin D, since Vi-
tamin D acts to increase the expression of nuclear factor-erythroid-2-related factor 2 (Nrf2),
a transcription factor that activates genes to enhance expression of antioxidants and detox-
ifying enzymes [46]. Vitamin D can also lower LVGCC expression and reduce L-type cur-
rents in neurons [47, 48]. In addition, activation of extrasynaptic NMDARs that lead to
long-term synaptic depression and synapse loss can be blocked by memantine [49], a drug
currently approved for treatment of moderate-to-severe AD.
1.2.3 Clinical Diagnosis
Clinically, AD progression occurs along a continuum, beginning with an asymptomatic
predementia phase called mild cognitive impairment (MCI) due to AD, followed by a
symptomatic dementia phase called probable AD. Probable AD is diagnosed when the
following diagnostic criteria are met [50]:
1. Progressive functional decline and cognitive impairment as assessed via history-
taking, information from a knowledgeable informant (e.g. spouse, partner, or close
friend), mental status examination, and neuropsychological testing
2. Neuropsychiatric symptoms that interfere with activities of daily life
3. Insidious onset over months to years
4. In addition to cognitive dysfunction in one other domain, the initial and most promi-
nent cognitive deficits are:
(a) In learning and recall of recently learned information (amnestic presentation)
(b) In language processing, visuospatial cognition, and/or executive function (non-
amnestic presentation)
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5. Other forms of dementias have been ruled out and cormorbidites or medications that
could have a substantial effect on cognition are not present
The clinical distinction between MCI and probable AD is drawn by whether or not neu-
ropsychological changes are significantly impairing activities of daily life. Those with MCI
generally maintain independent function, even with impairment of cognitive function [51].
However, it remains difficult to identify where an individual lies along the disease contin-
uum. Use of measurements of biomarkers of AD pathology, as well as volumetric, struc-
tural, functional, and metabolic measurements of the brain using various neuroimaging
modalities may provide complimentary information that can aid in staging the disease.
1.2.4 Treatment of Alzheimer’s Disease
Treatment options for AD are limited, and only five drug therapies have been approved
for the treatment of AD. Four of these therapies are cholinesterase inhibitors (ChEIs) de-
signed to enhance cholinergic activity by preventing the breakdown of acetylcholine in the
synapse, countering the effect of the widespread deficiency of cortical acetylcholine ob-
served in AD. Of these ChEIs, tacrine is rarely used due to liver toxicity. The other three
ChEIs, donepezil, galantamine, and rivastigmine, are regularly used for treating AD. A six
month treatment with these therapies can modestly improve cognitive function, activities
of daily living, and behaviour for those with mild, moderate, or severe dementia due to AD
[52]. However, since acetylcholine is the major neurotransmitter of the parasympathetic
nervous system, ChEIs can have unpleasant multi-system side-effects, such as nausea, gas-
trointestinal upset, diarrhoea, and bradycardia [53].
The fifth approved drug therapy is memantine, a non-competitive NMDAR antagonist
[54]. Memantine is designed to reduce glutamatergic neuroactivity, countering the effects of
glutamate excitotoxicity and calcium dysregulation observed in AD. A six to seven month
8
1.2. Alzheimer’s Disease
treatment with memantine is well tolerated and has been shown to provide a small im-
provement in cognition, activities of daily living, and behaviour for those with moderate
to severe dementia due to AD but not for those with mild AD [55].
Memantine, donepezil, galantamine, and rivastigmine are considered symptomatic
treatments for AD, as they do not modify the underlying disease processes. The develop-
ment of disease-modifying therapies is an active area of research. To date, the majority of
these agents are based on the “amyloid cascade” hypothesis of AD and are either molecules
that target the activity of the secretase enzymes that cleave APP or immunotherapies that
target the Aβ fibrils and oligomers directly [56]. Unfortunately, Phase III trials of both anti-
secretase agents such as segmagacestat [57] and anti-Aβ agents such as bapineuzumab
[58, 59] or solanezumab [60] failed to show improvement in cognition or functioning in
AD patients, despite observed changes in plasma, cerebrospinal fluid, and neuroimaging
biomarkers of Aβ load. As such, the development of interventions are shifting towards
targeting tau and the NFTs [61]. Since Aβ load plateaus early while NFT load continues
throughout the disease course [62, 63], therapies that target tau may have more potential
for altering the disease course.
1.2.5 Neuroimaging of Alzheimer’s Disease
In the context of AD, the current clinical use of neuroimaging is to rule out non-AD rea-
sons for cognitive decline, such as space-occupying lesions and cerebrovascular disease [64,
65]. However, with neuroimaging becoming more accessible to the clinical community, its
utility is extending beyond simply excluding surgically treatable causes of cognitive im-
pairment to supporting a physician’s diagnosis of AD. Various neuroimaging modalities
could provide information about the underlying pathology that can help place an individ-
ual along the disease continuum. Neuroimaging is also a powerful research tool, helping
us to better understand the pathology of AD in vivo with the aim of identifying biomark-
ers of disease progression and establishing their prognostic value. Importantly, identifying
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structural, functional, and metabolic measurements of the brain that have utility in both the
early detection of AD and in the prediction of which individuals with MCI will progress to
AD will be needed to determine who will benefit from disease-modifying treatments once
they become available.
1.2.5.1 Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is an imaging modality that excites protons using ra-
diofrequency (RF) energy and measures the RF signal emitted by the protons as they return
to their equilibrium energy state. Much of this signal comes from the protons of water due
to the high water content in brain tissue. Differences in tissue characteristics manifest as
changes in the RF signal allowing MRI to be sensitive to both volumetric and microstruc-
tural changes. Various structural imaging sequences such as MP2RAGE [66] can be used to
acquire high resolution (< 1 mm3) anatomical images to assess volumetric changes, while
diffusion tensor imaging (DTI) can be used to measure microstructural changes.
Spatial and temporal patterns of volumetric changes as measured by MRI match the
progression of NFT deposition described in Section 1.2.2.2 [67, 68]. Other volumetric
changes such as ventricular expansion have also been observed over the course of the dis-
ease [69]. These patterns of cerebral atrophy and ventricular expansion are strongly cor-
related with cognitive decline in AD [70]. Microstructural changes of the white matter as
measured by diffusion tensor imaging also occur as a function of cognitive impairment in
AD [71, 72]. Together, these observations suggest that structural MRI measurements have
prognostic and diagnostic value. Indeed, studies have shown that structural MRI measure-
ments are useful in identifying individuals with MCI that are likely to progress to AD [73,
74, 75] and in differentiating AD from other dementias [76].
However, the specificity of structural MRI measures in AD are limited by the fact that
similar patterns of change are observed in other diseases and some individuals with AD
may exhibit atypical patterns [77]. Further, structural changes seen on MRI occur after Aβ
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load has plateaued [78], suggesting that structural MRI is limited in the early detection of
AD.
1.2.5.2 Positron Emission Tomography
Insight in the early stages of AD may instead be gained by measuring brain metabolism,
since metabolic changes may precede changes in cellular microstructure, neuronal density,
and neuronal loss [79, 78, 80]. One common technique used to measure brain metabolism is
positron emission tomography (PET). PET imaging involves the injection of a biologically
active radiotracer. The radiotracer emits a positron that interacts with an electron to emit
a pair of 511 keV γ-rays in opposite directions. Coincident detection of the γ-rays enables
the reconstruction of the location and concentration of the radiotracer.
One of these radiotracers is the glucose analog, fluorodeoxyglucose (FDG). Since the
brain uses glucose as a major energy source, FDG uptake in the brain correlates with brain
metabolism. FDG-PET studies have shown progressive hypometabolism in the AD brain,
beginning with parietotemporal association cortices, posterior cingulate, and precuneus re-
gions and progressing to the frontal association cortices [81]. These patterns of FDG uptake
have also proven useful in discriminating those with AD from those with other dementias
and those who are healthy [82, 83]. FDG-PET is also useful in predicting the conversion
from MCI to AD, performing slightly better than structural MRI measurements [84].
Other PET tracers can target the neuropathology of AD directly. Approved agents that
target fibrillar Aβ plaques include Pittsburgh Compound B (PiB), florbetapir, flutemeta-
mol, and florbetaben. Studies using these agents have shown extensive Aβ deposition in
Alzheimer’s disease [85, 86, 87, 88] with good correspondence between patterns of tracer
uptake and Aβ load evaluated post-mortem [89, 90, 87, 91]. Patterns of Aβ uptake appear
to change and then plateau before the appearance of clinical symptoms [78]. This suggests
that Aβ-PET may have utility in the early detection of AD, but not in tracking disease
progression. Indeed, Aβ-tracer uptake is not well correlated with the severity of AD [86,
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92, 62]. Aβ-PET may be further limited as an estimated 20-30% of cognitively normal el-
derly have significant Aβ load as measured by PET [93, 77]. To address this drawback, PET
tracers that target NFTs have been developed. Patterns of tracer uptake using quinolone
derived PET tracers such as [18F]THK-5105 have been shown to be associated with AD
severity and brain atrophy [94].
1.2.5.3 Magnetic Resonance Spectroscopy
A less expensive, more accessible, and non-invasive method to measure in vivo brain
metabolism in AD is proton magnetic resonance spectroscopy (1H-MRS) [95]. Like struc-
tural MRI, 1H-MRS is a technique that excites protons using RF energy and measures the
emitted RF signal as the excited protons return to equilibrium. However, 1H-MRS is ca-
pable of detecting not just the protons of water, but also the protons of biologically active
metabolites. This allows 1H-MRS to simultaneously measure levels of several metabolites
relevant to neuronal function in specific brain regions. Metabolites visible to 1H-MRS and
most relevant to AD include N-acetylaspartate (NAA), glutamate (Glu), and myo-inositol
(Myo).
1.2.5.3.1 N-acetyl Aspartate (NAA)
NAA is a free amino acid present in the brain at in vivo concentrations of between 7.5–17
mM, and appearing as a prominent resonance at 2.01 ppm on a 1H-MRS spectrum [96].
It is synthesized in neurons by N-acetyltransferase-8 like protein (NAT8L) from acetyl-
coenzyme A (acetyl CoA) and aspartate [97, 98]. NAA synthesis occurs mostly in the cy-
toplasm and requires acetyl CoA levels in excess of neuronal metabolic requirements [98].
NAA synthesis also occurs in the mitochondria [98, 99], and NAA levels can be lowered by
inhibition of mitochondrial respiration [100]. Together, this suggests that low NAA levels
may reflect neuronal loss, mitochondrial dysfunction and low neuronal energy reserves.
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Since cerebral atrophy (see Section 1.2.5.1), mitochondrial dysfunction (see Section
1.2.2.3) and hypometabolism (see Section 1.2.5.2) have been reported in AD, it is unsur-
prising that NAA concentrations are decreased in MCI and AD compared to cognitively
normal elderly controls [101, 102, 103, 104]. NAA levels appear to decline as the disease
progresses [105] and are correlated with performance on cognitive tests in AD [106], sug-
gesting that NAA levels could be a biomarker of AD progression.
NAA levels could also be markers of treatment response, as they have been re-
ported to improve after treatment with rivastigmine [107] and donepezil [108], which
are acetylcholinesterase inhibitors. Acetylcholinesterase inhibitors prevent the breakdown
of acetylcholine in the synpase, which may reduce the rate of acetylcholine production
by cholinergic neurons. Since acetylcholine is also derived from acetyl CoA [109], re-
duced acetylcholine production would result in more acetyl CoA available for both neu-
ronal metabolism and NAA production. In this way, successful treatment with acetyl-
cholinesterase inhibitors could result in increased NAA levels.
Other functions of NAA include its involvement in myelination. NAA is catabolized
in oligodendrocytes by the sequential action of aspartoacylase II (ASPA-II) and acetyl CoA
synthetase-1 (AceCS-1) into acetyl CoA, which is then used by the oligodendrocytes for
the synthesis of myelin-associated lipids [110]. Thus, decreased NAA levels could nega-
tively affect myelination processes. This is supported by the finding of decreased NAA
in the demyelinated plaques of multiple sclerosis [111]. NAA is also a known osmolyte,
with the redistribution of NAA from the intracellular to extracellular compartment being
a mechanism by which neurons protect themselves against hypo-osmotic stress [112].
1.2.5.3.2 Glutamate
Glutamate is the primary excitatory neurotransmitter in the brain [113, 114], including in
the hippocampus, a region of the brain that is highly dependent on glutamate signalling
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[115]. It is present in the healthy brain in concentrations ranging from 6.0–12.5 mM and ap-
pears on a 1H-MRS spectrum as two multiplets in the range of 2.0–2.5 ppm and a doublet
of doublets at 3.74 ppm [96]. Detection of glutamate using 1H-MRS is complicated by the
fact that its resonances overlap with those of glutamine and macromolecules, but is pos-
sible with the appropriate selection of acquisition parameters such as echo time [116, 117,
118].
Measurement of glutamate using 1H-MRS is of interest in AD, as dysfunction of the glu-
tamatergic system is a large part of the neuropathology of AD (see Section 1.2.2.3). Briefly,
impaired glutamate reuptake from the synapse and chronic activation of NMDARs and
mGluRs lead to calcium dysregulation and eventual long-term synaptic depression, re-
duced glutamatergic transmission, and synaptic loss in AD. This process is reflected by de-
creases in glutamate concentration in AD as measured by 1H-MRS [101, 118], since 1H-MRS
measures of glutamate reflect glutamatergic activity [119]. Decreased glutamate could also
reflect neuronal hypometabolism and energy deficit in AD. The reason for this is two-fold:
(1) glutamatergic neuronal activity is intimately coupled with neuronal metabolism [120]
and (2) glutamate can be used as a substrate for energy production in a truncated tricar-
boxylic acid (TCA) cycle during energy depleted states [121, 122]. Additionally, glutamate
levels could be related to reductions in synaptic density as well as the balance between
excitatory and inhibitory synaptic activity [123].
The intimate involvement of glutamate with neuropathological mechanisms in AD sug-
gests that changes in glutamate level could reflect responses to interventions that affect
these mechanisms. Indeed, changes in glutamate concentrations as measured by 1H-MRS
have been reported in response to galantamine treatment and were correlated to cognitive
performance [124].
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1.2.5.3.3 myo-Inositol
myo-Inositol is a cyclic sugar alcohol present in the brain at concentrations of 4.0-9.0 mM
and is visible on an 1H-MRS spectrum as multiplets centred around 3.5 ppm [96]. The main
role of myo-inositol is its involvement in the intracellular secondary messenger signalling
system. It is the precursor to the membrane phospholipid phosphatidylinositol which is
converted to InsP3 by phospholipase C when receptors such as mGluRs are activated [125,
126]. InsP3 then goes on to faciliate intracellular calcium release from the endoplasmic retic-
ulum, before being metabolised back into myo-inositol [125].
Since increased InsP3 signalling may be a contributor to calcium dysregulation in AD
(see Section 1.2.2.3), metabolism of InsP3 may also be increased, suggesting that there may
be increased intracellular concentrations of myo-inositol in AD. Indeed, 1H-MRS studies
have shown increases in myo-inositol concentration in the AD brain [127, 128, 129]. Though
neurons maintain a high intracellular concentration of myo-inositol [130], increased myo-
inositol levels have also been associated with glial proliferation [111] and may also reflect
neuroinflammatory processes in AD.
1.2.5.3.4 Choline
The strong resonance at 3.2 ppm on a 1H-MRS spectrum comes from free choline and
the choline containing compounds glycerophosphorylcholine (GroPCho), and phospho-
rylcholine (PCho) even though the total brain concentration of choline is quite low (1-2
mM) [96]. GroPCho and PCho are the metabolic products of phosphatidylcholine, a mem-
brane phospholipid, that can be metabolised into free choline by various phospholipases
into free choline, which is further converted to acetylcholine [131]. Thus, GroPCho and
PCho are in equilibrium with both phosphatidylcholine and acetylcholine. As a result, the
choline resonance measured on 1H-MRS is correlated with acetylcholine levels in the brain
[132], but may be altered by changes in membrane phospholipid turnover.
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In AD, increases in choline levels as measured by 1H-MRS have been reported [133, 134,
135]. This may seem counter-intuitive as there is a deficiency of acetylcholine in AD (see
Section 1.2.2.2 and 1.2.4). Furthermore, AD-associated hypometabolism may also impair
brain synthesis of choline [136]. To understand this apparent inconsistency, it is important
to remember that the choline resonance in 1H-MRS has contributions from GroPCho and
PCho. Acetylcholine deficiency and impaired choline synthesis could shift the choline equi-
librium, upregulating phosphatidylcholine breakdown into GroPCho and PCho, thereby
promoting their metabolism into free choline. This compensentory mechanism would re-
sult in an increased 1H-MRS choline signal. Indeed, membrane breakdown is known to oc-
cur in chronic neurodegeneration [137] and has been proposed as a way for the AD brain
to compensate for declining acetlycholine [138].
1.2.5.3.5 The Metabolic Profile of AD
If 1H-MRS is to be used to aid in diagnosis and staging of AD, changes in metabolite lev-
els observed in AD should be specific to AD. However, decreased NAA, increased Myo,
and increased Cho have also been reported in other dementias such as vascular demen-
tia (VaD), Lewy body dementia (DLB), or frontotemporal dementia (FTD). Differentiating
AD from these other dementias requires consideration of both the degree of the metabolic
changes and the spatial pattern of the metabolic changes. For example, increased Myo lev-
els and decreased NAA levels are also observed in FTD, but individuals with FTD have
greater Myo increases and NAA decreases in the frontal lobe as compared to individuals
with AD [139]. In VaD, NAA levels are also decreased, but NAA levels of those with VaD
are greater than those with AD in the occipital lobe [140]. Comparisons of AD with VaD
also show greater posterior cingulate cortex Myo levels in AD than in VaD [133]. Similarly,
although NAA levels in DLB are also decreased in regions like the hippocampus and the
parasaggital cortex [141, 142], NAA levels are preserved in the posterior cingulate cortex
in DLB, while in AD they are not.
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1.2.6 Neuropsychological Testing in Alzheimer’s Disease
Assessing memory and cognition with neuropsychological testing is a crucial part of AD
assessment in both the clinical and research domains. Though the neuropsychological pro-
file of AD includes deficits in language and sematic memory, executive function, working
memory, and visuospatial processing [143], episodic memory impairment is among the ear-
liest and most severe cognitive changes in AD [144] and is considered the most clinically
relevant for assessing AD patients [145].
The episodic memory system is responsible for the encoding and retrieval of personal
experiences [146], and is associated with autonoetic awareness where a memory is framed
in a personal context and is retrived via mental re-enactment [147, 148]. Brain structures
underlying this system include the hippocampus, entorhinal and perirhinal cortices, the
retrosplenial and posterior cingulate cortex, and other structures of the Papez circuit [149,
146, 150]. Over the course of AD, NFTs spreads along these structures (see Section 1.2.2.2),
causing progressive episodic memory dysfunction.
Dysfunction of the episodic memory system results in decreases in the ability to learn
new information and to recall recently learned information [146]. Thus, common assess-
ments of episodic memory involve testing how well an individual learns new information
and recalls it after a delay. Such assessments include the logical memory subtest of the
Weschler Memory Scale [151] and the Rey-Osterrieth complex figure copy test [152, 153].
In the logical memory test, participants are read a short story and are asked to recall the
story immediately, and after a short delay. In the complex figure copy test, participants are
shown a specially-designed figure that resembles no existing object and are asked to re-
produce the figure. Then, after a short delay participants are asked to reproduce the figure
from memory. The delay used in these tests are typically 15-20 minutes. Variations of these
tests, such as the Craft Story 21 Recall [154] and the Benson Complex Figure Copy [155],
are included in standardized neuropsychological batteries used for AD research. One such
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battery is the National Alzheimer’s Coordinating Centre Neuropsychlogical Battery [156].
Episodic memory function in an AD patient may also be assessed by asking a collateral
source (i.e. a family member or close friend of the patient’s) about the details of a recent
salient personal experience, such as a vacation or wedding. Once the details of the expe-
rience are obtained, the patient is then asked to recall the experience. The accuracy of the
recall gives a physician or researcher insight into the patient’s episodic memory function.
This type of assessment may be done formally as part of the Clinical Dementia Rating Scale
(CDR) [157], a tool often used clinically to stage Alzheimer’s disease, or informally as part
of a collateral history taken by the physician. The CDR also includes tests of memory and
problem solving, as well as questions about orientation to time and place and activities
of daily living. This provides valuable information to the clinician about deficits of other
cognitive domains beyond episodic memory, and the severity of AD.
Other tools used clinically to assess memory and cognition include the Mini-Mental
State Examination (MMSE) [158] and the Montreal Cognitive Assessment (MoCA) [159].
The MMSE is a brief assessment of general cognitive function, while the MoCA is more
comprehensive. The MoCA includes specific tasks that assess memory recall, visuospatial
abilities, attention, concentration, working memory, and language. Attention and problem
solving may be further assessed using the Trail Making Test [160]. In the first part of this
test, participants are asked to connect 25 numbered circles distributed over a sheet of letter
paper as quickly as possible in ascending numerical order. In the second part of this test,
the circles contain either numbers or letters, and the participant must connect the circles as
quickly as possible while alternating between numbers and letters.
Finally, it is important to assess whether an AD patient has any associated psychiatric
symptoms, such as depression. This can be done by the clinician via a detailed social and
medical history, and with the help of tools such as the Geriatric Depression Scale [161].
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1.2.7 Transgenic Mouse Models of Alzheimer’s Disease
In order to examine the temporal progression of AD and to evaluate therapies in a highly
controlled manner, researchers have developed a plethora of genetically engineered mouse
models of AD. Though the range of neuropathology and behavioural phenotypes ex-
pressed in AD mouse models are highly variable, every credible mouse model of AD ex-
hibits progressive neuropathology of at least one neuropathological hallmark of AD, as
well as robust cognitive changes that are evident in different behavioural testing paradigms
targeting memory systems that involve brain structures affected in AD, such as the hip-
pocampus [162]. These mouse models may be categorized by the AD neuropathology they
aim to replicate: models that have amyloid pathology, models that have tau pathology, and
models that express both.
Transgenic mouse models with amyloid pathology are based on our current under-
standing of the genetics of Alzheimer’s disease, namely the APP, PS1, and PS2 mutations
that are implicated in familial AD (see Section 1.2.2.1). Engineering mice that overexpress
mutant APP results in mice that develop Aβ plaques and cognitive impairment [163]. Pro-
gressive synapse loss, gliosis, and neurochemical changes that model aspects of AD ob-
served in humans have also been reported [164]. A commonly used APP mutation is the
Swedish double mutation (K670N/M671L) usually referred to as APPSwe, first used by
Hsiao et al [165] to generate the Tg2576 transgenic mouse model. In the Tg2576 model,
deficits of spatial memory as measured by the Morris water maze [166] were evident by 9–
10 months, accompanied by elevated levels Aβ oligomers. Plaques were seen by 12 months
of age. Although the original study did not demonstrate neuronal loss, subsequent studies
have shown both impaired synaptic plasticity [167] and synaptic loss [168].
PS1 and PS2 mutations have also been used to generate AD mouse models with less
success. This is because mice that overexpress PS1 and PS2 mutations elevate levels of Aβ
oligomers but don’t result in plaque formation [169]. However, when presenilin transgenic
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mice are crossed with transgenic APP mice, extensive plaque formation is exhibited [170,
171]. These double transgenic mice produced using familial AD mutations (2xFAD) are
widely used in the study of AD. The 2xFAD mice used for investigations in this thesis are
APPSwe/PS1∆E9 mice that contain both the APPSwe mutation and the PS1 gene without
exon 9. Aβ plaque deposition and concomitant astrocytosis begins as early as 4 months in
the APPSwe/PS1∆E9 model and plateaus at 12 months [172]. When compared to wild-type
mice, spatial memory deficits are not apparent at 7 months of age [173], but appear at 11-
12 months of age [174, 175]. The temporal pattern of Aβ deposition plateauing before the
appearance of cognitive deficit mirrors the progression of AD in humans.
A major aspect of AD in humans that the APPSwe/PS1∆E9 model – or APP transgenic
mice in general – are unable to replicate is the presence of NFTs in the brain [163]. Devel-
opment of AD mouse models that exhibit tau pathology has been hampered by the fact
that the microtuble associated protein tau (MAPT) gene, implicated in other dementias
with tauopathies, does not appear to be causally related to AD [176]. Nevertheless, MAPT
mutations on chromosome 17 responsible for familial multiple system tauopathy with pre-
senile dementia [177] have been used to create mouse models such as JNPL3 that develop
NFTs as a function of age [178]. However, JNPL3 and other tau transgenic mice do not
exhibit Aβ plaques [163].
To enable the study of interactions between Aβ and tau, transgenic mice with APP, pre-
senilin, and tau mutations have been created [179]. These 3xFAD mice develop Aβ plaques,
NFTs, synaptic alterations, and cognitive deficits as a function of age [179, 180].
Though transgenic mouse models of AD have been useful for the study of AD, they
have some limitations. First, transgenic mouse models are based on genetic mutations im-
plicated in familial AD. Since individuals with sporadic AD do not possess APP, PS1, PS2,
or MAPT mutations, it is unclear whether or not these mice are accurately modelling all
aspects of sporadic AD. Furthermore, there is a discrepancy in the temporal progression
of the disease, with 2xFAD mice developing pathology over the course of a year, whereas
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humans develop pathology over the course of decades. As such, ageing effects on the pro-
gression of AD may not be properly represented by mouse models. Finally, human brains
appear to be more susceptible to AD pathology than mouse brains. For example, APP lev-
els have to be 8 times normal for Aβ plaques to develop in mice, whereas humans only
need a 2-fold increase [181]. These differences between modelled AD pathology and actual
AD pathology are important to consider when translating and applying knowledge gained
from the study of transgenic mice to humans.
1.3 Principles of Magnetic Resonance
The physical phenomenon of nuclear magnetic resonance arises from the quantum me-
chanical properties of the protons and neutrons that make up atomic nuclei. In proton
magnetic resonance imaging and spectroscopy, the nucleus of interest is 1H, and the main
magnetic field of the MR scanner, ~B0, is oriented along the z-axis. The probability that a 1H
nucleus is in an energy state where the longitudinal component of its magnetic moment
(µz) is aligned with ~B0 determines the net magnetic moment of an ensemble of 1H nuclei,
~M0, also called the equilibrium magnetization. For more details, see Appendix A.
1.3.1 Excitation and Adiabatic Pulses
The manipulation of ~M0 is called excitation and involves the application of another mag-
netic field, ~B1, that lies in the x̂, ŷ-plane with frequency ω. In other words, ~B1 is perpendic-
ular to ẑ and rotates about ẑ with frequency ω. Since ~B1 is rotating about ẑ at ω, the motion
of ~M0 in the presence of ~B1 may be more simply described in a frame of reference (x̂′, ŷ′, ẑ′)
that also rotates about ẑ at ω. The motion of ~M0 is described by the Bloch equation, which
is
δ ~M
δt
= γ ~M0 ×
(
ω0 −ω
γ
ẑ′ + B1 x̂′
)
= γ ~M0 × ~Beff (1.1)
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FIGURE 1.1: Excitation in the rotating frame (x̂′, ŷ′, ẑ′) (a) The effective field, ~Beff created by
the applied ~B1 field exerts a torque on ~M0 resulting in the rotation of ~M0 about ~Beff. (b) If
the adiabatic condition,
∣∣∣ dαdt ∣∣∣ γ ∣∣∣~Beff(t)∣∣∣, is met, ~M0 remains parallel with ~Beff. Then, ~M0
may be manipulated by manipulating ~Beff via frequency modulation ( f (t)) and amplitude
modulation (A(t)) of applied ~B1 pulse.
in the rotating frame. ~Beff is the effective field in the rotating frame created by the applied
~B1. This effective field exerts a torque on ~M0, resulting in the rotation of ~M0 about ~Beff
(Figure 1.1a). The angle through which ~M0 rotates is the flip angle, θ:
θ = γ
∫ T
0
Beff(t) dt (1.2)
where T is the duration of application of ~B1.
Since conventional human and animal MRI scanners use magnetic fields on the order of
several Tesla, the precession frequency of ~M0 lies in the radio-frequency (RF) range (Equa-
tion (A.9)). As a result, RF pulses are used to generate the ~B1 fields needed for excitation.
The amplitude of the RF pulse is equal to B1, the amplitude of the ~B1 field, while the fre-
quency of the RF pulse is equal to ω, the frequency of the ~B1 field. Both the amplitude
and frequency components of the RF pulse may be modulated, but conventional RF pulses
only use amplitude modulation, with the frequency held constant. Typically, on-resonance
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excitation is desired, and ω is set equal to ω0.
Adiabatic RF pulses, which are often used in high-field magnetic resonance spec-
troscopy, use both amplitude and frequency modulation, resulting in the following com-
ponents for ~Beff:
~Beff =
ω0 −ωmax
γ
f (t)ẑ′ + B1, maxA(t)x̂′ (1.3)
where f (t) and A(t) are the normalized frequency and amplitude modulation functions,
respectively. At the beginning of an adiabatic pulse, the frequency modulation is large, the
amplitude modulation is small and ~Beff is aligned with ẑ′. As time passes, the frequency
modulation decreases, the amplitude modulation increases, and ~Beff rotates towards the
x̂′, ŷ′-plane (Figure 1.1b). Once ~Beff has rotated through an angle α = 90◦, a half passage
is complete. Then, the frequency modulation increases again, the amplitude modulation
decreases, and ~Beff rotates towards −ẑ′. Once ~Beff is aligned with −ẑ′ and α = 180◦, a full
passage is complete. In this scheme, ~M0 begins parallel with ~Beff. If the adiabatic condition,∣∣∣ dαdt ∣∣∣ γ ∣∣∣~Beff(t)∣∣∣, is satisfied throughout the pulse and the pulse length is short relative to
T1 and T2 relaxation (see Section 1.3.2), ~M0 remains parallel with ~Beff throughout the pulse.
In this way, ~M0 may be manipulated by an adiabatic RF pulse.
1.3.2 Relaxation
After excitation, ~M0 undergoes relaxation, which occurs due to energy transfer. Energy
may transfer from the hydrogen nuclei (the ‘spins’) to the surrounding environment (the
‘lattice’) resulting in spin-lattice relaxation, also called T1 relaxation. This energy transfer
depends mainly on the motion of the neighbouring molecules and is most efficient when
the average rate of motion is at ω0. ~M0 will return to its original equilibrium state via T1
relaxation.
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Relaxation may also occur due to dynamic interactions between the hydrogen nuclei
without energy transfer to the lattice. This type of relaxation is called spin-spin relaxation
or T2 relaxation and causes the loss of phase coherence between nuclei. Loss of phase co-
herence between nuclei can also be a result of spatial variation in ~B0 (i.e. static field inho-
mogeneity). This type of relaxation is called T′2 relaxation. The combined effect of T2 and
T′2 relaxation is called T
∗
2 relaxation.
The motion of ~M0 during relaxation is best described by the Bloch equation in the rotat-
ing frame (Equation (1.1)). When written in terms of the components of ~M, Equation (1.1)
becomes:
dMx′
dt
= (ω0 −ω)My′ −
Mx′
T∗2
(1.4)
dMy′
dt
= −(ω0 −ω)Mx′ −
My′
T∗2
(1.5)
dMz′
dt
=
M0 −Mz′
T1
(1.6)
with solutions:
Mx′(t) = e−t/T
∗
2
(
Mx′(0) cos((ω0 −ω)t) + My′(0) sin((ω0 −ω)t)
)
(1.7)
My′(t) = e−t/T
∗
2
(
My′(0) cos((ω0 −ω)t)−Mx′(0) sin((ω0 −ω)t)
)
(1.8)
Mz′(t) = Mz′(0)e−t/T1 + M0(1− e−t/T1) (1.9)
where M0 is the magnitude of the magnetization in its original equilibrium state; Mx, My,
Mz are the components of the magnetization after excitation; t = 0 is the instant in time
immediately after excitation; T1 is the spin-lattice relaxation time constant; and T∗2 is the
time constant due to combined effects from spin-spin interaction (T2) and excitation field
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inhomogeneity (T′2). T
∗
2 is defined by the following relation:
1
T∗2
=
1
T2
+
1
T′2
(1.10)
Relaxation processes are important to consider because the relaxation time constants of
water and metabolites affect the choice of various parameters during imaging and spec-
troscopy. Specifically, T1 affects the choice of repetition time (TR) and T2 affects the choice
of echo time (TE). TR should be long enough to avoid signal saturation due to incomplete
T1 relaxation, while TE should be short enough to avoid T2 related signal loss.
Assuming on-resonance excitation (ω0 − ω = 0), Equations (1.7) and (1.8) can be sim-
plified and combined to describe the evolution of the magnetization in the transverse plane
(the x̂′, ŷ′-plane):
Mx′y′(t) = Mx′y′(0)e−t/T
∗
2 (1.11)
Since coils used for MR imaging are typically designed such that the sensitivity profile
is optimized to detect magnetization in the transverse plane, Mx′y′ is the source of the
detected MR signal. This detected signal is called the free induction decay (FID) signal.
1.3.3 Spatial Encoding
In order to form an image of an object with an MRI, spatial information is encoded in the
measured FID signals by adding linear gradients to the main magnetic field, ~B0:
~G(t) =
d~Bz(t)
d~r
(1.12)
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where ~Bz(t) = ~B0 + ~G(t) ·~r, and~r is the direction of ~Bz variation. At each instant in time,
the linear gradients impose a spatially dependent phase pattern on the spins:
φ(~r, t) = −γ
∫ t
0
~G(τ) dτ ·~r (1.13)
= −2π~k(t) ·~r (1.14)
The resulting effect is that all components in the object with the spatial frequency corre-
sponding to the phase pattern are now in phase and the recorded signal is sensitized to
that particular spatial frequency. This spatial frequency is described by the parameter,~k,
which is defined as follows:
~k(t) =
γ
2π
∫ t
0
~G(τ) dτ (1.15)
Each point in the space of~k corresponds to a different spatial frequency. When linear gra-
dients are present, k-space is traversed, different spatial frequencies are sampled, and a
frequency domain representation of the object is acquired. An image of the object can be
obtained by performing an inverse Fourier transform of the acquired data.
1.4 Proton Magnetic Resonance Spectroscopy
In the studies presented in this thesis, single-voxel proton magnetic resonance spec-
troscopy (1H-MRS) is used to non-invasively measure the levels of metabolites in vivo from
a particular brain region. The details of this technique are briefly described in the present
section.
1.4.1 Chemical Shift and J-Coupling
In MR imaging, the signal from the hydrogen nuclei of water is measured. In contrast, 1H-
MRS detects the signals from hydrogen nuclei present in metabolites. Since metabolites
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have a different chemical structure than water, the hydrogen nuclei in these molecules
experience a different local chemical environment.
Specifically, the chemical structure of a metabolite determines the electron distribution
around a hydrogen nucleus. In an external magnetic field, ~B0, electrons are in motion. Since
electrons have charge, their motion produces an induced magnetic field, ~Bind. This induced
magnetic field determines the local effective magnetic field at the nucleus, ~Bloc:
~Bloc = ~B0 − ~Bind = ~B0(1− σ) (1.16)
where σ is a constant that depends on the chemical environment of the nucleus. This effect
is called electron shielding. As a result, these nuclei resonate at a different frequency than
that of the hydrogen nuclei in water. This frequency offset is called the chemical shift,
which has dimensionless units of ppm and is defined as:
δ =
ν− νref
νref
× 106 (1.17)
Although the reference frequency, νref, can be set to the frequency of water, a 3-
trimethylsilyl propionate (TSP) is more typically used as the reference compound in 1H-
MRS. The reference compound is assigned δ = 0 ppm.
Since hydrogen nuclei have different chemical shifts, plotting their signals with respect
to chemical shift allows us to visualise a pattern of peaks along a ppm axis, or more simply,
a spectral pattern. Since the chemical shifts of the hydrogen nuclei are determined by the
chemical structure of the metabolite, each metabolite has a characteristic spectral pattern.
This spectral pattern can be complicated by spin-spin interactions between hydrogen
nuclei in a molecule called J-coupling. J-coupling is a phenomena where the electron shield-
ing of a nucleus is indirectly affected by the magnetic moment of neighbouring nuclei
through chemical bonds, resulting in changes in the local field at the nucleus (Equation
(1.16)). This depends on the spin orientations of the neighbouring nuclei. Thus, different
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combinations of electron shielding effects can manifest locally at the nucleus. This can re-
sult in a single peak at δ being split into multiple sub-peaks with slightly different fre-
quency shifts (Equation (1.16)). A coupling constant, J, simply defined as the frequency
shift difference between these sub-peaks, can be used to quantify the coupling effect.
Peak splitting behaviour is predictable if spins are weakly coupled (i.e. J|νA−νX |  1 for
nuclei A and X). An example of a weakly coupled spin system is lactate (Figure 1.2a). What
would have been a single peak at 1.3 ppm from the methyl (3CH3) hydrogens and a single
peak at 4.2 ppm from the methine (2CH) hydrogen without J-coupling splits into a doublet
and a quadruplet, when J-coupling is present (Figure 1.2b).
Consider the doublet methyl signal at νa = 1.3 ppm. The hydrogens of the methyl
group, Ha are weakly coupled to the neighbouring hydrogen of the methine group Hb
with a coupling constant 3 JHa Hb . The electron shielding experienced at Ha depends on the
nuclear spin orientation of Hb. Hb may be in a spin-up state (parallel with ~B0 or in a spin-
down state (anti-parallel with ~B0). Via Fermi contact and the Pauli exclusion principle, the
spin-up state of Hb results in less electron shielding and a greater local field at Ha, leading
to a peak at a slightly higher frequency, νa +
3 JHa Hb
2 (Figure 1.2c). Similarly, the spin-down
state of Hb results in more electron shielding and a lower local field at Ha, leading to a peak
at a slightly lower frequency νa −
3 JHa Hb
2 . These two peaks comprise the methyl doublet
observed at νa = 1.3 ppm and have an amplitude ratio of 1:1. The fact that an aligned,
spin-up state at the coupled nucleus leads to less electron shielding locally, and that an anti-
aligned, spin-down state at the coupled nucleus leads to more electron shielding locally,
can be extended to explain the observation of methine quadruplet observed at νb = 4.2
ppm (Figure 1.2d). This quadruplet has an amplitude ratio of 1:3:3:1. In general, if the
weak coupling condition, J|νA−νX |  1, is satisfied, a nucleus coupled to n neighbouring
peaks will appear as a multiplet with n + 1 peaks in an amplitude ratio defined by Pascal’s
triangle (1:1, 1:2:1, 1:3:3:1, etc.).
For a strongly coupled spin system, where J|νA−νX | ≈ 1, the splitting behaviour is not
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FIGURE 1.2: (a) The lactate molecule consists of an acetyl group at 1C, a methine group at
2C, and a methyl group at 3C. (b) The characteristic 1H-MRS spectrum of lactate consists of
a doublet at 1.3 ppm from the methyl group and a quadruplet at 4.2 ppm from the methine
group.
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FIGURE 1.2: (c) Consider the doublet at νa = 1.3 ppm. The hydrogens, Ha, from the methyl
group are coupled to the hydrogen, Hb, from the methine group with coupling constant
3 JHa Hb . The nuclear spin orientation of Hb may be aligned with ~B0 (spin-up) or anti-aligned
(spin-down). Via Fermi contact, a spin-up nuclear spin orientation leads to an energetically
favoured spin-down orientation for Hb’s electron spin. This electron spin orientation sets
the orientations of the electron spins in the downstream chemical bonds via Pauli’s ex-
clusion principle, resulting in a spin-up electron spin orientation at Ha. Since this electron
spin orientation is aligned with ~B0, there is less electron shielding, a greater local field,
and a peak at a higher frequency of νa +
3 JHa Hb
2 . In the same way, a spin-down nuclear
orientation of Hb leads to a spin-down electron spin orientation at Ha, resulting in more
electron shielding, a lower local field, and a peak at a lower frequency of νa +
3 JHa Hb
3 . These
two peaks comprise the doublet and are in a 1:1 amplitude ratio. (d) Consider the quadru-
plet at νb = 1.4 ppm, where the methine hydrogen is coupled to 3 methyl hydrogens.
Using the same explanation as in (c), an aligned, spin-up state at a methyl hydrogen leads
to less electron shielding at the methine hydrogen, and an anti-aligned, spin-down state
at a methyl hydrogen leads to more electron shielding at the methine hydrogens. There
are four magnetically distinct nuclear spin configurations for the 3 methyl hydrogens, re-
sulting in four levels of electron shielding at the methine hydrogens, and a quadruplet of
peaks in a 1:3:3:1 amplitude ratio.
intuitive, does not follow Pascal’s triangle, and requires more complicated mathematics to
describe (see Appendix B). However, whether or not J-coupling is strong or weak, it results
in a few undesirable effects:
1. If there is a time-dependence to the J-coupling (e.g. chemical exchange), then J-
coupling results in time-dependent fluctuations in the local magnetic field environ-
ment of nuclei and can therefore be a source of spin-spin relaxation.
2. J-coupling manifests as a frequency shift along the ppm axis, which leads to over-
lapping of peaks from different metabolites in vivo, complicating the process used to
determine the concentration of metabolites from the spectrum.
3. J-coupling results in peak splitting, which effectively reduces the amplitudes of the
peaks and decreases the SNR.
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1.4.2 Water Suppression
In high quality 1H-MRS data, the amplitudes of the peaks that comprise the spectrum of a
metabolite reflect the metabolite’s concentration. In the brain, the concentration of metabo-
lites are on the order of ∼1-15 M, and appears as low amplitude peaks on an acquired
1H-MRS spectrum. In contrast, the concentration of water is much greater – ∼45.2 M in
grey matter (GM), ∼40.3 M in white matter (WM), and ∼54 M in cerebrospinal fluid (CSF)
– and appears as a large resonance at 4.7 ppm. Artefacts present on such large resonances,
such as gradient coil vibration signal modulation [182], can overlap with metabolite peaks,
complicating their measurement. Thus, to consistently and reliably detect metabolite sig-
nals, water suppression is commonly used.
There are different methods used to suppress the water signal. The method used for
the studies presented in this thesis combines frequency selective excitation and gradient
dephasing. A series of narrow bandwidth RF pulses (∼ ± 0.5 ppm) centred on the fre-
quency of the water resonance are used excite the water magnetization. Each excitation
pulse is followed by a strong crusher gradient that dephases the water magnetization. The
result of this RF pulse train is the destruction of the water signal. The acquisition of the
metabolite signals immediately follows the water suppression scheme.
The exact order, timing, and amplitude of the frequency-selective RF pulses determines
the effectiveness of the water suppression scheme. The specific water suppression scheme
used in the studies presented in this thesis consists of seven variable power RF pulses with
optimized relaxation delays (VAPOR) [183] between the pulses. The RF pulse powers re-
quired for optimal water suppression is set by calibrating the nominal flip angle of the first
RF pulse. VAPOR is insensitive to RF pulse power, and provides excellent water suppres-
sion for nominal flip angles between 65◦ and 125◦.
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1.4.3 Localization
In single-voxel 1H-MRS of the brain, metabolite signals are localized to a specific voxel
placed in a region of the brain by using successive selective excitation. Selective excitation
involves the use of RF pulses in conjunction with linear gradients. As discussed in Section
1.3.3, linear gradients add to ~B0 and change the magnetic field that nuclear spins experi-
ence. By the Larmor equation (Equation (A.9)), nuclear spins that reside at different spatial
positions will precess at different resonant frequencies. Thus, RF pulses paired with gradi-
ents may be used to excite nuclear spins at specific spatial locations by carefully setting the
carrier frequency and bandwidth of the RF pulse.
It follows that the precision of spatially selective excitation depends on both the sharp-
ness of the RF pulse frequency profile as well as the spatial homogeneity of both ~B0 and
the applied RF field, ~B1. At high-field, such as 4T and above, achieving ~B0 and ~B1 homo-
geneity becomes more challenging, but use of adiabatic RF pulses for localization can help
to overcome this problem. With adiabatic pulses, as long as the adiabatic condition is well-
fulfilled, nuclear spins will behave as expected even in the presence of magnetic field in-
homogeneity. In other words, adiabatic pulses are insensitive to ~B0 and ~B1 inhomogeneity.
Compared to traditional RF pulses, adiabatic pulses also have sharper frequency profiles
and bandwidths independent of RF amplitude. Therefore, adiabatic RF pulses can achieve
selective excitation with greater precision in high-field applications and are preferred for
localization in high-field 1H-MRS.
The most common localization method in high-field 1H-MRS that utilizes adiabatic RF
pulses is the localization by selective refocusing (LASER) method [184]. The LASER pulse
sequence begins with a non-selective adiabatic half passage (AHP) pulse that excites all of
the spins into the transverse plane regardless of spatial position. This is followed by three
pairs of adiabatic full passage (AFP) pulses that invert the spins 180◦. Inversion reverses
the phase of the spins; spins with high phase at the time of inversion lose phase, while spins
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with low phase at the time of inversion gain phase. This causes the loss of phase coherence
due to T′2 relaxation (see Section 1.3.2) to be reversed. Spins regain phase coherence at the
echo time (TE) and generate a maximal signal that can be measured. The three pairs of
AFP pulses in the LASER pulse sequence inverts spins localised to three orthogonal spatial
slices. The intersection of these slices defines the three-dimensional voxel from which the
measured signal originates.
Compared to non-adiabatic localization methods such as point resolved spectroscopy
(PRESS) [185] and stimulated acquisition mode (STEAM) [186], the LASER pulse sequence
requires the use of a longer TE. The reason for this is two-fold. First, AFP pulses are applied
in pairs because the first AFP pulse introduces a non-linear phase dispersion across the ex-
cited slice which is refocussed by the second. Second, because adiabatic pulses deposit
more RF power than traditional pulses, they must be made longer in order to stay within
power deposition limits at high field. Power deposition is defined as the rate at which tis-
sue absorbs energy when exposed to an RF field, also called the specific absorption rate
(SAR). Limits on SAR are set by the U.S. Food and Drug Administration (FDA) and the In-
ternational Electrotechincal Commission (IEC). FDA and IEC guidelines limit whole body
SAR to <4 W/kg for any 15 minute average and whole head SAR to <3.2 W/kg for any 10
minute average. SAR over any 10 second period is also limited to less than two times the
stated values. The MRI scanner estimates SAR in real-time and if these limits are exceeded,
the scan will be automatically aborted.
These limitations may be partially addressed by replacing the non-selective AHP pulse
with a traditional selective 90◦ excitation pulse. Since the excitation pulse is selective, one
pair of AFP pulses becomes unnecessary. With two AFP pulses removed, and the AHP
pulse replaced by a traditional pulse, less RF power is deposited, and shorter TEs can be
achieved. This sequence is called the semi-LASER pulse sequence [187].
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1.4.4 Post-Acquisition Signal Processing
After acquisition, 1H-MRS signals are post-processed to correct lineshape distortions and to
ensure that metabolite lineshapes are Lorentzian. There are two major sources of lineshape
distortions.
The first source of lineshape distortions is ~B0 inhomogeneity in the voxel of interest.
Though ~B0 shimming is typically applied prior to acquisition to ensure that the magnetic
field experienced by the spins of interest is as homogeneous as possible, there may still
be some remaining ~B0 inhomogeneity in the spectroscopy voxel, resulting in a Gaussian
distribution of precession frequencies (Equation (A.9)) for the spins in the voxel. As a re-
sult, the acquired metabolite lineshapes will be more Gaussian than Lorentzian. This type
of lineshape distortion may be corrected using a reference signal from a sample that has
experienced the same magnetic inhomogeneities. Assuming that the reference and data
signals have the same phase, the contribution of ~B0 can be deconvoluted from the acquired
metabolite data signal by simply dividing the signals in the time domain [188]. This correc-
tion method is called QUALITY (QUAntification improvement by converting LIneshapes
to the lorentzian TYpe).
For in vivo experiments, the only available reference signal is the water signal collected
during the same scanning session from the same spectroscopy voxel used to collect the
metabolite data signal. This complicates the application of QUALITY to the data because
the T2 of water in the brain is shorter than the T2 of most metabolites of interest. In fact, at
7T, the T2 of water in the brain is roughly half that of metabolites [189]. Thus, at the end
of the time-domain signal, the water signal values are small, and dividing the metabolite
data signal by the water signal will result in signal spikes. These can be avoided by simply
restricting QUALITY to the beginning of the acquired metabolite data signal [190].
The second source of lineshape distortions are the rapidly switching magnetic field
gradients used during the localization of the 1H-MRS signal. Due to Faraday’s Law, the
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switching gradients induce eddy currents in conductive structures including the main
magnet, the shim coil, and the gradient coils themselves, resulting in shifts in ~B0 and
time-dependent variations in the gradient fields. Eddy current effects manifest as time-
dependent phase changes in the acquired metabolite data signal, leading to lineshape dis-
tortions in the frequency domain, and may be corrected by subtracting the phase of a ref-
erence signal, such as the water signal, from the phase of the acquired data [191]. Unlike
QUALITY, eddy current correction (ECC) can be applied to the whole data signal without
introducing artefacts.
1.4.5 Spectral Fitting
Acquired in vivo 1H-MRS data is comprised of signals from all metabolites, lipids, and
macromolecules present in the voxel of interest. The amplitude of a metabolite signal in the
time-domain is equivalent to the area under the metabolite spectrum in the frequency do-
main [96], and is proportional to the metabolite’s concentration. Thus, to quantify the con-
centration of each metabolite, the acquired data must be decomposed into its constituent
metabolite signals. This can be achieved by fitting signal models of metabolites of interest,
such as the model of glutamate (Equation (3.1)), to the data.
The sum of all signal models to be fitted produces the prior knowledge template:
FID[n] =
M
∑
m
(
Ame−(t[n]+TE)/T2,m
K
∑
k
ckej(ωk(t[n]+t[0])+φk)e−παk |t[n]+t[0]|
)
(1.18)
The prior knowledge template contains M metabolite models. Each metabolite model is the
sum of K frequency components, or peaks, and has an associated scaling factor (Am) and
T2 value (T2,m). For each peak, an amplitude parameter (ck), a frequency shift parameter
(ωk), a phase parameter (φk), and a Lorentzian linewidth parameter (αk) are defined.
The prior knowledge template defined in Equation (1.18) is a discretized function of
time (t[n]). Alternatively, the template can be defined in the frequency domain. However,
35
Chapter 1. Introduction
since the data is acquired in the time domain, spectral fitting is also often done in the time
domain. Moreover, since the data acquisition time is finite, truncation of the time-domain
data will occur, which introduces frequency-domain artefacts that complicate frequency-
domain fitting.
Although time-domain fitting avoids truncation-related frequency-domain artefacts,
it is affected by residual water signal not destroyed by water suppression. In the time-
domain, residual water signal is spread throughout the entire acquired FID. Removal of
the residual water signal is necessary, as it will affect the fitting process and subsequent
metabolite quantification. This can be done by identifying frequency components of the
FID that are close to that of water (4.7 ppm) using a Hankel singular value decomposition
(HSVD) algorithm [192] and subtracting those components from the FID.
1.4.6 Metabolite Simulations for Prior Knowledge
Fitting performance can be improved by reducing the number of independent parame-
ters in the prior knowledge template. To do this, parameters within metabolites and/or
between metabolites can be constrained by defining relationships between the parameters.
These parameter relationships can be defined either empirically or by using numerical sim-
ulation.
The empirical approach requires the acquisition of high quality 1H-MRS data from a
solution of each metabolite included in the prior knowledge template with the same ac-
quisition sequence and magnetic field strength used to acquire in vivo data. This approach
is both time and resource intensive, especially if different RF pulse shapes, pulse sequence
parameters, pulse sequences, or field strengths are used in an experimental protocol.
A more efficient way to obtain and constrain a prior knowledge template is to use the
results from numerical simulations. Numerical simulations implement a quantum mechan-
ical representation of ensembles of metabolite spin-systems. The J-coupling interactions be-
tween spins and the interactions of spins with RF pulse shapes can be fully described using
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quantum mechanical equations (see Appendix B). The different RF pulse shapes from the
MRI scanner can be exactly replicated and the exact pulse sequence reproduced, allow-
ing the simulations to generate the expectation values of metabolite amplitude, phase, and
shift parameters that result from the application of the pulse sequence. Multiple simula-
tions can also be run simultaneously for all metabolites included in the prior knowledge
template. In this way, the values needed to define parameter relationships can be quickly
obtained.
1.4.7 Metabolite Quantification
After fitting the prior knowledge template to the data, the fitted amplitude values (ck in
Equation (1.18)) of the metabolites are compared to the signal amplitude of a reference
compound with known concentration in order to determine the absolute metabolite con-
centrations. For in vivo spectroscopy, the reference signal is typically a water-unsuppressed
spectrum collected from the same spectroscopy voxel as the water-suppressed metabolite
spectrum. The water-unsuppressed spectrum is simply the water signal – the same signal
used for QUALITY and ECC (Section 1.4.4). A water signal is used as the internal reference
rather than the signal of another metabolite such as creatine because water concentration
in the brain is uniformly distributed and varies over only a small range in pathological
states [193].
Using an internal water reference, the tissue metabolite concentration, [M], may be cal-
culated as follows:
[M] =
Ŝm
ŜW
× 55.14 M (1.19)
where 55.14 M is the concentration of pure water [96], Ŝm is the corrected metabolite am-
plitude value, and ŜW is the corrected water amplitude value. Corrections applied to the
spectra include:
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• A correction for the number of averages used during data acquisition.
• A correction for any gain and scaling factors applied to the data during acquisition
and post-processing.
• A correction for the T1 and T2 relaxation rates of metabolites and water in the gray
matter (GM), white matter (WM), and cerebrospinal fluid (CSF) compartments.
• A correction for the relative proton density of water in GM, WM, and CSF as com-
pared to that of pure water.
A more detailed explanation of the applied corrections is given in Appendix C.
1.4.8 Sources of Variability
Measurements of metabolite concentrations made using single-voxel 1H-MRS may be af-
fected by several sources of variability. Some of these are discussed below.
1.4.8.1 Spectroscopy Voxel Placement and Participant Movement
As discussed in Section 1.4.3, metabolite signals are localized to a specific voxel placed in a
region of the brain. The location of this voxel is often prescribed manually by the operator
of the MRI scanner using anatomical landmarks from a separately acquired anatomical
image of the participant. Because of this, intra- and inter-operator variability, as well as
participant movement between the acquisition of the anatomical image and the acquisition
of the 1H-MRS data are sources of variability. Participant motion during the acquisition
can also result in frequency and phase drifts that introduce artefacts into the spectrum.
Fortunately, some of these artefacts can be corrected post-acquisition using methods such
as spectral registration [194]. However, spectral quality may still be reduced (e.g. increased
linewidth and lower SNR).
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1.4.8.2 Field Inhomogeneity
Spatially-dependent variations in ~B0 and ~B1 as well as time-dependent variations in ~B0
and the gradient fields are other sources of variability. Spatially-dependent variations can
affect the localization of the 1H-MRS signal, while time-dependent variations can result
in lineshape distortions. These may be mitigated by using adiabatic RF pulses (see Section
1.4.3) and by using QUALITY correction, ECC correction, or combined QUALITY and ECC
correction (see Section 1.4.4).
1.4.8.3 Chemical Shift Displacement Error
The location of the spectroscopy voxel defined using successive selective excitation as-
sumes on-resonance excitation. As discussed in Section 1.4.1, hydrogen nuclei of metabo-
lites resonate at a different frequency than that of the hydrogen nuclei in water (i.e. off-
resonance) resulting in metabolite signals that are measured from locations slightly shifted
from that of the defined spectroscopy voxel. Such chemical shift displacement errors (CS-
DEs) are a source of variability and must be considered, especially at high field, as CSDE
increases linearly with field strength. Minimizing the CSDE requires the use of gradients
with high amplitude and RF pulses with large bandwidths.
1.4.8.4 Signal Bleed
Another source of variability is the unintended measurement of signal that originates from
outside of the defined spectroscopy voxel. This phenomonen, also known as outer volume
signal bleed, occurs because RF pulses implemented on an MRI scanner do not have per-
fect excitation profiles and spins outside of the defined spectroscopy voxel will be excited.
Outer volume signal bleed needs to be considered, especially for spectroscopy voxels pre-
scribed in brain regions near other tissues such as skin, because strong outer volume signals
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(e.g. from lipids) can overlap with and obscure metabolite signals. Fortunately, outer vol-
ume signal bleed can be minimized by saturating spins outside the defined spectroscopy
sequence using an outer volume suppression scheme that immediately precedes the local-
ization sequence such as in [187].
1.4.8.5 Macromolecule Signals
It is not only outer volume signals that overlap with metabolite signals. Macromolecule
signals from within the voxel of interest can also overlap with metabolite signals, which
complicates the metabolite fitting and quantification process. Macromolecule contributions
can be estimated and accounted for using several approaches including spline fitting [195],
direct measurement of the macromolecule signal with inversion recovery techniques [196],
and by using a model of the macromolecule lineshapes in the prior knowledge template
[117]. The choice of approach can significantly impact the quantification of metabolites and
contribute to the variability in their measurements.
1.4.8.6 Signal-to-Noise Ratio, Linewidth, and the Cramér-Rao Lower Bound
The variability in the calculated metabolite concentrations can also be impacted by fac-
tors such as the signal-to-noise ratio (SNR) of the acquired data and the linewidth of the
metabolite peaks [197].
SNR of the acquired data depends on the concentration of metabolite in the voxel of
interest (which determines the amount of available metabolite signal), the size of the voxel
of interest, and the number of averages. It is typically calculated by dividing the height
of the largest metabolite peak by the standard deviation of the noise. Low SNR spectra
affects spectral fitting by increasing the uncertainty in the estimated model parameters
used to calculate metabolite concentrations. This, in turn, increases the variability of the
measurement.
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The lowest expected variation of an estimated model parameter is quantified using a
value called the Cramér-Rao Lower Bound (CRLB). Put another way, the CRLB is the min-
imum expected error associated with modelling the data. CRLBs decrease in proportion
with the level of noise, meaning that better SNR results in more precise estimates of model
parameters and a lower variability of calculated metabolite concentrations. Increasing the
spectroscopy voxel size and the number of averages will increase SNR and decrease mea-
surement variability.
CRLBs are also affected by the linewidth of the metabolite peaks. Increased linewidths
causes increased overlap of adjacent peaks of different metabolites (e.g. peaks of gluta-
mate and glutamine) that results in greater uncertainty of estimated model parameters and
increased variability in calculated metabolite concentrations. Since linewidths are driven
by the quality of the shim, a high quality shim can ensure narrow linewidths and reduce
metabolite measurement variability.
1.4.8.7 Intrinsic Variation of Metabolite Levels
Another source of variability that should be considered is related not to the measurement of
the signal, but rather to human physiology. Metabolite levels in the brain can fluctuate with
circadian rhythm, diet, medication, exercise, and sleep. For example, diurnal variations can
be detected using magnetic resonance spectroscopy [198]. Thus, making the measurement
at different times of day can introduce variability in the calculated metabolite concentra-
tions between participants. Variations in the mediators of circadian rhythm, such as brain
temperature, hydration, and osmotic regulation may also contribute to measurement vari-
ability.
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1.5 Diffusion Tensor Imaging
In the study presented in Chapter 2, metrics derived from diffusion tensor imaging were
used to indirectly measure the white matter structure in the brain and were related to 1H-
MRS measurements made in the hippocampus and posterior cingulate cortex. This imag-
ing technique is briefly detailed in this section.
1.5.1 Water Diffusion in Tissue
As discussed in Section A.1, MRI is sensitive to the magnetization of an ensemble of 1H
nuclei. Though some of these 1H nuclei are part of more complicated molecules such as
metabolites and lipids, the overwhelming majority of the 1H nuclei in tissue are part of
water molecules. Whether the tissue is live or fixed, water molecules experience transla-
tional motion as a result of random thermal fluctuations. This random thermal motion is
called Brownian motion.
In free fluids, Brownian motion results in isotropic diffusion governed by Einstein’s
equation:
r2 = 6Dt (1.20)
where r is the distance of diffusion, D is the diffusion coefficient, and t is the diffusion time.
Thus, free water molecules travel a distance that is proportional to
√
6Dt.
However, water in tissue diffuses within, around, and through anatomical structures
that hinder the diffusion of water. Thus, by measuring the apparent diffusion of water in
tissue, the underlying anatomical microstructure can be probed.
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1.5.2 Diffusion Weighting of the MRI Signal
The MRI signal can be sensitized to the diffusion of water by utilizing the magnetic field
gradients. As discussed in Sections 1.3.3 and 1.4.3, magnetic field gradients add a linear
spatial variation to the main magnetic field causing nuclear spins at different spatial posi-
tions to experience a different local magnetic field. As water molecules diffuse and move
through space in the presence of a gradient, the proton nuclear spins experience different
local magnetic fields and acquire random phase changes. The more diffusion that a water
molecule experiences, the more phase is accrued by its spins. After the gradient is turned
off, any diffusion also results in incomplete rephasing when a second gradient is applied.
The result is an attenuation of the MRI signal that depends on the diffusion of water. Thus,
both the length of the diffusion gradient and the time between gradients can be used to
encode information about the diffusion of water in the MRI signal, resulting in a diffusion
weighted image.
Mathematically, the signal attenuation observed in each voxel of a diffusion weighted
image is described by the following equation:
S = S0 e−bD (1.21)
where S is the signal after diffusion induced attenuation, S0 is the measured signal without
the use of diffusion gradients, D is the apparent diffusion coefficient (ADC), and b is a
diffusion sensitivity parameter determined by the magnitude and duration of the diffusion
gradients, as well as the timing of the RF pulse sequence used.
A common pulse sequence used for diffusion imaging is the diffusion-weighted spin-
echo sequence (Figure 1.3). The spin-echo sequence begins with a 90◦ excitation pulse
which excites water spins into the transverse plane. This is followed by a 180◦ refocusing
pulse at time TE/2, which inverts the spins 180◦. As described in Section 1.4.3, inversion
allows spins to regain phase coherence at TE, generating a maximal signal that can be
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measured.
Diffusion gradients spaced ∆ apart with amplitude G and duration δ are placed be-
tween the RF pulses. The b-value is determined by these parameters. In the example shown
in Figure 1.3a, where imaging gradients are not shown or considered, b = γ2δ2G2
(
∆− δ3
)
.
This solution for the b-value is also called the Stejskal-Tanner equation. Practically, because
imaging gradients are applied before the diffusion gradients, some interaction between the
imaging gradients and the diffusion gradients occur. Due to this interaction, the actual an-
alytical equation for b is a complicated function of both the imaging and diffusion gradient
parameters.
Manipulating the gradient parameters allows diffusion weighted images with differ-
ent b-values to be collected. At least two b-values are needed in order to determine the
diffusion coefficient D at each image voxel using Equation (1.21):
D =
1
(bm − bn)
ln
(
S(bn)
S(bm)
)
(1.22)
Typically, bm is 0 s/mm2 in order to obtain S0 at each voxel. The S0 image is needed to cor-
rect image distortions caused by the imaging gradients. On the other hand, bn is usually on
the order of 1000 s/mm2. More than two b-values can be used to more accurately estimate
D (Figure 1.3b).
1.5.3 The Diffusion Tensor
The value of D estimated with Equation (1.22) is the value of the diffusion coefficient in
the direction of the gradients. For example, if the two gradients in Figure 1.3 are in the
x and y directions, Dxy would be estimated. Multiple gradients can be used to define a
non-orthogonal direction and estimate D in the direction of any arbitrary vector.
Usually, D along many different directions are estimated in order to fully describe the
anisotropic diffusion of water in the brain. Water diffusion in the brain is mainly hindered
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FIGURE 1.3: (a) A diffusion-weighted spin-echo sequence with echo time TE is depicted.
The RF pulses, the diffusion gradients, and the generated MRI signal are shown. Imag-
ing gradients are not shown. The diffusion gradients have amplitude G and duration δ.
The time between gradients is ∆. (b) The b-value of the acquisition is determined by these
gradient parameters. Multiple acquisitions with different gradient parameters allows dif-
fusion weighted images at different b-values to be obtained and the diffusion coefficient D
to be estimated at each image voxel.
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by axonal bundles. Water tends to move more easily along axonal bundles rather than
through or around them resulting in the anisotropic diffusion rather than isotropic diffu-
sion. Thus, the ability to accurately measure anisotropic diffusion is needed in order to
probe the anatomical structures of the brain.
The simplest way to model the anisotropic diffusion in each image voxel is by using a
rank 2 diffusion tensor:
D =

Dxx Dxy Dxz
Dyx Dyy Dyz
Dzx Dzy Dzz
 (1.23)
By applying different gradients Gk and acquiring the corresponding signals Sk along K
directions, a system of equations can be set up to determine the elements of the diffusion
tensor:
~AD̄ = ~B
ḠT1
ḠT2
...
ḠTK

D̄ =

ln S1/S0b1
ln S2/S0b2
...
ln SK/S0bK

k = 1 · · ·K, K ≥ 6 (1.24)
where Ḡk = [G2x G2y G2z 2GxGy 2GxGz 2GyGz]T, and D̄ = [Dxx Dyy Dzz Dxy Dxz Dyz]T.
If K = 6, this system of equations can be solved with one unique solution. However, in
practice, many different directions are acquired (i.e. K  6) in order to improve SNR. With
K > 6, the system of equations becomes overdetermined and there is no unique solution.
In this case, D̄ may be solved by employing the pseudoinverse of ~A and by using singular
value decomposition approaches.
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FIGURE 1.4: The diffusion tensor D is depicted for isotropic diffusion in (a) and for
anisotropic diffusion in (b). λ1, λ2, and λ3 are the eigenvalues of D and v1, v2, and v3
are the eigenvectors of D. The eigenvalues and eigenvectors of D enables the calculation
of metrics such as fractional anisotropy (FA). In the isotropic condition, λ1 ≈ λ2 ≈ λ3 and
FA is low. In the anisotropic condition, λ1  λ2 ≈ λ3 and FA is high.
After D is estimated, it is diagonalized to obtain D′:
D′ =

λ1 0 0
0 λ2 0
0 0 λ3


v1
v2
v3
 (1.25)
where λ1, λ2, and λ3 are the eigenvalues of D and v1, v2, and v3 are the eigenvectors of
D. The eigenvalues and eigenvectors of D characterizes diffusion at each voxel (Figure
1.4) and enables the voxelwise calculation of metrics such as mean diffusivity (MD), axial
diffusivity (AxD), radial diffusivity (RD), and fractional anisotropy (FA). These metrics are
used to infer information about the underlying anatomical brain structures.
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1.5.3.1 Mean Diffusivity
The mean diffusivity metric is the directionally averaged diffusivity of water within a
voxel:
MD =
λ1 + λ2 + λ3
3
(1.26)
MD describes the magnitude of the overall amount of water diffusion in each voxel and
has units of µm/ms. Changes in the amount of water diffusion can be due to changes
in the tissue. Increasing structure within cells can impede water diffusion, lowering MD
[199]. Processes such as demylenation, inflammation, and oedema can increase water dif-
fusion, in turn increasing MD [200]. Thus, MD is a sensitive but non-specific measure of
underlying structural changes.
1.5.3.2 Fractional Anisotropy
Fractional anisotropy is calculated using MD and the eigenvalues of the diffusion tensor:
FA =
√
(λ1 −MD)2 + (λ2 −MD)2 + (λ3 −MD)2
2
(
λ21 + λ
2
2 + λ
2
3
) (1.27)
FA is bounded between 0 and 1, and describes the degree to which diffusion is anisotropic.
FA is considered a measure of axonal density, with dense packing resulting in more re-
stricted, anisotropic water diffusion and higher FA [199]. Both demylenation and axonal
degeneration cause axons to be less tightly packed together and lowers FA. Thus, FA is a
sensitive but non-specific measure of microstructural changes in axonal fibre tracts of the
brain.
However, the interpretation of FA is complicated by different confounding factors such
as physiological and thermal image noise, image artefacts due to eddy currents or head
motion, partial volume averaging between tissues, as well as crossing fibres within voxels
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[200]. Various post-processing methods can compensate for the first three confounds, but
the last confound is unavoidable. Crossing fibres cause the diffusion tensor to appear more
similar to the tensor depicted in Figure 1.4a, thus decreasing the calculated FA. The amount
of decrease is modulated by the angle and relative volume fractions of crossing fibres.
1.5.3.3 Combinations of Eigenvalues
Other combinations of eigenvalues can be calculated in order to demonstrate more specific
microstructural changes in white matter fibre tracts of the brain. Two such combinations
are the axial diffusivity (AxD) and the radial diffusivity (RD):
AxD = λ1 (1.28)
RD =
λ2 + λ3
2
(1.29)
Changes in AxD are more specific to axonal degeneration, while changes in RD are more
specific to myelin changes [201].
1.5.4 Tractography
The interpretation of MD, FA, RD, and AxD metrics are simplified if the analysis is re-
stricted to particular fibre tracts in specific anatomical regions. For example, within a fibre
tract that is homogeneous in direction, with few crossing fibres, changes in FA are much
more likely to reflect real microstructural changes.
Identifying fibre tracts is the domain of tractography. In general, tractography identifies
fibre tracts in a step-wise manner [200]:
1. Tractography begins by starting at a particular location called the seed point.
2. The next direction of travel is then estimated using the diffusion tensor at each voxel.
3. Finally, a small step is taken in that direction.
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By repeating this process, an axonal tract may be followed voxel-by-voxel and identified
[202]. Typically, constraints on this process are defined to refine the tracts that are identi-
fied. Examples of constraints include defining a maximum deflection angle that the next
direction can have or the use of an FA threshold to terminate the process.
There are a plethora of methods to accomplish tractography, but they all fall into either
the categories of deterministic tractography or probablistic tractography. Typically, deter-
ministic tractogrophy uses the primary eigenvector of each voxel to define the trajectory
of the fibre tract [199, 202]. On the other hand, probablistic tractography uses the distribu-
tion of the diffusion tensors to estimate a distribution of probable fiber orientations at each
voxel [203, 204]. Effectively, uncertainty about the orientation of axonal fibres is taken into
account when identifying fibre tracts, making probabilistic methods better at identifying
tracts in regions of crossing fibres than deterministic methods [199].
Once a fibre tract of interest is identified using tractography, the diffusion metrics can
be mapped onto the tract, allowing the analysis along the fibre tract and the comparison of
metric values of the same fibre tract across individuals.
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[113] M. Erecińska and I. A. Silver. “Metabolism and role of glutamate in mammalian
brain”. In: Progress in Neurobiology 35.4 (Jan. 1990), pp. 245–296.
[114] F. Fonnum. “Glutamate: A Neurotransmitter in Mammalian Brain”. In: Journal of
Neurochemistry 42.1 (Jan. 1984), pp. 1–11.
62
1.6. References
[115] C. A. Tamminga et al. “Glutamate dysfunction in hippocampus: Relevance of den-
tate gyrus and CA3 signaling”. In: Schizophrenia Bulletin 38.5 (Sept. 2012), pp. 927–
935.
[116] F. Schubert et al. “Glutamate concentrations in human brain using single voxel pro-
ton magnetic resonance spectroscopy at 3 Tesla”. In: NeuroImage 21.4 (Apr. 2004),
pp. 1762–1771.
[117] D. Wong, A. L. Schranz, and R. Bartha. “Optimized in vivo brain glutamate mea-
surement using long-echo-time semi-LASER at 7 T”. In: NMR in Biomedicine 31.11
(Nov. 2018), e4002.
[118] R. Rupsingh et al. “Reduced hippocampal glutamate in Alzheimer disease”. In:
Neurobiology of Aging 32.5 (May 2011), pp. 802–810.
[119] C. J. Stagg et al. “Relationship between physiological measures of excitability and
levels of glutamate and GABA in the human motor cortex”. In: Journal of Physiology
589.23 (Dec. 2011), pp. 5845–5855.
[120] N. R. Sibson et al. “Stoichiometric coupling of brain glucose metabolism and glu-
tamatergic neuronal activity”. In: Proceedings of the National Academy of Sciences 95.1
(Jan. 1998), pp. 316–321.
[121] M. Yudkoff et al. “Tricarboxylic acid cycle in rat brain synaptosomes. Fluxes and
interactions with aspartate aminotransferase and malate/aspartate shuttle.” In: The
Journal of biological chemistry 269.44 (Nov. 1994), pp. 27414–20.
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2
Reduced hippocampal glutamate and
posterior cingulate NAA in MCI and
AD is associated with episodic
memory performance and white
matter integrity in the cingulum
A version of this chapter has been accepted with minor revisions at the Journal of Alzheimer’s Disease:
Dickson Wong, Samir Atiya, Jennifer Fogarty, Manuel Montero-Odasso, Stephen H. Pasternak,
Chris Brymer, Michael J. Borrie, Robert Bartha, “Reduced hippocampal glutamate and posterior
cingulate N-acetyl aspartate in mild cognitive impairment and Alzheimer’s disease is associated
with episodic memory performance and white matter integrity in the cingulum,” October 2019.
Abstract: Identification of biological changes underlying the early symptoms of Alzheimer’s dis-
ease (AD) will help to identify and stage individuals prior to symptom onset. The limbic system,
which supports episodic memory and is impaired early in AD is a primary target. In this study,
brain metabolism and microstructure evaluated by high field (7 Tesla) proton magnetic resonance
spectroscopy (1H-MRS) and diffusion tensor imaging (DTI) were evaluated in the limbic system of
eight individuals with mild cognitive impairment (MCI), nine with AD, and sixteen normal elderly
controls (NEC). Left hippocampal glutamate and posterior cingulate N-acetyl aspartate concentra-
tions were reduced in MCI and AD compared to NEC. Differences in DTI metrics indicated volume
and white matter loss along the cingulum in AD compared to NEC. Metabolic and microstruc-
tural changes were associated with episodic memory performance assessed using Craft Story 21
Recall and Benson Complex Figure Copy. The current study suggests that metabolite concentrations
measured using 1H-MRS may provide insight into the underlying metabolic and microstructural
processes of episodic memory impairment.
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2.1 Introduction
Alzheimer’s disease (AD), the most common form of dementia, is a neurodegenerative dis-
order of the brain that results in progressive impairments across cognitive domains such as
memory, language, and executive function [1]. Although neurofibrillary tangles and amy-
loid plaques are hallmarks of AD pathology, the biological mechanisms underlying the
development of AD are complex and heterogeneous. No clear cause [1] or chain of events
have been identified that lead to the clinical presentation of AD [2].
Clinically, AD progression is considered a continuum, beginning with an asymptomatic
phase that transitions into a symptomatic predementia phase called mild cognitive impair-
ment (MCI) due to AD, followed by a symptomatic dementia phase called probable AD.
However, identifying where an individual lies along the disease continuum requires sub-
jective clinical judgment, with greater diagnostic uncertainty early in the disease contin-
uum. Incorporating biomarkers of AD pathology, such as measures of amyloid-beta (Aβ)
load, could help reduce this uncertainty [3, 4]. Additionally, volumetric measures of brain
structure derived from magnetic resonance imaging (MRI) [5], white matter microstruc-
tural integrity derived from diffusion tensor imaging (DTI) [6], functional connectivity de-
rived from functional MRI (fMRI) [7], and glucose uptake measured by fluorodeoxyglucose
positron emission tomography (FDG-PET) [8] provide complementary information that
can also aid in staging the disease. Despite the availability of these sophisticated measures
it remains difficult to predict when and who will progress from mild cognitive impairment
to AD. Even though disease-modifying treatments for AD are being investigated [9], they
are not yet clinically available. Nevertheless, improving the ability to place an individual
along the AD continuum, especially during the predementia phases, will help patients re-
ceive timely care and symptomatic treatment that could improve their quality of life [10].
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Both the hippocampus and the posterior cingulate cortex (PCC) are known to be in-
volved early in the pathological progression of AD [11]. Interestingly, both the hippocam-
pus and PCC are connected by white matter fibres that run through the cingulum and are
components of the Papez brain circuit, also known as the medial limbic system [12, 13,
14, 15, 16]. Damage to the grey matter and white matter structures of the Papez circuit is
associated with episodic memory impairment [17, 18, 19]. Episodic memory impairment
is among the earliest and most severe cognitive changes in AD [20], and is considered the
most clinically relevant for assessing AD patients [21]. Structural changes in both the hip-
pocampus and posterior cingulate cortex [22, 17, 5, 23, 24, 25], as well as changes in white
matter microstructural integrity within the cingulum [22, 26, 6, 27, 28, 29, 30] have previ-
ously been shown in AD and MCI.
In addition to brain structure, measures of brain metabolism may provide insight into
disease stage, particularly since there is evidence that metabolic changes may precede
changes in cellular microstructure, neuronal density and death [31, 32, 33]. This suggests
that measurement of brain metabolism could aid in the prediction of cognitive decline prior
to the detection of structural changes at early stages of the disease. Though FDG-PET is a
common measure of in vivo brain metabolism in AD, a less expensive, more accessible, and
non-invasive method is proton magnetic resonance spectroscopy (1H-MRS) [34]. Several
metabolites relevant to neuronal function can be simultaneously measured by 1H-MRS in
specific brain regions. Previous studies have shown decreased N-acetyl aspartate (NAA)
to creatine (Cr) ratio [35, 36, 37, 38, 39], decreased NAA concentration [40, 41, 42], and de-
creased glutamate (Glu) concentration [43, 39] in the hippocampus and posterior cingulate
cortex (PCC) of individuals with AD.
Although previous studies have independently shown altered brain metabolite levels
in the posterior cingulate and hippocampus as well as altered microstructure in the cingu-
lum in people with MCI and AD, it is unclear whether these changes occur simultaneously
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in the same individuals. The purpose of the current study was to determine whether al-
tered metabolism in the hippocampus and PCC was associated with altered white matter
microstructure in the cingulum of individuals with MCI and AD. Measuring metabolism
using 1H-MRS and white matter microstructure using DTI within regions of the Papez cir-
cuit that are associated with episodic memory could provide valuable information to help
support a diagnosis of MCI or probable AD. Thus, the main objectives of this study were
to: (1) correlate 1H-MRS measurements in the hippocampus and PCC with MRI-derived
measures of microstructural integrity in the cingulum, and (2) correlate 1H-MRS measure-
ments in the hippocampus and PCC with measurements of episodic memory performance.
We hypothesized that glutamate and NAA concentrations as measured by 1H-MRS would
be lower in the PCC and left hippocampus of individuals with AD, and significantly cor-
related with both MRI-derived measures of microstructural integrity in the cingulum and
measurements of episodic memory performance.
2.2 Materials and Methods
2.2.1 Subjects
In total, 33 subjects were recruited from the Aging Brain and Memory Clinic at Parkwood
Institute and the Geriatric Clinic at the Mount Hope Centre for Long Term Care in Lon-
don, Ontario, Canada. Of these, sixteen subjects were cognitively normal elderly controls
(NEC), eight subjects had a clinical diagnosis of mild cognitive impairment (MCI), and nine
subjects had a clinical diagnosis of probable AD. This study was approved by the Western
University Health Sciences Research Ethics Board. Informed consent was acquired accord-
ing to the Declaration of Helsinki.
MCI and AD subjects were diagnosed according to the most recent core clinical crite-
ria put forward by the National Institute of Aging and Alzheimer’s Association (NIA-AA)
working Groups [3, 4]. The MCI criteria were consistent with the previously published
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Petersen criteria [44, 45, 46]. The AD criteria were consistent with the National Institute
of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Re-
lated Disorder’s Association (NINCDS/ADRDA) criteria [47]. Clinical head CTs and MRIs
were also used to investigate non-AD causes of cognitive impairment such as white matter
loss or lacunar infarcts. Any subject with a significant number of lacunar infarcts, a sin-
gle strategically located lacunar infarct, or significant white matter loss (>25%) were not
considered for this study.
Additional exclusion criteria for the study were: (1) uncontrolled mood or psychiatric
symptoms in the 6 months prior to study enrolment; (2) use of anti-depressant with anti-
cholinergic side effects; (3) use of psychoactive medication excluding anti-depressants,
neuroleptics, chronic anxiolytics, opioid pain relievers, or sedative hypnotics within the
four weeks prior to study enrolment; (4) enrolment in a clinical trial using an investiga-
tional medication; and (5) contraindications to ultra-high field MRI scanning. All subjects
were aged between 55-90 years old and had a Geriatric Depression Score (GDS) less than
6. Subjects taking cholinesterase inhibitors and/or memantine were included if they were
on a stable dose for at least 12 weeks prior to study enrolment. In general, the inclusion,
exclusion, and diagnostic criteria used in this study were consistent with the criteria used
by the Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2) study [48].
2.2.2 Data Acquisition
2.2.2.1 Magnetic Resonance Imaging
All subjects were scanned on a 7 T/70 cm Siemens MAGNETOM (Siemens, Erlangen, Ger-
many) head-only MRI system at the Centre for Functional and Metabolic Mapping, Ro-
barts Research Institute with an 8-channel transmit, 32-channel receive whole head array
[49]. The scanner is equipped with eight 1000W radiofrequency amplifiers and a gradient
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system (80 mT/m maximum gradient strength, 350 mT/m/s slew rate) that includes sec-
ond order, third order, and Z4 shims. Whole-brain, 3D T1-weighted anatomical images and
T1 maps were acquired using the MP2RAGE pulse sequence [50] with 0.75 mm isotropic
resolution, a repetition time (TR) of 6000 ms, and an echo-time (TE) of 2.83 ms.
2.2.2.2 Magnetic Resonance Spectroscopy
1H-MRS data were acquired from all subjects using an implementation of the semi-LASER
(localization by adiabatic selective refocusing) sequence described in detail elsewhere
[51, 52, 53]. Voxel positions were manually positioned within the high-resolution, 3D T1
weighted anatomical images using anatomical landmarks. Examples of the voxel place-
ments are given in Figure 2.1a and Figure 2.1b. Water suppressed and unsuppressed 1H-
MRS data were collected from a 23× 12× 12 mm3 voxel in the left hippocampus (Figure
2.1a) and a 16× 20× 18 mm3 voxel in the PCC (Figure 2.1b) with the following parameters:
TR=7500 ms, TE=60 ms, number of points=2048, bandwidth=6024 Hz, averages=64 for the
water suppressed data, averages=4 for the water unsuppressed data. Hippocampal spec-
troscopy data could not be acquired in two NEC subjects, one MCI subject, and three AD
subjects. PCC spectroscopy data were successfully acquired from all subjects.
2.2.2.3 Diffusion Weighted Imaging
Diffusion weighted images covering the whole brain were also acquired from all subjects
using a single-shell, multi-shot, diffusion-weighted, spin-echo, echo-planar imaging (EPI)
sequence with b=1000 s/mm3, 64 gradient directions, 2× 2× 2 mm3 resolution, TR=5100
ms, and TE=50.2 ms. To facilitate corrections of distortions induced by the EPI sequence,
two b=0 s/mm3 images were acquired with the same sequence – one with the phase en-
code direction in the anterior-to-posterior direction and the other with the phase encode
direction in the posterior-to-anterior direction.
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FIGURE 2.1: Examples of spectroscopy voxel placement and representative spectra in the
left hippocampus (a, c) and PCC (b, d). The fitted model is shown in (c) and (d) along with
the individual metabolite components. In the left hippocampus (e), MCI and AD subjects
had significantly lower glutamate concentrations measured by 1H-MRS than NEC subjects
(p < 0.05). In the PCC (f), the average N-acetyl aspartate (NAA) concentrations measured
by 1H-MRS were lower in MCI and AD compared to NEC subjects (p < 0.05). Standard
errors are shown in (e) and (f).
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2.2.2.4 Cognitive Testing
Subjects were first assessed using the Clinical Dementia Rating (CDR) scale and the Geri-
atric Depression Scale (GDS) to ensure that the inclusion criteria for the study were met.
Since MCI and AD subjects were already assessed using the mini-mental state examina-
tion (MMSE) and the Montreal cognitive assessment (MoCA) as part of standard clinical
care, the episodic memory of study subjects was tested using neuropsychological tests not
used in clinic to avoid learning effects. Specifically, the Craft Story 21 Recall (CSR) [54] and
the Benson Complex Figure Copy (BCFC) [55] tests from the National Alzheimer’s Co-
ordinating Centre Neuropsychological Battery Version 3.0 [56] were used. Research staff
administering the cognitive testing were trained by a licensed neuropsychological in ac-
cordance with Washington University protocols. Raw test scores were converted into age,
sex, and years of education adjusted z-scores based on published norms [56]. Test z-scores
were used for all further analyses. One NEC subject did not agree to provide information
about their years of education and was therefore excluded from all analyses involving their
cognitive testing data.
2.2.3 Data Processing
2.2.3.1 Post-Processing of Acquired Images
Brain extraction was performed on the T1 weighted anatomical images, T1 maps, and diffu-
sion weighted images using a registration-based method. First, a transformation between
T1-space and standard MNI152-space was found by registering the T1 weighted anatomi-
cal image and the MNI152 T1 weighted template. The registration was performed by first
using a 6 degree-of-freedom (DOF) linear registration, followed by a 12 DOF linear registra-
tion, and non-linear registration. Linear and non-linear registrations were performed using
FMRIB’s linear image registration tool (FLIRT) [57, 58] and FMRIB’s non-linear imaging
registration tool (FNIRT), respectively. These tools are part of FMRIB’s Software Library
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(FSL), version 5.0.10 [59, 60, 61]. Using the resulting transformation matrix, the MNI152
brain mask was then transformed in T1-space and applied to the anatomical images and
T1-maps.
Since EPI sequences are prone to susceptibility distortions, the diffusion weighted im-
ages were distortion-corrected using an estimated susceptibility off-resonance field, de-
rived from the two b=0 s/mm3 images acquired with opposite phase encode directions.
The topup tool from FSL [62] was used to apply this correction. Other distortions induced
by eddy currents and subject motion were then corrected using the FSL eddy tool [63]. This
processing also generated a distortion-corrected b=0 s/mm3 image.
A transformation from T1-space to diffusion-space was found by linearly registering
the T1 weighted anatomical image and the distortion-corrected b=0 s/mm3 image using
the FSL epi_reg script. Applying the previously found MNI152-space to T1-space transfor-
mation matrix and the T1-space to diffusion-space transformation matrices in series trans-
formed the MNI152 brain mask into diffusion-space for brain extraction of the diffusion
weighted images. Then, using the FSL dtifit command-line program, a diffusion tensor
model was fitted to every voxel within the brain-extracted diffusion weighted images, and
subject-specific fraction anisotropy (FA), radial diffusivity (RD), and axial diffusivity (AxD)
maps were produced. An example of a subject-specific FA map generated from diffusion
tensor fitting of brain-extracted diffusion weighted images is shown in Figure 2.3a.
2.2.3.2 Quantification of Metabolite Concentrations
The 1H-MRS data were first lineshape and eddy current corrected using combined QUAL-
ITY deconvolution and eddy current correction (QUECC) [64] with 400 QUALITY (quan-
tification improvement by converting lineshapes to the Lorentzian type) points [65]. Resid-
ual water in the water suppressed spectrum was removed by subtracting peaks between
4.2 ppm and 5.7 ppm identified by a Hankel singular value decomposition fitting routine
that required no prior knowledge.
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Simulated 7 T semi-LASER prior knowledge templates that included an empirically
measured macromolecule model were fitted in the time-domain to the water suppressed
data using in-house software called fitMAN [66], which uses a Levenberg-Marquardt al-
gorithm [67] to minimize the difference between the data and the template. A detailed
description of the simulations and macromolecule model were described previously [53].
Briefly, the following metabolites were included in the prior knowledge template used to
fit the water suppressed data from the PCC: NAA, N-acetylaspartyl glutamate (NAAG),
choline (Cho), creatine (Cr), myo-inositol (Myo), glutamate (Glu), glutamine (Gln), glu-
tathione (GSH), phosphorylethanolamine (PEth), scyllo-inositol (Scyllo), taurine (Tau), ala-
nine (Ala), glucose (Glc), γ-aminobutyric acid (GABA), glycine (Gly), and lactate (Lac). The
multiplets of NAA were fitted independently, because they experience a different rate of T2
relaxation than the singlet at 2.01 ppm [68]. The prior knowledge template used to fit the
water suppressed data from the left hippocampus did not include PEth and Gly, because
the lower signal-to-noise ratio (SNR) of these data made it difficult to reliably fit these low
amplitude signals.
To reduce the number of variables to be fitted, many parameters describing the line-
shapes of the metabolites were constrained within the prior knowledge template (Table
2.1). Within metabolites, the peak amplitudes, shifts, and phases were fixed relative to one
another. Relative peak amplitudes were not fixed between metabolites, since these are ex-
pected to vary across subjects. Relative peak positions and phases between some metabo-
lites were fixed. For example, the positions and phases of low-amplitude metabolites (e.g.
Ala, GABA, Lac) were linked to the positions and phases of higher-amplitude metabolites
(e.g. NAA, myo-inositol, glutamate). A summary of the parameter constraints is given in
Table 2.1.
Hippocampal and PCC metabolite concentrations ([M]) were obtained as previously
described [69] by using the fitted and corrected amplitudes of the metabolite signals (Ŝm),
the corrected water signal amplitude (ŜW) from each spectroscopy voxel as an internal
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Spectroscopy
Voxel
Reference
metabolite
Linked metabolites Comments
Shift Phase
Left
Hippocampus
NAA NAAG, Lac,
Asp, Glu,
Gln, GSH,
GABA
NAAG, Lac,
Asp, Glu,
Gln, GSH,
GABA,
Myo, Ala,
Glc, Scyllo,
Tau
• Shifts, phases, and ampli-
tudes for Cho and Cr were
not fixed relative to any
reference metabolite. Cho
and Cr were fitted inde-
pendently.
• Relative peak amplitudes
were not fixed between
metabolites, since these
may vary across subjects.
• A single linewidth param-
eter was defined for all
metabolites.
• A single delay time pa-
rameter was defined for
all metabolites.
Myo Ala, Glc,
Scyllo, Tau
Posterior
Cingulate
Cortex
NAA NAAG, Lac,
Asp
NAAG, Lac,
Asp, Ala,
Glc, Gly,
PEth, Scyllo,
Tau, GABA
Myo Ala, Glc,
Gly, PEth,
Scyllo, Tau
Glu Gln, GSH,
GABA
Gln, GSH
TABLE 2.1: A summary of relationships between metabolite parameters in the prior knowl-
edge template [66]. Peak positions (shifts) and phases of low-amplitude metabolites were
linked to the shifts and phases of higher-amplitude metabolites. Within metabolites, peak
amplitudes, shifts, and phases were fixed relative to one another. The following metabo-
lites were included in the prior knowledge template used to fit 1H-MRS data from the PCC:
NAA, NAAG, Cho, Cr, Myo, Glu, Gln, GSH, PEth, Scyllo, Tau, Ala, Glc, GABA, Gly and
Lac. The prior knowledge template used to fit 1H-MRS data from the left hippocampus
did not include PEth and Gly.
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reference, and the concentration of pure water (55.14 M) (Equation (2.1)):
[M] =
Ŝm
ŜW
× 55.14 M× 1
fGM + fWM
(2.1)
where fGM and fWM are, respectively, the grey matter (GM) fraction and white matter (WM)
fraction in the spectroscopy voxels. Multiplication by 1fGM+ fWM in Equation (2.1) produces
tissue concentrations. Without this factor, concentrations within the entire volume of the
spectroscopy voxel would be calculated. Since metabolite signals detected by 1H-MRS orig-
inate from the tissue and not the cerebrospinal fluid (CSF), such voxel concentrations are
biased by the CSF partial volume. Instead, tissue concentrations, which are not affected by
the amount of CSF in the voxel, were calculated in the present study.
The corrected water signal amplitudes from the hippocampus and PCC were obtained
by fitting the water unsuppressed data acquired from the respective regions with a prior
knowledge template containing a single Lorentzian at 4.7 ppm. The fitted amplitude was
first corrected for the number of averages used during data acquisition (NWavg), for any gain
and scaling factors applied to the data (GW), and for the number of 1H-MRS visible nuclei
in water (ρW). Next, a correction for the T1 and T2 relaxation rates of water in GM, WM,
and CSF was applied. This requires the GM, WM, and CSF fractions in the spectroscopy
voxels, as well as the T1 and T2 values of water in each tissue compartment. To estimate the
GM, WM, and CSF fractions in the spectroscopy voxels, image voxels in the T1 weighted
anatomical images were first classified as GM, WM, or CSF using FMRIB’s Automated
Segmentation Tool (FAST) [70]. Then, within each spectroscopy voxel, the number of GM,
WM, and CSF image voxels were divided by the total number of image voxels to obtain
the GM fraction ( fGM), the WM fraction ( fWM), and CSF fraction ( fCSF), respectively. The
T1 values used for this correction were 2.1 s, 1.2 s, and 4.4 s for water in GM, WM, and
CSF, respectively, and were obtained directly from literature [71]. The T2 value of water in
GM, WM, and CSF were estimated using T2 measurements made by [68] in the occipital
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lobe, motor cortex, and cerebellum. Estimated T2 relaxation time constants of water were
47 ms, 45 ms, and 66 ms for GM, WM, and CSF, respectively. A correction for the relative
proton density of water in GM (αWGM), WM (α
W
WM), and CSF (α
W
CSF) as compared to that of
pure water was also incorporated into this correction. Values used for αWGM, α
W
WM, and α
W
CSF
were 0.82, 0.73, and 1.00, respectively, and were obtained from [72]. The corrections applied
to the fitted water signal amplitude (AW) are summarized in Equation (2.2) adapted from
[69], where RWGM, R
W
WM, and R
W
CSF are relaxation correction terms using the tissue specific T1
and T2 relaxation rates of water. For example, RWGM =
(
1− e
−TR
TW1,GM
)(
e
−TE
TW2,GM
)
, where TW1,GM
is the T1 of water in GM (2.1 s) and TW2,GM is the T2 of water in GM (47 ms). R
W
WM and R
W
CSF
are similarly defined.
ŜW =
AW
NWavg ρW GW
(
fGMαWGMR
W
GM + fWMα
W
WMR
W
WM + fCSFα
W
CSFR
W
CSF
) (2.2)
The fitted amplitudes of the metabolite signals were also corrected for the number of
averages used during data acquisition (Nmavg), for any gain and scaling factors applied to
the data (Gm), for the number of 1H-MRS visible nuclei in the metabolite (ρm), and for the
T1 and T2 relaxation rates of metabolites in grey matter (GM) and white matter (WM). T1
values of metabolites in GM and WM were obtained from literature, while T2 values of
metabolites in GM and WM were estimated using measurements made by Marjańska et al.
[68] in the motor cortex and cerebellum, Wong et al. [53] in the motor cortex, and Ryan et
al. [73] in the motor cortex.
Reported tissue fractions and metabolite T2 values were incorporated into the estima-
tion. The T1 and T2 values used for relaxation rate correction are summarized in Table 2.2.
All corrections applied to the fitted metabolite amplitudes are summarized in Equation
(2.3) from [69], where K is the number of peaks for metabolite m and Amk is the kth peak
of the metabolite. RmGM and R
m
WM are relaxation correction terms using the T1 and T2 relax-
ation rates of metabolite m in GM and WM. For example, RmGM =
(
1− e
−TR
Tm1,GM
)(
e
−TE
Tm2,GM
)
,
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where Tm1,GM is the T1 of metabolite m in GM and T
m
2,GM is the T2 of metabolite m in GM.
RWWM is similarly defined.
Ŝm =
∑Kk A
m
k
Nmavg ρm Gm
(
fGM
fGM+ fWM
RmGM +
fWM
fGM+ fWM
RmWM
) (2.3)
2.2.3.3 Tractography and Diffusion Metrics in the Cingulum
To study the relationship between spectroscopy measurements to MRI-derived measures
of neuronal injury in the cingulum, the left cingulum of each subject was reconstructed
using diffusion-based tractography. Two separate segments, as defined by Wakana et al.
[77], were identified: the cingulate gyrus portion that runs along the cingulate gyrus, and
the hippocampal portion that runs along the ventral side of the hippocampus. As shown
in Figure 2.2, the cingulate gyrus portion passed through the spectroscopy voxel placed in
the PCC, while the hippocampal portion passed through both spectroscopy voxels.
The cingulate gyrus portion was identified using whole-brain tractography followed by
an atlas-based technique to select only those tracts that belonged to the cingulum. First, the
T1 weighted anatomical image was transformed into diffusion-space using the previously
found transformation matrix. From this image, a WM mask was generated using FSL FAST.
Then, Bayesian probabilistic tracking with a diffusion tensor model [78] was performed on
the brain-extracted diffusion weighted images (Figure 2.3a) using every voxel in the WM
mask as a seed voxel. The produced tracts were refined using an exclusion region of interest
(ROI) defined based on the left cingulum/cingulate gyrus mask (label #5) from the 2 mm
probabilistic John’s Hopkins white matter tractography atlas thresholded at zero [79, 80].
This thresholded atlas was included with FSL. The mask was transformed from MNI152-
space into the subject-specific diffusion-space using the previously found transformation
matrices (Figure 2.3b1). Only tracts that lay completely within this mask were retained.
Any tracts that touched the edge of the mask were discarded. Tracts that were shorter than
86
2.2. Materials and Methods
Metabolite T1 [s] T2 [ms]
GM WM Reference GM WM Reference
NAA 1.83 1.9
Xin et al. [74]
224 143 Estimated using
reported values
from Marjańska
et al. [68], Wong
et al. [53], and
Ryan et al. [73]
NAAG 1.21 0.94 224b 143b
Ala 1.28a 1.19a 201a 71a
GABA 1.334d 1.334d Andreychenko
et al. [75]
87d 87d Andreychenko
et al. [75]
Asp 1.28a 1.19a
Xin et al. [74]
201a 71a
Estimated using
reported values
from Marjańska
et al. [68], Wong
et al. [53], and
Ryan et al. [73]
Cho .151 1.32 248 102
Cre 1.74 1.78 148 119
Glc 1.28a 1.19a 201a 71a
Glu 1.61 1.75 176 57
Gln 1.64 1.74 176c 57c
GSH 1.14 1.06 86 89
Gly 1.28a 1.19a 201a 71a
Myo 1.28 1.19 201 71
Scy 1.31 1.23 148 115
Lac 1.28a 1.19a 201a 71a
PEth 1.31 1.32 201 71
Tau 2.15 2.09 142 86
a T1 and T2 values of metabolites which could not be determined were assumed to be similar
to that of Myo [76, 68].
b T2 values of NAAG were assumed to be similar to that of NAA [68].
c T2 values of Gln were assumed to be similar to that of Glu [68].
d T1 and T2 values of GABA were assumed to the same in both GM and WM, as Andreychenko
et al. [75] did not report separate values for GM and WM.
TABLE 2.2: A summary of the metabolite-specific T1 and T2 values used for relaxation
correction of the fitted metabolite signals. T1 values were obtained directly from the liter-
ature, whereas T2 values were estimated using different reported values in literature (see
text for details). The same T1 and T2 values were used for spectra acquired from both the
hippocampus and the PCC.
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FIGURE 2.2: Three dimensional transparent whole brain (grey) of a single subject in two
different orientations showing the position of the spectroscopy (green shaded regions) in
relation to the left cingulum fibre tracts reconstructed using diffusion-based probabilis-
tic tractography. Two separate segments as defined by Wakana et al. [77] were identified
(black labels): the cingulate gyrus portion that runs along the cingulate gyrus, and the
hippocampal portion that runs along the ventral side of the hippocampus. The cingu-
late gyrus portion passed through the spectroscopy voxel (green shaded region) placed in
the PCC, while the hippocampal portion passed through both spectroscopy voxels (green
shaded regions). The colours in the fibre tracts represent the FA values along the cingulum.
the mean tract length minus one standard deviation were also discarded. An example of
the result is shown in Figure 2.3c1.
The hippocampal portion of the cingulum was also identified using Bayesian tractog-
raphy. However, instead of using an atlas, the tractography was constrained by the spec-
troscopy voxels. Every image voxel within the left hippocampal spectroscopy voxel was
used to seed the tractography and every image voxel within the PCC spectroscopy voxel
was used as a waypoint. With this approach, only tracts that began in the hippocampal
spectroscopy voxel and passed through the PCC spectroscopy voxel were identified. Tracts
were grouped based on geometric similarity using spectral clustering [81, 82] and only the
cluster of tracts with a geometry that matched the hippocampal portion of the cingulum
was retained (Figure 2.3b2). Of those tracts, any that were shorter than the mean tract length
of the cluster minus one standard deviation were also discarded. An example of the result
is shown in Figure 2.3c2.
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The identified tracts were then modelled as cubic B-splines and re-parameterized to
33 vertices to facilitate between-group statistical analysis [83]. Diffusion metrics were as-
signed to each vertex of the B-spline by selecting the metric value from the corresponding
image voxel in the previously generated FA, RD, and AxD maps. An example of this is
shown in Figure 2.2, Figure 2.3c1, and Figure 2.3c2, where the colours represent the FA
measurement along the tracts. Tissue T1 values were also assigned to each vertex, by first
transforming the T1 map to diffusion-space using the previously found transformation ma-
trix, and then selecting the T1 value from the corresponding image voxel. The metrics were
averaged across corresponding vertices to obtain mean measures of FA, RD, AxD, and T1
along the cingulum. An example of the mean FA plotted with respect to position along the
cingulum for a single subject is shown in Figure 2.3d1 and Figure 2.3d2.
2.2.4 Statistical Analyses
Statistical analyses for the spectroscopy data were performed using GraphPad Prism 7.00
for Windows (GraphPad Software, La Jolla, California, United States of America). Before
analysis, outliers were first identified using Grubbs’ method [84] with the significance level
(α) set to 0.05. As a result, one AD subject was an outlier and removed from the analysis
of the hippocampal spectroscopy data. A one-way analysis of variance (ANOVA) was per-
formed for each measured metabolite to identify between-group differences at α = 0.05. If
a significant difference among group means was found, a post-hoc between-group compar-
ison using Fisher’s least significant differences (LSD) test was performed. For three groups
at α = 0.05, Fisher’s LSD guarantees that the familywise error rate (FWER) does not exceed
0.05 [85].
Cognitive testing data were analyzed in a similar way. An ANOVA was performed
for each of the scores obtained from the CSR and BCFC tests to identify between-group
differences at α = 0.05. If the group effect was significant, a post-hoc LSD test with α = 0.05
was performed to identify statistically significant differences between groups.
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FIGURE 2.3: Diffusion-based tractography of the left cingulum. For both the cingulate
gyrus portion and hippocampal portion of the cingulum, Bayesian probabilistic track-
ing with a diffusion tensor model [78] was performed on the brain-extracted diffusion
weighted images shown in (a).
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FIGURE 2.3: The produced tracts were refined using an atlas-based exclusion region of
interest (b1), to identify the cingulate gyrus portion of the cingulum (c1). Using the spec-
troscopy voxels as seeds and waypoints, and discarding those tracts that were not geomet-
rically similar to the hippocampal portion of the cingulum (b2), the hippocampal portion
of the cingulum was identified (c2). The identified tracts of the cingulum were modelled as
B-splines, and diffusion metrics were assigned to each vertex of the B-spline, as shown in
(c1) and (c2), where the colours represent the FA values along the cingulum. These metrics
were averaged across corresponding vertices to obtain mean measures along the cingu-
lum, as shown in (d1) and (d2).
To determine whether along-cingulum metrics changed between groups, a linear mixed
effect regression as described in [83] was performed for each metric and for each pairwise
comparison. The regression contains a vertex-by-group interaction that tests whether the
effect of group on a metric varies based on position along the tract. If an ANOVA of the
vertex-by-group interaction term was significant at α = 0.05, linear mixed effect regres-
sions were performed at each vertex to test whether there was an effect of group on a
metric. If the effect was significant at a level of α = 0.05, the metric was considered to
be different between groups at that tract position. Statistical analyses of along-cingulum
diffusion measures were performed in R [86].
For both the hippocampal and cingulate gyrus portions of the cingulum, the diffusion
metric values in the largest continuous region of statistical difference between groups were
averaged and used to examine association with the spectroscopy measurements that were
significantly different between groups. The averaged diffusion metric values were also
correlated with the CSR and BCFC scores. Finally, the spectroscopy measurements that
differed between groups were correlated with the CSR and BCFC scores. All correlations
were Pearson correlations performed at the one-tailed α of 0.05 using GraphPad Prism 7.00.
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2.3 Results
2.3.1 Magnetic Resonance Spectroscopy
Spectra acquired in the hippocampus (Figure 2.1c) had an average (± SD) SNR of 28± 10,
defined as the height of the absolute signal at the position of the NAA CH3 peak divided
by the standard deviation (SD) of the noise. The average (± SD) linewidth was 17.4± 6.3
Hz. The voxel contained on average (± SD) 56± 8% grey matter, 25± 6% white matter,
and 19± 9% CSF. There was a significant group effect on glutamate concentration in the
left hippocampus (F(2, 24) = 3.61, p < 0.05). As shown in Figure 2.1e, post-hoc analysis
indicated that MCI and AD subjects had significantly lower left hippocampal glutamate
levels than NECs (p < 0.05). Group differences were not detected in other metabolite con-
centrations in the left hippocampus.
Spectra acquired in the PCC (Figure 2.1d) had an average (± SD) SNR of 94± 24 and
an average (± SD) linewidth of 14.0 ± 3.5 Hz. The voxel contained on average (± SD)
52± 7% grey matter, 29± 6% white matter, and 19± 8% CSF. In the PCC, a significant group
effect on NAA concentration was found (F(2, 30) = 6.91, p < 0.01). Post-hoc analysis
indicated that AD subjects had significantly lower NAA levels in the PCC than NECs (p <
0.01, Figure 2.1f). MCI subjects also had significantly lower NAA levels in the PCC than
NECs (p < 0.05, Figure 2.1f). Group differences were not detected in other metabolite
concentrations in the PCC.
2.3.2 Diffusion in the Cingulum
In the hippocampal portion of the cingulum, no significant vertex-by-group effect was
found for the FA metric (Figure 2.4b). No significant vertex-by-group effects were found
for any metric when comparing NEC subjects to MCI subjects. However, when compar-
ing NEC subjects to AD subjects, a significant vertex-by-group effect was found for the
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RD (F(32, 640) = 1.68, p < 0.05), AxD (F(32, 640) = 2.78, p < 1 × 10−6), and T1
(F(32, 640) = 1.935, p < 0.01, Figure 2.4e) metrics. A significant vertex-by-group effect was
also found for the RD (F(32, 352) = 1.78, p < 0.01), AxD (F(32, 352) = 1.95, p < 0.01), and
T1 (F(32, 352) = 2.08, p < 0.001) metrics when comparing MCI subjects to AD subjects.
Along-tract analyses showed that the AD group had significantly higher RD (p < 0.05,
Figure 2.4c), AxD (p < 0.05, Figure 2.4d), and T1 (p < 0.05, Figure 2.4e) in the first 25% of
the hippocampal cingulum than the NEC and MCI groups. These differences are shown in
the p-value plots provided in Figure 2.4b-e, where p < 0.05 between groups is highlighted
in green.
In the cingulate gyrus portion of the cingulum, no significant vertex-by-group effect
was found for any metric when comparing NEC subjects to MCI subjects. A significant
vertex-by-group effect was found for the FA (F(32, 704) = 1.82, p < 0.01) and RD
(F(32, 704) = 1.46, p < 0.05) when comparing NEC subjects to AD subjects. When com-
paring MCI subjects to AD subjects, a significant vertex-by-group effect was also found for
the FA (F(32, 448) = 1.52, p < 0.05), and RD (F(32, 448) = 1.95, p < 0.01) metrics. No
other significant vertex-by-group effects were found. Along-tract analyses showed that the
AD group had significantly lower FA (p < 0.05, Figure 2.5b) and higher RD (p < 0.05, Fig-
ure 2.5c) than the NEC and MCI groups in the last 60-90% of the cingulate gyrus portion of
the cingulum.
2.3.3 Tests of Episodic Memory
Significant group effects were found for the CSR verbatim z-scores (immediate: F(2, 31) =
15.9, p < 0.0001; delayed: F(2, 31) = 20.92, p < 0.0001) and the CSR paraphrase z-scores
(immediate: F(2, 31) = 16.44, p < 0.0001; delayed: F(2, 31) = 28.45, p < 0.0001). Post-
hoc analysis showed that MCI and AD subjects had lower verbatim scores than NEC sub-
jects (immediate: p < 0.001, delayed: p < 0.0001). MCI and AD subjects also had lower
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FIGURE 2.4: Diffusion metrics plotted as a function of the position along the hippocampal
portion of the cingulum. The position along this tract is defined in (a), with the start of
the tract in the left hippocampus and the end of the tract in the posterior cingulate cortex.
In each of (b), (c), (d), and (e), the diffusion metric of individual subjects at each position
along the tract are shown semi-transparently in the background of the top panels and are
overlaid with the smoothed estimates of the group means (thick lines). The pointwise 95%
confidence intervals are shown in grey. In the bottom panels, the results of between-group
analyses are plotted with respect to position. No differences between groups were found
along the tract for the FA metric (b). As shown in (c), (d), and (e), respectively, the AD
group had significantly higher RD (p < 0.05), AxD (p < 0.05), and T1 (p < 0.05) in the first
25% of the hippocampal cingulum than the NEC and MCI groups. This pattern of changes
in the AD group may be interpreted as the result of a loss of neurons in the hippocampus.
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FIGURE 2.5: Diffusion metrics (FA and RD) as a function of the position along the cingulate
gyrus portion of the cingulum. The position along this tract is defined in (a), with the
start of the tract in the anterior cingulate cortex and the end of the tract in the posterior
cingulate cortex. In (b) and (c), the diffusion metric of individual subjects at each position
along the tract are shown semi-transparently in the background of the top panels and are
overlaid with the smoothed estimates of the group means (thick lines). The pointwise 95%
confidence intervals are shown in grey. In the bottom panels, the results of between-group
analyses are plotted with respect to position. As shown in (b) and (c), respectively, the AD
group had significantly lower FA (p < 0.05) and higher RD (p < 0.05) than the NEC and
MCI groups in the last 60-90% of the cingulate gyrus portion of the cingulum. This pattern
of changes in the AD group may be interpreted as a demyelination process.
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paraphrase scores (immediate: p < 0.001, delayed: p < 0.0001). For the BCFC test, a sig-
nificant group effect was found for the BCFC delayed verbatim z-score (F(2, 31) = 17.9,
p < 0.0001). Post-hoc analysis revelaed that MCI and AD subjects ahd lower scores than
NEC subjects (p < 0.0001). Means and standard deviations of the test scores are provided
in Supplementary Table 2.S1.
2.3.4 Correlations
Metabolite levels in the hippocampus and PCC shown to be different between groups were
examined for associations with diffusion measures in the cingulum (Figure 2.6). Specif-
ically, left hippocampal glutamate level was inversely correlated with the average RD
(r = −0.40, p < 0.05, Figure 2.6a) and AxD (r = −0.51, p < 0.01, Figure 2.6b) in the
first 25% of the hippocampal cingulum. NAA levels in the PCC were also inversely cor-
related with the average RD (r = −0.46, p < 0.01, Supplemental Figure 2.S1a) and AxD
(r = −0.35, p < 0.05, Supplemental Figure 2.S1b) in this portion of the cingulum. In the
last 60-90% of the cingulate gyrus portion of the cingulum, NAA level in the PCC was in-
versely correlated with RD (r = −0.42, p < 0.05, Figure 2.6c), T1 (r = −0.61, p < 0.001,
Figure 2.6d), and positively correlated with FA (r = 0.37, p < 0.05, Figure 2.6e).
Metabolite levels in the hippocampus and PCC that were different between groups
were also examined for associations with measures of episodic memory performance (Fig-
ure 2.7). Left hippocampal glutamate levels were positively correlated with the delayed
CSR paraphrase z-score (r = 0.40, p < 0.01, Figure 2.7a), the delayed BCFC z-score
(r = 0.40, p < 0.05, Figure 7b), and the delayed CSR verbatim z-score (r = 0.39, p < 0.05,
Supplemental Figure 2.S2). NAA levels in the PCC were also positively correlated with
CSR and BCFC z-scores. Specifically, NAA in the PCC was correlated with the delayed
CSR paraphrase z-score (r = 0.43, p < 0.01, Figure 2.7c), the delayed BCFC z-score
(r = 0.46, p < 0.01, Figure 2.7d), the immediate CSR verbatim z-score (r = 0.43, p < 0.01,
Supplemental Figure 2.S3a), the immediate CSR paraphrase z-score (r = 0.47, p < 0.01,
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FIGURE 2.6: Significant correlations between the left hippocampal glutamate concentra-
tion and the average RD (r = −0.40, p < 0.05) and AxD (r = −0.51, p < 0.01) in the first
25% of the hippocampal portion of the cingulum are shown with 95% confidence bands
in (a) and (b), respectively. Significant correlations between the NAA concentration in the
PCC and the average RD (r = −0.42, p < 0.05), T1 (r = −0.61, p < 0.001), and the average
FA (r = 0.37, p < 0.05) in the last 60-90% of the cingulate gyrus portion of the cingulum
are shown with 95% confidence bands in (c), (d), and (e), respectively.
97
Chapter 2. Reduced hipp. Glu & PCC NAA is assoc. with ep. memory & WM integrity
FIGURE 2.7: Significant correlations between left hippocampal glutamate concentration
and the delayed Craft Story 21 Recall (CSR) paraphrase score (r = 0.40, p < 0.05)
and the delayed Benson Complex Figure copy (BCFC) score (r = 0.39, p < 0.05) are
shown with 95% confidence bands in (a) and (b), respectively. Significant correlations
between posterior cingulate NAA concentration and the delayed CSR paraphrase score
(r = 0.43, p < 0.05) and the delayed BCFC score (r = 0.46, p < 0.01) are shown with 95%
confidence bands in (b) and (c), respectively.
Supplemental Figure 2.S3b), and the delayed CSR verbatim z-score (r = 0.39, p < 0.05,
Supplemental Figure 2.S3c).
2.4 Discussion
Using 1H-MRS at 7 T, this study measured concentrations of metabolites within the
episodic memory system of people with normal cognition and of people with a clinical
diagnosis of MCI and probable AD. Significant decreases in left hippocampal glutamate
concentration and in posterior cingulate cortex NAA concentrations were found (Figure
2.1) in the MCI and AD groups. Within the cingulum, diffusion-based indicators of white-
matter microstructural integrity showed that the AD group had significantly higher RD,
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AxD, and T1 in the first 25% of the hippocampal cingulum (Figure 2.4) and significantly
lower FA and higher RD in the last 60-90% of the cingulate gyrus portion of the cingulum
(Figure 2.5) compared to the NEC and MCI groups. Both hippocampal glutamate concen-
tration and NAA concentration in the PCC were significantly associated with altered water
diffusion and T1 relaxation within the cingulum (Figure 2.6), as well as episodic memory
performance measured by the CSR and BCFC neuropsychological tests (Figure 2.7).
2.4.1 Posterior Cingulate Cortex
Compared to NEC subjects, both MCI and AD subjects had significantly lower NAA con-
centration in the PCC. This result is consistent with previous studies that have also reported
lower NAA concentration in the PCC of AD and MCI subjects compared to NECs [43, 41,
42].
Since NAA synthesis in the brain requires acetyl-coenzyme A (acetyl CoA) levels that
exceed neuronal metabolic requirements [87], a decrease in NAA concentration in the PCC
likely indicates that energy reserves are low in this region. Indeed, studies using FDG-PET
have consistently shown energy deficits in the PCC of people with AD [88, 89, 90, 91]. This
energy deficit would result in lower acetyl CoA levels and compromise NAA synthesis.
Impaired NAA synthesis could have detrimental downstream effects. NAA is synthe-
sized in neurons, but the enzyme that catabolizes NAA into its component aspartate and
acetate moieties is localized exclusively to oligodendrocytes [92, 93, 94]. The sequential
action of this enzyme, aspartoacylase II (ASPA-II), along with acetyl CoA synthetase-1
(AceCS-1), will convert NAA-derived acetate into acetyl CoA, which could be used by
oligodendrocytes for the synthesis of myelin-associated lipids [95]. Thus, impaired NAA
synthesis could negatively affect myelin repair and remyelination processes.
MRI-derived measures of white matter microstructural integrity in the current study
are consistent with this interpretation. Specifically, the last 60-90% of the cingulate gyrus
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portion of the cingulum, which corresponds anatomically to the posterior cingulate cor-
tex (Figure 2.2, Figure 2.3c1), showed significant differences in MRI-derived measures of
microstructural integrity between AD subjects and NEC subjects. AD subjects had lower
FA, higher RD, but no difference in AxD. This pattern of changes in diffusion metrics is
characteristic of an underlying demyelination process [96]. Further, NAA concentration in
the PCC was significantly associated with this pattern of change – that is, lower NAA con-
centration was associated with lower FA and higher RD. These results, together with the
finding that a lower NAA concentration in the PCC was significantly associated with worse
CSR and BCFC scores, suggests that NAA deficit in the PCC of people with AD could in-
dicate a demyelinating process in the region that manifests as poorer episodic memory
performance.
Importantly, lower NAA concentrations were observed in both MCI and AD subjects
compared to NEC subjects, whereas differences in diffusion metrics were only observed
in AD subjects compared to NECs. This suggests that a decrease in the posterior cingulate
NAA concentration may precede microstructural changes indicative of demyelination in
the region, although a longitudinal study would be required to confirm this hypothesis.
2.4.2 Hippocampus
In the left hippocampus, lower glutamate levels in MCI and AD subjects were observed
in the current study. Consistent with this result, a previous study by our group [39] at 4T
in a different cohort also found significantly lower hippocampal glutamate concentration
in AD subjects compared to NEC subjects, but no significant differences between MCI and
NEC subjects. The lower glutamate levels observed in MCI subjects in the current study is
likely due to the increased sensitivity of 7 T MR spectroscopy or could be attributed to dif-
ferences in the cohort studied. An important methodological difference to consider is that
Rupsingh et al. positioned the spectroscopy voxel in the right hippocampus, while the left
hippocampus was examined in the present study. Measurements in the left hippocampus
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may be sensitive to earlier changes exhibited at the MCI stage, as it is well-known that left
hippocampal atrophy precedes right hippocampal atrophy in AD [23, 97].
The MRI-derived measures of microstructural integrity showed that compared to NEC
subjects, AD subjects had significantly greater RD, AxD, and T1 in the first 25% of the left
hippocampal cingulum, which corresponds anatomically to the left hippocampus (Figure
2.2, Figure 2.3c2). The pattern of RD and AxD changes is characteristic of increased CSF
[98], which could result from overall tissue atrophy. The observed T1 differences also sup-
port this interpretation, as the T1 of CSF water is greater than the T1 of tissue bound water
[71]. Thus, the reduced left hippocampal glutamate concentrations observed in AD sub-
jects may be a result of a loss of neurons in the hippocampus, a region of the brain that is
highly dependent on glutamate signalling [99, 100].
Interestingly, these microstructural changes were not observed in the MCI subjects,
which suggests that the reduced glutamate concentration observed in the MCI subjects
was not the result of the loss of glutamatergic neurons. Rather, it may be related to an
energy deficit in the hippocampus. Reduced glucose metabolism will reduce citrate pro-
duction in neurons, in turn reducing ATP production via the tricarboxylic acid (TCA)
cycle. Indeed, reduced glucose metabolism in the hippocampus of individuals with MCI
have been previously reported [31, 101]. To meet the energy demands of the neuron, glu-
tamate and oxaloacetate can be used by aspartate aminotransferase (AAT) as alternative
substrates for α-ketoglutarate production in a truncated TCA cycle [102]. Interestingly, ex-
cess acetate is produced in this process, which may be acetylated into NAA by L-aspartate
N-acetyltransferase (Asp-NAT). Increased NAA production would facilitate the AAT re-
action, by removing the product inhibition from acetate. In fact, there is evidence of an
upregulated rate of NAA synthesis in AD [103]. Increased NAA production and increased
glutamate consumption due to neuronal energy deficit could also explain why a significant
reduction in left hippocampal glutamate concentration, but no difference in left hippocam-
pal NAA concentration, was observed in the present study.
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This result from the current study is consistent with results previously published by our
group in the right hippocampus, in which no differences in right hippocampal NAA con-
centration were found [39]. However, others have reported NAA concentration differences
in mean bilateral hippocampal NAA concentrations between AD and NEC subjects [40],
as well as significant differences in left hippocampal NAA concentrations between NEC,
MCI, and AD subjects [41]. Methodological differences with respect to the corrections for
the relaxation rates of metabolite signal in each of the GM, WM, and CSF compartments
of the spectroscopy voxel could explain why lower NAA was not observed in either the
current study or in Rupsingh et al.
Left hippocampal glutamate concentration was also observed to be significantly as-
sociated with better CSR and BCFC scores. This, together with the previously discussed
results, suggests that lower glutamate concentration in the left hippocampus could indi-
cate impaired neuro-energetics or a loss of glutamatergic neurons, ultimately manifesting
as poorer episodic memory performance.
2.4.3 Study Limitations
There are several limitations to the present study that should be considered. First, the gen-
eralizability of the results is limited by the small sample size. Nevertheless, significant
differences in metabolite concentrations and diffusion metrics were observed, which may
be due to the improved precision of both spectroscopy and diffusion tensor imaging at the
high magnetic field (7 T) used. In particular, the size of the group effect as measured using
Hays’ ω2 [104] was large for both the hippocampal glutamate concentration (ω2 = 0.162)
and the posterior cingulate NAA concentration (ω2 = 0.264), implying that the study was
sufficiently powered. The results of the present study are also consistent with prior studies,
providing further confidence in the results. Specifically, other studies have independently
shown decreased glutamate in the hippocampus [39, 105], decreased NAA in the posterior
cingulate cortex [42, 43, 105, 106], and microstructural changes in the limbic system [22, 30,
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107, 108] in individuals with AD. Also, power was increased for all correlational analyses
as these were done using all study subjects with successfully acquired spectroscopy data
(N=27 for hippocampal data and N=33 for PCC data), without consideration for group
membership.
Second, participants of this study with AD likely reflected a subset of the clinical pop-
ulation. In addition to changes in episodic memory, many individuals diagnosed with AD
also present with neuropscyhiatric symptoms such as apathy, anxiety, agitation, and de-
pression which typically worsen as the disease progresses [109, 110]. However, the exclu-
sion criteria used in the present study excluded potential participants with neuropsychi-
atric symptoms. All participants int he current study had GDS scores that were less than 6,
indicating none had depressive symptoms. Thus, MCI and AD participants of this study
likely reflect a clinical population with mild disease that lies earlier along the AD con-
tinuum. Furthermore, the inclusion of only subjects without neuropscyhiatric symptoms
eliminates this variable as a cause of the metabolic and microstructural changes observed
in the current study.
Third, the present study used single-voxel 1H-MRS to study metabolite concentrations
in the left hippocampus and the posterior cingulate cortex. The metabolite concentration
measured using single-voxel 1H-MRS is the average tissue concentration within the entire
spectroscopy voxel. As a result, it is not possible to discern whether the observed differ-
ences in hippocampal glutamate concentrations arise from the metabolic pool or the neuro-
transmitter pool. In the PCC, it is also not possible to say whether the observed differences
in the NAA concentration are localized to the neuronal compartment, the oligodendro-
cyte compartment, or both compartments. Another point of caution is that the method of
metabolite quantification used in the present study incorporated T1 and T2 relaxation cor-
rection using values obtained from literature and assumed that metabolite T1 and T2 values
in GM and WM do not change with disease. This was done as it wasn’t possible to measure
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subject-specific metabolite T1 and T2 values due to scan-time constraints. It is also impor-
tant to note here that a field strength of 7 Tesla was used in the present study. 1H-MRS
at ultra-high magnetic fields (4 Tesla and above) benefits from increased SNR and greater
spectral dispersion. This is especially important for glutamate detection, as there is better
separation of glutamate from the overlapping resonances of glutamine and GABA. How-
ever, at clinical field strengths (3 Tesla and below), focused detection of glutamate changes
may benefit from spectral editing techniques such as MEGA-sLASER or MEGA-PRESS
[111, 112].
Fourth, an atlas-based method of tractography was used, rather than the gold stan-
dard of guiding the tractography using manually drawn inclusion and exclusion ROIs. Al-
though an atlas-based method does not suffer from problems such as operator experience,
intra- and inter-operator reproducibility, and ROI placement feasibility [113], it is affected
by the quality of the registration between the subject scan and the atlas. However, even
with just a simple linear registration to the atlas, Zhang et al. has shown good agreement
between manually-guided tractography and an atlas-based technique employing the same
atlas as that used in the present study [114]. Despite the potential loss of precision with
an atlas-based approach to tractography, we were still able to show statistically significant
differences in diffusion metrics along the cingulum between groups.
2.5 Conclusion
This cross-sectional study compared metabolite concentrations in the left hippocampus
and in the PCC between people with MCI, people with AD, and NECs. NAA concentration
in the PCC and glutamate concentration in the left hippocampus were significantly lower
in both MCI and AD subjects and were significantly associated with both MRI-derived
measures of microstructural changes in the cingulum and with episodic memory perfor-
mance. The observed metabolite differences and associated microstructural differences are
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consistent with brain energy deficits caused by AD pathology. Thus, metabolite concentra-
tions measured using 1H-MRS may provide valuable insight into the underlying metabolic
and microstructural processes of episodic memory impairment.
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2.8 Supplementary Figures
FIGURE 2.S1: Significant correlations between NAA levels in the PCC and the average RD
(r = −0.46, p < 0.01) and AxD (r = −0.35, p < 0.05) in the first 25% of the hippocampal
portion of the cingulum are shown with 95% confidence bands in (a) and (b), respectively.
FIGURE 2.S2: Left hippocampal glutamate levels were positively correlated with the de-
layed CSR verbatim z-score (r = 0.39, p < 0.05).
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FIGURE 2.S3: As shown in (a), NAA concentration in the PCC was correlated with the
immediate CSR verbatim score (r = 0.43, p < 0.01). As shown in (b), NAA in the PCC was
correlated with the immediate CSR paraphrase score (r = 0.47, p < 0.01). As shown in (c),
NAA in the PCC was corelated with the delayed CSR verbatim z-score (r = 0.39, p < 0.05).
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2.9 Supplementary Tables
Group
Craft Story Recall (Immediate) Craft Story Recall (Delayed)
Verbatim Paraphrase Verbatim Paraphrase
Mean SD SE Mean SD SE Mean SD SE Mean SD SE
NEC -0.43 0.99 0.25 -0.37 0.95 0.24 -0.37 0.91 0.23 -0.22 0.87 0.22
MCI -2.57 1.06 0.35 -2.69 1.29 0.43 -268 1.16 0.39 -3.20 1.35 0.45
AD -1.90 0.82 0.27 -2.08 0.96 0.32 -2.10 0.65 0.22 -2.47 0.93 0.31
Benson Complex Figure Copy (Immediate) Benson Complex Figure Copy (Delayed)
Mean SD SE Mean SD SE
NEC 0.025 1.18 0.29 -0.22 0.94 0.24
MCI -0.96 1.99 0.66 -2.78 1.66 0.55
AD -0.40 1.19 0.40 -2.58 1.08 0.37
TABLE 2.S1: The group means, standard deviations (SD), and standard errors (SE) of the
Craft Story 21 Recall and Benson Complex Figure Copy z-scores are shown in this table.
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Optimized in vivo glutamate
measurement using long-echo-time
semi-LASER at 7 T
A version of this chapter has been published in NMR in Biomedicine: Dickson Wong, Amy L. Schranz,
and Robert Bartha, “Optimized in vivo brain glutamate measurement using long-echo-time semi-
LASER at 7 T,” NMR Biomed., vol. 31, no. 11, p. e4002, Nov. 2018.
Abstract: A short echo time (TE) is commonly used for brain glutamate measurement by 1H MRS
to minimize drawbacks of long TE such as signal modulation to J evolution and T2 relaxation.
However, J coupling causes the spectral patterns of glutamate to change with TE, and the shortest
achievable TE may not produce the optimal glutamate measurement. The purpose of this study
was to determine the optimal TE for glutamate measurement at 7 T using semi-LASER (localiza-
tion by adiabatic selective refocusing). Time-domain simulations were performed to model the TE
dependence of glutamate signal energy, a measure of glutamate signal strength, and were verified
against measurements made in the human sensorimotor cortex (five subjects, 2× 2× 2 cm3 voxel,
16 averages) on a 7 T MRI scanner. Simulation showed a local maximum of glutamate signal energy
at TE = 107 ms. In vivo, TE = 105 ms produced a low Cramér-Rao lower bound of 6.5± 2.0% across
subjects, indicating high-quality fits of the prior knowledge model to in vivo data. TE = 105 ms also
produced the greatest glutamate signal energy with the smallest inter-subject glutamate-to-creatine
ratio (Glu/Cr) coefficient of variation (CV), 4.6%. Using these CVs, we performed sample size calcu-
lations to estimate the number of participants per group required to detect a 10% change in Glu/Cr
between two groups with 95% confidence. 13 were required at TE = 45 ms, the shortest achievable
echo time on our 7 T MRI scanner, while only 5 were required at TE = 105 ms, indicating greater
statistical power. These results indicate that TE = 105 ms is optimum for in vivo glutamate mea-
surement at 7 T with semi-LASER. Using long TE decreases power deposition by allowing lower
maximum RF pulse amplitudes in conjunction with longer RF pulses. Importantly, long TE mini-
mizes macromolecule contributions, eliminating the requirement for acquisition of separate macro-
molecule spectra or macromolecule fitting techniques, which add additional scan time or bias the
estimated glutamate fit.
122
3.1. Introduction
3.1 Introduction
Glutamate is the primary excitatory neurotransmitter in the brain enabling synaptic com-
munication between neurons [1]. Levels of glutamate have been shown to be altered in
several neurological conditions including Alzheimer’s disease [2] and epilepsy [3]. Such
changes are thought to precede structural alterations and may be a valuable biomarker for
disease detection and treatment.
Proton MRS (1H-MRS) may be used to non-invasively and directly measure levels of
metabolites, such as glutamate. Using chemical shift imaging or single-voxel acquisition
techniques, spectra can be acquired from specific brain regions relevant to various neuro-
logical diseases, such as the primary motor cortex [4], the hippocampus [2], and the an-
terior cingulate cortex [5]. Although glutamate can be difficult to resolve at clinical field
strengths, 1H-MRS at ultra-high magnetic fields, such as 4 T and above, benefits from
increased signal-to-noise ratio (SNR) and greater spectral dispersion. These factors lead
to better separation of glutamate from the overlapping resonances of glutamine and γ-
aminobutyric acid (GABA), increasing quantification accuracy and precision [6, 7].
However, high-field 1H-MRS suffers from increased chemical shift displacement error,
increased B1 inhomogeneity, greater power deposition, and shorter T∗2 relaxation times. Lo-
calization by adiabatic selective refocusing (LASER) [7, 8], or variants such as semi-LASER
[9, 10], can overcome many of these limitations by utilizing adiabatic full passage (AFP)
refocusing pulses. AFP pulses are robust to B1 inhomogeneity and have a bandwidth in-
dependent of B1 amplitude, reducing the chemical shift displacement error and producing
well-defined excitation profiles. A downside to AFP pulses is that they must be made rel-
atively long to reduce peak B1 amplitude and stay below power deposition limits. Also,
to refocus non-linear phase dispersion across an excited slice, AFP pulses must be used in
pairs, increasing the total number of RF pulses that are played out. These requirements typ-
ically limit the minimum achievable echo times to be in the 38–50 ms range at 7 T [11, 10],
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in contrast to the widely used spectroscopy sequences PRESS (point-resolved spectroscopy
[12]) and STEAM (stimulated echo acquisition mode [13]), where echo times under 10 ms
can be achieved at high field [14, 15, 16, 17].
To detect and measure strongly J-coupled spin systems such as glutamate using 1H-
MRS, the shortest achievable echo time is normally used to minimize signal modulation
due to J evolution and T2 relaxation. However, J coupling causes the spectral patterns of
glutamate to change in a complex pattern as a function of echo time. Thus, it is possible that
the shortest achievable echo time does not produce the optimal glutamate measurement
using semi-LASER at 7 T, and that a longer echo time is preferred. Shorter echo times
also increase the contribution of macromolecule resonances that overlap with glutamate
resonances [18], which confounds metabolite fitting and quantification. A longer echo time
would remove this complication.
The purpose of this study was to determine the optimal echo time for glutamate mea-
surement at 7 T using semi-LASER. Time-domain simulations were initially performed to
model the echo-time dependence of the glutamate signal energy, a measure of glutamate
signal strength. Human in vivo experiments and phantom in vitro experiments performed
on a 7 T MRI scanner showed a similar echo-time dependence to the simulations. In vivo,
the shortest achievable echo time was suboptimal, as both glutamate signal energy and
measurement precision were maximized at longer echo times.
3.2 Methods
3.2.1 Time-domain simulations
To investigate glutamate signal amplitude changes as a function of echo time, the gluta-
mate spectrum was simulated for 7 T using the PyGAMMA library of the VeSPA (Versatile
Simulation, Pulses and Analysis) software suite [19]. Direct use of the PyGAMMA code li-
brary rather than the VeSPA graphical user interface allowed the exact replication of the RF
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pulse shapes from the MRI scanner, the calibration of the pulses to ensure adiabaticity, and
the running of multiple simulations in parallel, all within a single Python program. The
simulations only included the RF pulses of the semi-LASER sequence. No spatial localiza-
tion was included in the simulations, as RF pulse bandwidths minimized chemical shift
artefacts. Previously measured chemical shift and J-coupling constants [20] were used to
define the glutamate spin system. These values were used by PyGAMMA to perform time-
domain density matrix calculations and to incorporate J-coupling effects into the simula-
tion outputs. Positions, amplitudes, and phases of the glutamate peaks were obtained from
the simulations. Using these parameters, the glutamate free-induction decay (FID) signal
was reconstructed as a function of time (t) using
FID(t) = e−
t+TE
T2 e−παt ∑
k
ckej(2πωkt+φk) (3.1)
where TE is echo time, T2 is the T2 relaxation time constant of glutamate in the motor
cortex (98 ms) [21], ωk is the chemical shift, ck is the amplitude, and φk is the phase of
the kth peak of glutamate. α is the Lorentzian linewidth for all peaks and was set to 10 Hz,
which was typically observed in our in vivo data collected from the sensorimotor cortex.
Equation (3.1) is consistent with the model equation described by Bartha et al. [22], which
was used in the present study to analyse in vivo spectra. This consistency allows the direct
comparison of simulation results with in vivo results.
After reconstruction of the glutamate FID, the energy of the signal, a measure of signal
strength, was calculated using [23]
E =
∫ T
0
|FID(t)|2 dt (3.2)
where T is the total acquisition time of the FID. Signal energy was used as the optimization
metric rather than simply optimizing over peak area in the frequency domain because the
magnitude of the FID incorporates both peak area and T2 information [24].
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This process was repeated for echo times ranging from 45 ms to 215 ms (1 ms step size).
These echo times represent the shortest and longest achievable echo times for semi-LASER
on our 7 T MRI scanner.
3.2.2 1H-MRS acquisition
3.2.2.1 Hardware and shimming
All 1H-MRS data were collected on a 7 T/70 cm Siemens MAGNETOM (Siemens, Erlangen,
Germany) head-only MRI system at the Centre for Functional and Metabolic Mapping,
Robarts Research Institute. An 8-channel transmit, 32-channel receive whole head array
[25] that can achieve a maximum transmit B1 of 16 µT in the sensorimotor cortex was used.
The scanner is equipped with eight 1000 W RF amplifiers and a gradient system (80
mT/m maximum gradient strength, 350 mT/m/s slew rate) that includes second order,
third order, and Z4 shims. Prior to data collection, localized B0 and B1 shimming were
performed. The B0 field was optimized using a two-echo gradient recalled echo shimming
technique [26, 27, 28, 29]. The B1 field was optimized using an algorithm in which the
phases of the transmit channels were set to add constructively within the MRS voxel. This
maximized the B1 field in the MRS voxel, producing the most power efficient shim. B1 field
optimization incorporated field mapping as outlined by Curtis et al [30].
3.2.2.2 Pulse sequence
The semi-LASER pulse sequence was used to acquire all spectral data. This sequence has
been described in detail by Öz and Tkáč [9]. In the current implementation, a 4 ms asym-
metric, slice-selective, sinc excitation pulse [31] and 8 ms hyperbolic secant AFP refocus-
ing pulses (HS4, R = 25) [10] were used. Interleaved VAPOR (variable pulse power and
optimized relaxation delays) water suppression and outer-volume suppression (OVS) pre-
ceded the semi-LASER sequence. The VAPOR scheme was identical to that described by
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Öz and Tkáč [9]. The OVS scheme was also identical, except that the crusher gradients
ranged from 1 to 7 ms in duration and from 1 to 6 mT/m in strength. Prior to each experi-
ment, the strength of the excitation pulse and the flip angle for VAPOR water suppression
were optimized. The readout time was 340 ms with a 166 µs dwell-time (N = 2048, SW =
6024 Hz).
3.2.3 In vivo data
3.2.3.1 Acquisition
In vivo 1H-MRS data were obtained from five healthy individuals (four males, one female,
average age 25± 3 years). Informed consent was obtained according to the procedures ap-
proved by the Health Sciences Research Ethics Board at The University of Western Ontario.
1H-MRS data were collected from a single 2× 2× 2 cm3 voxel in the left sensorimotor cor-
tex (see Figure 3.2e later) at echo times ranging from 45 ms to 215 ms (10 ms step size).
Both water suppressed (16 averages) and unsuppressed (4 averages) data were acquired.
To minimize T1 saturation effects, a TR of 7500 ms was used, which is roughly five times the
T1 value of the 2.01 ppm N-acetyl aspartate (NAA) singlet at 7 T [32]. The total acquisition
time was approximately 2 h.
3.2.3.2 Post-processing
All in vivo spectra were lineshape and eddy current corrected using combined QUAL-
ITY deconvolution and eddy current correction (QUECC) with 400 QUALITY (quantifica-
tion improvement by converting lineshapes to the Lorentzian type) points [6]. To remove
any residual water not suppressed by VAPOR, resonances between 4.2 ppm and 5.7 ppm
were fitted using a Hankel singular value decomposition fitting routine requiring no prior
knowledge [33] and subtracted from the spectrum.
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The quality of the acquired data was assessed by calculating the linewidths of the water
signal and by measuring the in vivo SNR. The water signal linewidths were calculated by
fitting a single Lorentzian peak to the unsuppressed water spectra. SNR was measured
by dividing the height of the absolute signal at the position of the NAA CH3 peak by the
standard deviation (SD) of the noise after Fourier transforming the first 100 ms of the FID.
3.2.3.3 Prior knowledge
Simulated, echo-time-specific 7 T semi-LASER prior knowledge templates were used to fit
the post-processed spectra. The metabolite spectra were modelled with PyGAMMA [19]
using previously measured metabolite-specific shifts and coupling constants [20] and the
RF pulses of the semi-LASER pulse sequence. The following metabolites were included in
the prior knowledge template: NAA, N-acetylaspartyl glutamate (NAAG), choline (Cho),
creatine (Cr), myo-inositol, glutamate, glutamine, glutathione, phosphorylethanolamine
(PEth), scyllo-inositol (Scyllo), taurine (Tau), alanine (Ala), glucose (Glc), GABA, glycine
(Gly), and lactate (Lac). Glutamate and glutamine were included as separate metabolites,
since the increased spectral dispersion at 7 T allows these metabolites to be resolved in vivo
[7]. The multiplets of NAA and NAAG were fitted independently, because the multiplets
experience a different rate of T2 relaxation from the singlets [21, 34]. From the simulations,
the peak positions, amplitudes, and phases, as well as the number of peaks, were obtained
for each metabolite. These parameters were used to create the corresponding model func-
tion using Equation (3.1) in Bartha et al. [22]
A macromolecule model created using previously acquired macromolecule data was
also included in the prior knowledge template. As described by Penner and Bartha[11],
these data were acquired from 12 healthy participants at 7 T using a semi-LASER sequence
with a double-inversion metabolite-nulling method. Two datasets were acquired per par-
ticipant and all 24 datasets were averaged. Eleven Lorentzian lineshapes were used to pa-
rameterize the averaged macromolecule data (Figure 3.1) and were included in the prior
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knowledge template.
Metabolite lineshapes were constrained in the prior knowledge template before fitting
to the in vivo data. Since QUECC correction was used, all metabolite peaks were mod-
elled as Lorentzian functions. A single Lorentzian linewidth parameter and a single delay
time was defined for all metabolite peaks. Within metabolites, the peak amplitudes, shifts,
and phases were fixed relative to one another. Relative peak amplitudes were not fixed
between metabolites, since these may vary across subjects. Relative peak positions and
phases between some metabolites were fixed. For example, the positions and phases of
low-amplitude metabolites (e.g. Ala, GABA, Lac) were linked to the positions and phases
of higher-amplitude metabolites (e.g. NAA, myo-inositol, glutamate). These constraints are
summarized in Table 3.1.
Macromolecule lineshapes were also constrained. Relative amplitudes and linewidths
between macromolecule resonances were fixed, and one phase parameter was defined for
all macromolecular resonances.
3.2.3.4 Spectral fitting
The prior knowledge templates were fitted to the post-processed in vivo spectra using
the fitMAN [22] software developed in-house. fitMAN uses a Levenberg–Marquardt mini-
mization algorithm [35] to minimize the difference between the prior knowledge template
and the in vivo data in the time domain. Initial parameter values of metabolites and macro-
molecule basis functions were manually adjusted such that the prior knowledge template
resembled the data to be fit. After fitting, the quality of the model fit was assessed using
Cramér-Rao lower bounds (CRLBs). At each echo time, CRLBs were calculated for all fitted
metabolites and averaged across the five subjects. From the fitted model, glutamate peak
positions, amplitudes, and phases were obtained. Using these parameters, the glutamate
FID signal was reconstructed using Equation (3.1), with α set to 10 Hz. The energies of the
reconstructed glutamate signals were calculated using Equation (3.2).
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FIGURE 3.1: The macromolecule model included in the prior knowledge template is
shown in orange. To create the model, an average macromolecule baseline was param-
eterized with 11 Lorentzian lineshapes (lm1-lm11). The average macromolecule baseline
was obtained by averaging 24 in vivo metabolite-nulled spectra acquired at 7 T with semi-
LASER.
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Reference
Metabolite
Linked Metabolites Comments
Shift Phase
NAA NAAG, Lac NAAG, PEth,
Scyllo, Tau, Ala,
Glc, GABA, Gly,
Lac
• Shifts, phases, and
amplitudes for Cho
and Cr were not fixed
relative to any
reference metabolite.
Cho and Cr were
fitted independently.
• Relative peak
amplitudes were not
fixed between
metabolites, since
these may vary across
subjects.
• A single linewidth
parameter was
defined for all
metabolites.
• A single delay time
parameter was
defined for all
metabolites.
Myo Ala, Glc, Gly, PEth,
Scyllo, Tau
Phases of other
metabolites were
not fixed to Myo.
Glu Glu, Gln, GSH,
GABA
Glu, Gln, GSH
TABLE 3.1: A summary of relationships between metabolite parameters in the prior knowl-
edge template. Peak shifts and phases of low-amplitude metabolites were linked to the
shifts and phases of higher-amplitude metabolites. Within metabolites, the peak ampli-
tudes, shifts, and phases were fixed relative to one another. The following metabolites were
included in the prior knowledge template: NAA, NAAG, Cho, Cr, myo-inositol (Myo), glu-
tamate (Glu), glutamine (Gln), glutathione (GSH), PEth, Scyllo, Tau, Ala, Glc, GABA, Gly,
and Lac.
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Similarly, peak positions, amplitudes, and phases were obtained for other typical
metabolites of interest, including NAA, Cr, Cho, myo-inositol, and glutathione. As above,
their FID signals were reconstructed and their signal energies calculated for each echo time.
These results are presented in Supplementary Figure 3.S1.
3.2.3.5 Glutamate-to-creatine ratio (Glu/Cr)
At each echo time, Glu/Cr was calculated by dividing the sums of amplitudes of glutamate
and Cr resonances after T2 correction:
∑k,Glu ck,Glu/e−TE/T2,Glu
∑k,Cr ck,Cr/e−TE/T2,Cr
× 1/ρGlu
1/ρCr
(3.3)
where ∑k,Glu ck,Glu is the sum of the amplitudes of all k glutamate resonances, ∑k,Cr ck,Cr is
the sum of the amplitudes of all k resonances from the N(CH3) group of creatine, T2,Glu is
the T2 relaxation time-constant of glutamate, T2,Cr is the T2 relaxation time-constant of the
N (CH3) group of creatine, ρGlu is the number of glutamate protons, and ρCr is the number
of protons of the N(CH3) group of Cr.
The T2 values used above were determined by fitting a two-parameter (amplitude and
T2) mono-exponential function to the in vivo metabolite amplitudes obtained from Sub-
jects V1-V4 using a Levenberg–Marquardt minimization (the lm method in SciPy’s [36]
optimize.curve_fit() function). The results were averaged to obtain the final T2 values.
The goodness of fit was evaluated by correlating the fitted result with the raw data using
SciPy’s [36] stats.spearmanr() function. This function returns Spearman’s correlation co-
efficient, rs, and a two-sided p-value for a hypothesis test whose null hypothesis is that
two sets of data are uncorrelated. T2 values were also measured for other metabolites of
interest, including NAA, choline, myo-inositol, and glutathione.
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3.2.3.6 Effect of macromolecule contribution
At shorter echo times, the increased contribution of macromolecule resonances that overlap
with glutamate resonances [18] confounds glutamate fitting and quantification. To demon-
strate this effect, variations of the macromolecule model were included in the prior knowl-
edge template used to fit the TE = 45 ms data from Subject V1. The amplitude of the lm5
and lm6 macromolecule lineshapes was changed from 20% of its original value to 220% of
its original value (see Figure 3.4d later). The data from Subject V1 were then fit using the
same methods as described above, and the signal energies calculated.
3.2.3.7 Sample size calculations
To assess the practical impact of the choice of echo time on future study design, we per-
formed a sample size calculation to estimate the number of participants per group required
to detect a 10% change in Glu/Cr between two groups with a 95% confidence level given
a specific echo time. This calculation is given in Equation (3.4), a modified version of the
formula described by Fox et al. [37]:
n =
⌈
(u + v)2 ×
(2× σ2TE)
(∆× µTE)2
⌉
(3.4)
where u = 1.28 for 90% power, v = 1.96 for a 95% confidence level, ∆ = 0.1 for a 10%
change, σTE is the SD of in vivo Glu/Cr at echo time TE, and µTE is the mean in vivo
Glu/Cr at echo-time TE. This calculation assumes that the SD of Glu/Cr stays constant
with changes in Glu/Cr.
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3.2.4 In vitro data
3.2.4.1 Acquisition
In vitro data were obtained from a 900 mL aqueous phantom. The phantom contained glu-
tamate, glutamine, and GABA at concentrations of 92.5mM, 45mM, and 15mM, respec-
tively. These concentrations are approximately 10 times the average physiological con-
centrations in the normal adult human brain [20]. The conductivity of the phantom was
adjusted to be similar to that of the human brain by adding sodium chloride (5 g). No
relaxation agent was added. The phantom was adjusted to have a pH of 7.04 at room tem-
perature with the addition of sodium hydroxide. Water suppressed in vitro 1H-MRS data
were collected from a 2.5× 2.5× 2.5 cm3 voxel placed in the centre of the phantom at echo
times ranging from 45 ms to 215 ms (5 ms step size). Since no relaxation agent was added,
only a single-shot FID was acquired at each echo time. To allow the magnetization to return
to equilibrium, a delay of 1 min was used between each acquisition.
3.2.4.2 Post-processing, prior knowledge, and spectral fitting
The methods of post-processing, generating prior knowledge, and spectral fitting used for
the in vitro spectra was the same as described above for the in vivo spectra, except for the
following changes. Although the quality of the acquired data was also assessed via water
signal linewidth and SNR, the in vitro SNR was calculated differently. Instead of using the
signal of the NAA CH3 peak, SNR was measured using the height of the tallest peak of the
absolute spectra.
The prior knowledge template used to fit the in vitro data was also different. Instead of
including all metabolites, only glutamate, glutamine, and GABA were included in the prior
knowledge template. Relative peak positions and phases between glutamate, glutamine,
and GABA were not fixed and a separate Lorentzian linewidth parameter was defined for
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each metabolite. After spectral fitting, the FID signals and signal energies were calculated
for all three metabolites.
3.3 Results
3.3.1 Spectral quality
Examples of spectra collected in vivo are shown in Figure 3.2c, d. Examples of spectra
collected in vitro are shown in Figure 3.3c, d. The spectra shown in Figure 3.2 and Figure
3.3 are representative of the high-quality, artefact-free data obtained from the semi-LASER
sequence in this study. Excellent water suppression and outer-volume suppression was
consistently achieved across all echo times. Localized B0 shimming produced narrow water
linewidths in vivo and in vitro. The in vivo mean (±SD) water signal linewidth across all
subjects and all echo times was 10.1 ± 1.1. Hz and the in vitro mean (±SD) water signal
linewidth across all echo times was 4.4 ± 0.2 Hz. The in vivo mean (±SD) SNR across all
subjects and echo times was 119± 30 and was observed to decrease with echo time. Linear
regression of the SNRs averaged across subjects showed a 0.58 SNR decrease for every 1
ms echo time (p < 0.0001). The in vitro mean (±SD) SNR across all echo times was 542 ±
193. In vitro SNR also decreased with echo time, with linear regression showing an SNR
decrease of 3 for every 1 ms echo time (p < 0.0001).
3.3.2 Echo-time dependence of glutamate signal energy
The results from the time-domain simulations and the in vivo acquisition are summarized
in Figure 3.2. Time-domain simulations (Figure 3.2a) showed that the relationship between
glutamate signal energy and echo time is not a simple exponential decay between TE =
45 ms and TE = 215 ms, but rather a curve with two local maxima. The glutamate signal
energy was greatest at TE = 45 ms, with another local maximum observed at 107 ms.
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FIGURE 3.2: a, b, The calculated signal energies of glutamate from simulated data (a) and
average in vivo data (b) are plotted from TE = 45 ms to TE = 215 ms. Standard errors are
shown for the in vivo data.
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FIGURE 3.2: Signal energies were normalized to the maximum signal energy to allow com-
parison between experiments. The maximal signal energy occurred at 45 ms for the simu-
lated data, and at 45 ms for the in vivo data. A secondary local maximum occurred at 107
ms and 105 ms for the simulated and in vivo data, respectively. c, d, Examples of in vivo
1H-MRS spectra collected from a 2× 2× 2 cm3 voxel in the left sensorimotor cortex at TE
= 45 ms and TE = 105 ms respectively using the semi-LASER sequence. The orange line
shows the result after fitting the spectrum with the simulated prior knowledge template.
The residual following fitting is shown by the green line. At TE = 105 ms, the resonances
from macromolecules are reduced, and the main glutamate peak at about 2.3 ppm appears
prominently. e, The voxel position. f, When examining the in vivo glutamate spectral pat-
tern as a function of echo time, the main glutamate peak at about 2.3 ppm is entirely in
phase at TE = 105 ms. A simulated glutamate spectrum generated from a pulse-acquire
experiment (TE = 0 ms) with a 10 Hz linewidth is included for reference.
The in vivo (Figure 3.2b) results showed the same pattern of variation in the glutamate
signal as a function of echo time. In almost perfect agreement with the simulations, the
in vivo spectra also had the greatest glutamate signal energy at 45 ms, with another local
maximum observed at 105 ms. The in vivo echo-time dependence of signal energy for
other metabolites of interest (NAA, Cr, Cho, myo-inositol, and glutathione) are shown in
Supplementary Figure 3.S1.
In vitro, the glutamate signal also varied with echo time in a similar way (Figure 3.3a).
Like the simulated and in vivo results, the curve had two local maxima. Glutamate signal
energy was greatest at TE = 100 ms, with another local maximum observed at 45 ms. Com-
paring the glutamate signal energy with the glutamine and GABA signal energies with
respect to echo time revealed that the maximal difference in signal energy between gluta-
mate and glutamine signals occurred at TE = 105 ms (Figure 3.3b). The maximal difference
in signal energy between glutamate and GABA signals occurred at TE = 100 ms.
3.3.3 In vivo spectral fitting quality
In vivo glutamate CRLBs plotted across echo time are shown in Figure 3.4a. All glutamate
CRLBs between TE = 45 ms and TE = 145 ms were under 20%. The minimum glutamate
CRLB (6.2 ± 0.9%) occurred at TE = 100 ms, which is close to the echo time at which the
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FIGURE 3.3: a, The calculated signal energies of glutamate, glutamine, and GABA from
in vitro data obtained using a mixed-metabolite phantom from TE = 45 ms to TE = 215
ms. Signal energies were normalized to the signal energy of glutamate at TE = 105 ms.
The maximal signal energy for glutamate occurred at 100 ms, with a secondary local max-
imum at 45 ms. b, The differences in signal energy between the glutamate signal and the
glutamine and GABA signals from TE = 45 ms to TE = 215 ms. The maximal difference in
signal energy occurred at TE = 105 ms for glutamate versus glutamine, and at TE = 100
ms for glutamate versus GABA. c, d, Examples of in vitro 1H-MRS spectra collected from
a 2.5× 2.5× 2.5 cm3 voxel in the centre of the phantom at TE = 45 ms and TE = 105 ms
respectively. Since the average linewidth of the phantom spectra was 4 Hz, a 6 Hz expo-
nential filter was applied to the phantom spectra such that the linewidth matched what
was typically observed in our in vivo data (10 Hz). At TE = 105 ms, peaks of glutamate
and glutamine in the 2–3 ppm range that are present at TE = 45 ms are reduced, resulting
in little overlap between the peaks of the three metabolites in the 2–3 ppm region.
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secondary glutamate signal energy maximum was observed in vivo (TE = 105 ms, CRLB =
6.5 ± 2.0%).
Inter-subject coefficients of variation (CVs) of Glu/Cr were also calculated. Glu/Cr CVs
are plotted as a function of echo time in Figure 3.4b. All Glu/Cr CVs between TE = 45 ms
and TE = 130 ms were below 25%. The minimum Glu/Cr CV (4.6%) was observed at TE =
105 ms. Glu/Cr at TE = 105 ms was 0.95 ± 0.04.
At the shorter echo times, the glutamate fit is directly influenced by the macromolecule
fit. Specifically, the energy of the glutamate signal decreased (Figure 3.4c) as the amplitude
of the lm5 and lm6 lineshapes in the macromolecule model was increased (Figure 3.4d).
3.3.4 Sample size calculations
The estimated number of participants per group required to detect a 10% change in Glu/Cr
between two groups with a 95% confidence level at each echo time is shown in Figure 3.5.
The minimum estimated required number of participants was 5 per group and occurred
at TE = 105 ms. The estimated required number of participants at TE = 45 ms was 13 per
group.
3.3.5 T2 relaxation times
The average T2 relaxation times of the metabolites are shown in Table 3.2. The quality of
the exponential fits, indicated by the average Spearman’s correlation coefficient rs, and
associated p-values, are also shown in Table 3.2. The associated p-values were all less than
0.01 for the listed metabolites, indicating a significant correlation between the raw data and
the exponential fit.
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FIGURE 3.4: a, CRLBs for the glutamate fit are plotted as a function of echo time with stan-
dard errors shown. The minimum glutamate CRLB was 6.2 ± 0.9% at TE = 100 ms, which
is close to the echo time at which the secondary glutamate signal energy maximum was
observed in vivo (105 ms). The glutamate CRLB at TE = 105 ms was 6.5 ± 2.0%. b, Inter-
subject coefficients of variance of Glu/Cr are plotted against echo time. The minimum
Glu/Cr CV was 4.6% at TE = 105 ms. c, The energy of the glutamate signal fitted to in
vivo data acquired at TE = 45 ms from Subject V1 as a function of the lm5 and lm6 macro-
molecule amplitude. d, The macromolecule model was varied by changing the lm5 and
lm6 macromolecule line shape from 20% of its original value to 220% of its original value.
The altered macromolecule model was incorporated into the prior knowledge template
used to fit the TE = 45 ms in vivo data of Subject V1.
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FIGURE 3.5: Estimated number of participants per group required to detect a 10% change
in Glu/Cr between two groups at a 95% confidence level are plotted across echo time. The
minimum required number of participants per group was 5 at TE = 105 ms. The number
of participants per group required at TE = 45 ms was 13.
Metabolite Group Type T2 (ms) rs p
NAA 2CH3 Singlet 138 ± 11 0.96 < 0.001
3CH2 Multiplet 69 ± 4 0.86 < 0.001
Creatine N(CH3) Singlet 120 ± 1 0.99 < 0.001
2CH2 Singlet 87 ± 3 0.97 < 0.001
Choline Entire molecule Singlet 128 ± 9 0.90 < 0.001
Myo-inositol Entire molecule Multiplet 102 ± 8 0.78 < 0.001
Glutamate Entire molecule Multiplet 72 ± 5 0.95 < 0.001
Glutathione Entire molecule Multiplet 63 ± 16 0.82 < 0.01
TABLE 3.2: T2 values (mean ± SD) of various metabolites of interest measured from a
voxel in the sensorimotor cortex of Subjects V1, V2, V3, and V4. Statistically significant fits
were obtained with rs ≥ 0.80, except for myo-inositol, which had rs = 0.78.
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3.4 Discussion
The goal of this work was to determine the optimal echo time for glutamate measurement
at 7 T using the semi-LASER pulse sequence. Time-domain simulations of the glutamate
system showed a local signal energy maximum at an echo time of 107 ms. This echo time
was in agreement with the results from the in vivo and in vitro experiments, which showed
a local signal energy maximum at 105 ms and 100 ms, respectively. Additionally, the low-
est in vivo CRLBs, indicating the highest-quality model fits, and the lowest measurement
variability associated with Glu/Cr, were achieved at TE = 100–105 ms. Taken together these
results indicate that TE = 105 ms maximizes glutamate signal energy in vivo while also
maximizing glutamate measurement precision, and suggests that this echo time is optimal
for in vivo glutamate measurement at 7 T with semi-LASER.
This result is counter-intuitive, as the current practice in 1H-MRS is to use the shortest
achievable echo time to maximize the signal of J-coupled metabolites, including glutamate.
Previous phantom work by Zhong and Ernst [14] at 4 T using the PRESS sequence com-
pared the resonances of glutamate at TE = 8 ms and TE = 30 ms. They found virtually no
dephasing due to J coupling and minimal signal loss at TE = 8 ms compared with TE = 30
ms, suggesting increased SNR and improved metabolite quantitation.
Along this line of reasoning, the shortest possible echo times have traditionally been
selected when using the semi-LASER sequence at high field. A variety of echo times have
been chosen, as the minimum TE achieved depends strongly on hardware capabilities,
pulse settings, and sequence parameters [38]. These dependencies include the maximum
available B1 amplitude, pulse duration, and crusher gradient duration. Echo times as short
as 36 ms (Reference [39]) and 38 ms (Reference [11]) have been achieved at 7 T. An even
shorter echo time of 26 ms (Reference [40]) was achieved using 16 RF amplifiers (1 kW
each), which provided greater B1 amplitude, allowing for shorter adiabatic pulses. Trape-
zoidal adiabatic pulses, which can achieve more spectral bandwidth with less B1 amplitude
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than hyperbolic secant adiabatic pulses, also allows for shorter pulse lengths and thus even
shorter echo times. For example, Boer et al. [41] achieved an echo-time of 25 ms using trape-
zoidal adiabatic pulses, despite having only two 4 kW RF amplifiers. With only eight 1 kW
RF amplifiers and conventional hyperbolic secant pulses, the minimum achievable echo-
time was 45 ms in the current study.
Regardless of the available hardware, acquiring short-echo-time spectra has the added
complication of a more pronounced macromolecule signal, which complicates the subse-
quent fitting and quantification of metabolites, particularly glutamate. In fact, Zhong and
Ernst showed that the intensity of the macromolecule peak at 0.9 ppm doubled at TE =
8 ms compared with TE = 30 ms [14]. Several approaches can be used to estimate the
macromolecule contribution including spline fitting (LCModel [42]), measuring the macro-
molecule signal using inversion recovery techniques and including the lineshape as a ba-
sis function in the prior knowledge template [38, 39, 40, 41, 43], use of a parameterized
mathematical model of the macromolecules in the prior knowledge template [6, 22, 44,
45], or acquisition of a subject-specific metabolite-nulled macromolecule spectrum that is
subtracted from the full spectrum [11, 46]. Not surprisingly, Schaller et al. [45] showed
that the approach used to remove the macromolecule signal when using short echo times
can significantly impact glutamate quantification, which contributes to variability in the
glutamate measurement and complicates the comparison of glutamate levels from stud-
ies that use different methods for macromolecule signal removal. The current study has
also demonstrated that the magnitude of the estimated macromolecule contribution to the
spectrum significantly impacts the measured glutamate level. The use of long echo times
to minimize macromolecule contributions greatly reduced measurement variability.
In the present study, we observed the greatest in vivo glutamate signal at the shortest
echo time (TE = 45 ms). However, the glutamate fit at that echo time was highly variable
between subjects, probably due to variations in the macromolecule model contribution.
Uncertainty in the TE = 45 ms measurement was evidenced by the CVs of Glu/Cr and the
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CRLBs of the glutamate fits. Both improved as the echo time approached 105 ms, with the
lowest Glu/Cr CV occurring at 105 ms. This lower variability translated into practical ben-
efits for study design. The estimated number of participants per group required to detect
a 10% change in Glu/Cr between two groups at TE = 105 ms was 5, compared with 13 at
TE = 45 ms. However, it should be noted that the signal of other metabolites decreases at
longer echo times (Supplementary Figure 3.S1) and that the use of a long-echo-time mea-
surement of glutamate may result in greater measurement variability for other metabolites
in the spectrum.
The measured Glu/Cr of 0.95 ± 0.04 at TE = 105 ms was in good agreement with pre-
vious measurements in healthy individuals. For example, using a 7 T system, Choi et al.
[47] reported a Glu/Cr of 1.16 ± 0.11 measured using PRESS (TE = 100 ms) and 1.22 ± 0.13
measured using STEAM (TE = 14 ms) in the medial prefrontal cortex. Using 1H-MRS imag-
ing at 7 T (free induction decay acquisition with acquisition delay T∗E = 1.3 ms), Bogner et
al. reported Glu/Crs of 0.99 ± 0.16 in a white matter voxel in the right frontal lobe, 1.07 ±
0.1 in a gray matter voxel in the center of the frontal lobe, and 1.0 ± 0.14 in a white matter
voxel in the left frontal lobe [48]. Similarly, using a spectrally selective refocusing method
at 3 T (TE = 128 ms), Choi et al. reported a Glu/Cr of 1.21 ± 0.06 in the prefrontal cortex
[49]. Therefore, the use of long TE to measure Glu/Cr provides measurements comparable
to those made using shorter echo times with different pulse sequences and at lower field
strengths when correction for number of protons and T2 relaxation is incorporated.
The necessary T2 correction required when using a long TE may be a disadvantage
when incorporating spectroscopic measurements in multi-modality MR imaging protocols,
as is the case with most clinical studies. In these studies, it is usually infeasible to perform a
T2 measurement for each participant due to the lengthy scan time required. Use of literature
values for T2 correction is generally accepted in the field of 1H-MRS, although errors in
measured metabolite levels could occur due to T2 changes in disease. When short TE is
used, T2 correction is still required, but measured metabolite levels are less sensitive to
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T2 differences. However, increased sensitivity to T2 may be an acceptable trade-off for the
demonstrated improvement in measurement variability at TE = 105 ms.
The glutamate CRLBs that we reported (Figure 3.4a) were higher than previously re-
ported CRLBs in other 1H-MRS studies performed with a similar number of participants at
7 T. For example, Choi et al [47] reported a mean glutamate CRLB of 2% across six healthy
subjects when using PRESS at TE = 100 ms. Similarly, Pradhan et al. [50] reported mean glu-
tamate CRLBs of 2.5–4.8% across four healthy subjects when using semi-LASER at TE = 32
ms. The higher glutamate CRLBs that we report can be attributed to methodological differ-
ences. First, Choi et al. and Pradhan et al. used spectroscopy voxels that are approximately
three times larger than the voxel used in the present study. Second, Choi et al. and Pradhan
et al. used 64 averages (four times more than the present study) and 32 averages (twice
as many as the present study), respectively, to collect water-suppressed spectroscopy data.
The larger voxel sizes and greater number of averages combine to produce spectra with
greater SNR, resulting in a lower CRLB. In fact, Pradhan et al. report an SNR of 135 ± 28 at
TE = 32 ms. Replicating their method of SNR calculation with our TE = 45 ms data, we ob-
tain an SNR of 59 ± 11. Thus, it is unsurprising that we obtained higher glutamate CRLBs.
However, we did achieve a glutamate CRLB comparable to the 4.8% CRLB reported by
Pradhan et al. in the centrum semiovale at the proposed optimal echo time of TE = 105 ms
(CRLB = 6.5 ± 2.0%). The greater number of averages reported by Choi et al. and Prad-
han et al. is typical of clinical spectroscopy studies. More averages would improve SNR
and lower the glutamate CRLBs. As a result, Glu/Cr variability across subjects would de-
crease, subsequently increasing statistical power to detect differences in Glu/Cr at TE = 105
ms.
The determination of the optimal TE for glutamate measurement has previously been
studied using PRESS at 7 T and 3 T [47, 51, 52], but not for semi-LASER. Notably, Snyder
and Wilman [51] used numerical simulation to optimize the PRESS timings at various field
strengths. The results showed that an echo time of 105 ms (TE1 = 20 ms, TE2 = 85 ms)
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yielded optimal separation of glutamate and glutamine peaks and optimal glutamate and
glutamine amplitudes at 7 T. Similarly, Choi et al. [47] verified this result by collecting in
vivo spectra from the medial prefrontal cortex of six healthy volunteers, finding that TE =
100 ms provided improved resolution of these metabolites, reduced macromolecule signal,
and a more reliable measurement.
These results are consistent with the current study using semi-LASER. Specifically, our
in vitro experiments showed that TE = 100 ms maximized the difference between gluta-
mate and GABA signal energies, while TE = 105 ms maximized the difference between the
glutamate and glutamine signal energies (Figure 3.3b). This suggests that the glutamine
and GABA signals are reduced relative to glutamate at TE = 100–105 ms. Comparing the in
vitro spectra at TE = 45 ms (Figure 3.3c) and at TE = 105 ms (Figure 3.3d) reveals that some
peaks of glutamate and glutamine in the 2–3 ppm range that are present at TE = 45 ms are
reduced at TE = 105 ms. The remaining peaks at TE = 105 ms have little overlap in the 2–3
ppm region, resulting in better separation between the glutamate and glutamine spectra.
Others have also taken different approaches to detect glutamate, including using spec-
tral editing to separate glutamate from overlapping resonances [53, 54]. Using MEGA-
PRESS at 3 T, Waddell et al. reported a Glu/Cr of 1.16 ± 0.10 in the anterior cingulate
and 0.70 ± 0.07 in the cerebellar vermis [54]. These measurements are comparable to the
Glu/Cr reported in this study (0.95 ± 0.04 at TE = 105 ms in the sensorimotor cortex). The
inter-subject Glu/Cr CV reported by Waddell et al. was 8.9% in the anterior cingulate and
11% in the cerebellar vermis. Both are higher than the value we achieved at TE = 105 ms
with the semi-LASER sequence (4.0%). Spectral editing also has several drawbacks. Since
the echo time of the editing sequence is determined by the J coupling of the metabolite, a
TE of around 70 ms is required for glutamate detection [53, 54, 55], leading to co-editing
of macromolecules and requiring incorporation of methods to reduce the macromolecule
contribution. Quantification of metabolite concentrations also becomes more complicated,
requiring additional corrections for editing efficiency, co-editing, and chemical exchange
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in addition to the corrections for relaxation and B1 inhomogeneities that are already neces-
sary for quantification of unedited spectra [56]. Further study directly comparing spectral
editing and long-echo-time semi-LASER is needed to determine which technique measures
glutamate with greater accuracy and precision at 7 T.
There are some limitations of this study that should be considered. First, only one ap-
proach to modelling the macromolecule contributions at short echo times was utilized in
the current study. Other approaches as described above may improve glutamate measure-
ment reproducibility at short echo times. However, all such techniques introduce uncer-
tainty. Therefore, use of such techniques would probably not result in a better CV than that
achieved at TE = 105 ms. Second, the absolute concentration of glutamate was not mea-
sured in vivo. This is because high-resolution structural scans were not acquired in order
to keep the total scan time to 2 h. Such images are needed to determine the tissue partial
volume within the voxel for accurate metabolite quantification.
3.5 Conclusions
In vivo, the semi-LASER sequence at TE = 105 ms produced the greatest glutamate sig-
nal energy while also maximizing glutamate measurement precision, and consequently
increasing statistical power to detect differences in Glu/Cr. Therefore, we conclude that
TE = 105 ms is the preferred echo time for in vivo glutamate measurement at 7 T with
semi-LASER. Using this long echo time has several advantages. It allows the use of a lower
maximum B1 in conjunction with longer RF and gradient pulses, resulting in less power
deposition into the tissue. As shown by in vitro measurements in the present study, overlap
between glutamate, glutamine, and GABA peaks are minimal at TE = 105 ms. Most impor-
tantly, macromolecule contributions at TE = 105 ms are minimal, eliminating the need for
macromolecule removal or fitting techniques that add additional scan time or can directly
bias the estimated glutamate fit.
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FIGURE 3.S1: The calculated signal energies of NAA, creatine, choline, myo-inositol, and
glutathione from average in vivo data are plotted from TE = 45 ms to TE = 215 ms.
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Chronic Vitamin D deficiency in adult
APP/PS1 mice: Effect on memory
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levels
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Li, Marco Prado, Olivier Beauchet, Cédric Annweiler, Manuel Montero-Odasso, Robert Bartha,
“Chronic Vitamin D deficiency in adult APP/PS1 mice: Effect on memory performance and brain
metabolite levels,” In preparation. Jun 2019.
Abstract: Amyloid-beta (Aβ) plaques and neurofibrillary tangles are the pathological hallmarks
of Alzheimer’s disease (AD), but their contribution to neurodegeneration in AD remains unclear.
Calcium dysregulation and oxidative stress are additional biological mechanisms thought to be
involved in the AD process. Vitamin D (VitD) is a secosteroid hormone that can act in the brain
to protect against the effects of calcium dysregulation and oxidative stress, suggesting that VitD
deficiency may potentially exacerbate AD progression. However, literature on VitD deficiency in
AD remains inconsistent. The purpose of this study was to thoroughly evaluate the role of chronic
VitD deficiency in an adult transgenic mouse model of AD. 6 month old APPSwe/PS1∆E9 mice
were fed either a VitD deficient diet (< 1 IU/kg VitD3) or a nutritionally sufficient control diet
(1000 IU/kg VitD3). Longitudinal serum 25(OH)D levels were measured using radioimmunoassay.
Magnetic resonance spectroscopy, magnetic resonance imaging, and the Barnes and Morris water
mazes were used to assess longitudinal neurochemical, anatomical, and spatial memory changes,
respectively. Measurements were made at 6 months, 9 months, 12 months, and 15 months of age.
VitD deficiency did not change ventricle volume, an MRI marker of neuronal loss, but did result in
changes in metabolite concentrations consistent with astrocytosis and gliosis. Overall VitD deficient
mice also performed better or improved on measures of spatial memory than mice on the control
diet. Since the APPSwe/PS1∆E9 mouse is a mild model of Aβ toxicity, the results of this study
suggest that VitD deficiency may improve memory by upregulating beneficial astrocytosis in the
prodromal stages of AD.
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4.1 Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder of the brain, presenting as pro-
gressive impairment over several cognitive domains [1]. Although it is well established
that amyloid beta (Aβ) plaques and neurofibrillary tangles (NFTs) are the pathological
hallmarks of AD, their contribution to neurodegeneration in AD is less clear. Additional
biological mechanisms thought to be involved in the disease process include calcium dys-
regulation and oxidative stress [2].
Calcium dysregulation involves the activation of L-type voltage gated calcium channels
(LVGCC) [3]. These channels have increased activity and expression due to Aβ [4, 5, 6, 7],
leading to increased intracellular calcium. The extra calcium may be taken up by mitochon-
dria, producing increased reactive oxygen species (ROS) [8, 9]. Interestingly, the secosteroid
hormone Vitamin D (VitD) can help protect neurons against ROS-induced damage. Specif-
ically, VitD can enhance the expression of antioxidants and detoxifying enzymes [10] and
can lower LVGCC expression and reduce L-type currents in neurons [11, 12]. Other pro-
tective effects of VitD include the regulation of neurotrophic factors and the reduction of
inflammation [13]. Additionally, both VitD receptors and the 1α-hydroxylase enzyme that
converts VitD into its biologically active form are known to be expressed in the human
brain and are localized to brain regions affected by AD such as the hippocampus and the
cingulate gyrus [14]. Together, this suggests a role for VitD in AD, with VitD deficiency
potentially exacerbating AD progression.
In line with this view, epidemiological studies have shown that VitD deficiency is
prevalent in AD [15] and is associated with a substantially increased risk for AD [16]. In
addition, low VitD has been associated with impaired cognition, a greater rate of cognitive
decline [17, 18], and increased incidence of AD [19]. In contrast, two studies have shown no
association of VitD levels with episodic memory function in older adults [20, 21]. Research
using rodent models of aging and AD is also inconsistent, with some studies showing
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worsened spatial memory after VitD deficiency but no effect of supplementation [22, 23].
and other studies showing the opposite effect. These studies showed no effect of VitD de-
ficiency on spatial memory [24, 25], but better spatial memory after VitD supplementation
[24, 26].
In light of this contradictory evidence, the aim of the present study was to thoroughly
evaluate the role of chronic VitD deficiency in AD by establishing VitD deficiency in an
adult transgenic AD mouse model and to comprehensively examine the resulting lon-
gitudinal neurochemical, anatomical, and memory changes in the brain. Neurochemical
changes were assessed using proton magnetic resonance spectroscopy (1H-MRS), while
anatomical changes were assessed using high resolution magnetic resonance imaging
(MRI) – both techniques that are well established in the study of AD in humans. Memory
was carefully assessed by using two independent spatial tasks and measuring potential
confounding variables. Spatial tasks were chosen as they mimic aspects of episodic mem-
ory [27], the type of memory that is one of the earliest and most severely affected in hu-
man AD [28]. Based on previous evidence in humans and rodent models, we hypothesized
that VitD deficiency would decrease N-acetyl aspartate (NAA) concentrations (a 1H-MRS
marker of neuronal health), increase ventricle volume (an MRI marker of volume loss), and
worsen spatial memory performance.
4.2 Methods
4.2.1 Subjects
60 male transgenic (Tg) mice carrying the Swedish mutation of the human amyloid pre-
cursor protein (APPSwe) and the exon-9 deleted mutation of the human presenilin-1 pro-
tein (PS1∆E9) on a (C57BL/6 x C3H)F2 genetic background were obtained from Jackson
Laboratories (JAX MMRC Stock #034829; Bar Harbour, ME, USA) at 10 weeks of age. A
cohort of 5 mice arrived every two weeks until 60 mice were obtained. Upon arrival, mice
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were housed individually in standard tub cages under fluorescent lighting on a 12/12 h
day/night schedule (lights on at 7 am) with ad libitum access to food and water. Other than
a covered shelter, mice were provided no environmental enrichment. Mice were eutha-
nized at 15 months of age. All animal experiments were performed by the same individual
between the hours of 9 am and 6 pm. Ethics approval for this study was obtained from the
University of Western Ontario Animal Use Subcommittee.
4.2.2 Diets and Vitamin D Status
All mice were fed a standard AIN-76A rodent diet from Research Diets Inc. (D10001; New
Brunswick, NJ, USA) from 10 weeks of age to 6 months of age. This control diet contained
1000 IU Vitamin D3 (VitD3) per kg. The 56 mice that survived to 6 months of age were ran-
domized to one of four groups. The control group (n=14) continued to receive the control
diet for the remainder of the study. The number of mice receiving the control diet was 14
at 9 months of age, and 13 at 12 and 15 months of age. The other three groups (n=42) re-
ceived a VitD deficient (VitD-) diet from Research Diets Inc. (D08090903; New Brunswick,
NJ, USA) with < 1 IU VitD3 per kg from 6 months to 9 months of age. The VitD- diet is iden-
tical to the standard AIN-76A diet, except no VitD was included in the diet’s vitamin mix.
One group (n=14) continued to receive the VitD- diet for the remainder of the study. The
other two groups received further interventions that are not presented herein. The number
of mice receiving the VitD deficient diet was 41 at 9 months of age, 13 at 12 months of age,
and 10 at 15 months of age. A summary of the study design is shown in Figure 4.1a.
To verify that the diets were affecting VitD levels in the mice as intended, a tail knick
procedure was performed on each mouse under anaesthesia and blood was drawn from
the tail. This was performed at all time points. To ensure that the anaesthesia did not af-
fect behavioural measurements, blood samples were acquired after all behavioural studies
were complete. After collection, blood samples were sent to Heartland Assays (Ames, IA,
USA) for radioimmunoassay to determine the serum 25(OH)D levels.
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FIGURE 4.1: A summary of the study design is shown in (a). 10 week old APPSwe/PS1∆E9
mice received the AIN-76A control diet containing 1000 IU Vitamin D (VitD) from 10
weeks to 6 months of age. 14 mice continued to receive this diet for the remainder of the
study. Starting at 6 months of age, the remainder of the mice received a VitD deficient diet,
which was identical to the control diet except that it contained < 1 IU VitD. 41 of these mice
survived to 9 months of age. Of these 41 mice, 13 continued to receive the VitD deficient
diet, while the other 28 received further intervention not presented herein. At each time
point, all mice were assessed over a 2 week period according the schedule summarized
in (b). Mice were tested on the elevated plus maze on Day 1, the wire hang experiment
on Day 4, the Barnes maze on Days 5-9, and the Morris water maze on Days 10-14. Blood
was collected for measurement of serum 25(OH)D levels after the behavioural testing was
completed, so anaesthesia would not affect the behavioural measurements. For the same
reason, the scanning session to collect MRI and 1H-MRS data was also scheduled after all
behavioural measurements were completed.
161
Chapter 4. Chronic VitD deficiency in adult APP/PS1 mice
4.2.3 Behavioural Studies
Behavioural studies were performed on all mice at 6, 9, 12, and 15 months of age. At each
time point, mice completed the behaviour studies before any diet changes occurred. Mice
were evaluated over a two week period, beginning with the elevated plus maze (EPM) on
the first day. On the fourth day, mice underwent the wire hang test. On days 5 to 9, mice
were evaluated on the Barnes maze (BM). Finally, on days 10 to 14, mice were evaluated
on the Morris water maze (MWM). While the Barnes maze was performed at every time
point, the MWM was performed only at 12 months and 15 months of age. A summary of
the behavioural assessment schedule is shown in Figure 4.1b.
4.2.3.1 Morris Water Maze
The Morris water maze (MWM) is a task frequently used to assess spatial memory and
learning. The MWM consisted of a submerged target platform made of clear plastic placed
in the centre of one quadrant of a round pool with a 2 metre diameter. The pool contained
clear water heated to a temperature of 25 degrees Celsius to prevent hypothermia [29]. The
water was filled to a level such that mice could still see distal visual cues in the room, but
could not jump out of the maze once they were on the platform. Visual cues were on three
of the four walls of the MWM testing room. The room was lit with two incandescent light
bulbs located at two adjacent corners of the room. An overhead webcam mounted on the
ceiling recorded all mouse activity.
Mice were evaluated over a five day period. For the first four days, mice were trained to
find the target platform with four trials per day. Each trial began with the mouse entering
the maze from either the North, South, East, or West locations. For each mouse, the set of
starting locations were constructed in a semi-random fashion such that all four locations
were used and one trial each day was from each of the four locations [30]. Trials began as
soon as the mouse entered the water and ended once the mouse found the target platform
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or the maximum trial time of 90 seconds was reached. If the mouse did not find the tar-
get platform, it was gently guided to the platform by the experimenter. Regardless of how
the mouse arrived at the target platform, it remained there for 20 seconds once it found
the platform. At the end of the 20 seconds, the mouse was returned to its home cage. The
four trials were conducted in a spaced fashion, with the all mice completing the first trial
before the first mouse began its second trial. Mice waiting for their turn in the maze were
placed in cages with no access to food or water located behind an opaque curtain, where
they had no view of the maze or the room cues. After the four training days, a probe trial
was conducted on the fifth day to assess reference memory. For the probe trial, the sub-
merged target platform was removed, and mice were allowed to explore the maze freely
until the maximum trial time of 60 seconds was reached. In this case, the starting position
for each mouse was random. Videos of the training and probe trials were analyzed using
Any-MAZE software (Stoetling Co., Wood Dale, IL, USA) and in-house software written in
Python (Python Software Foundation, https://www.python.org/) using the OpenCV 3.4.3
libraries (OpenCV Team, https://opencv.org/). Metrics obtained from Any-MAZE soft-
ware included the time to find the platform (primary latency), distance travelled to find
the target (primary path length), average proximity to the target, and time spent in the
quadrant containing the target platform (target quadrant time). The in-house software was
used to generate spatial maps of mouse activity (Figure 4.2a) for the probe trials, which
were used to compare probe trial activity in the MWM between groups and between time
points.
Since mice were tested in the MWM at both 12 months of age and 15 months of age, the
location of the target platform was changed for each time point to minimize longitudinal
learning effects. At 12 months of age, mice were randomized without consideration of diet
group membership to be trained to find the target platform in either Quadrant 1 or Quad-
rant 2. At 15 months of age, mice that were trained to find the target platform in Quadrant
1 at 12 months of age were then trained to find the target platform in Quadrant 3. Similarly,
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FIGURE 4.2: In house software written using Python and OpenCV 3.4.3 was used to auto-
matically track mouse activity from recorded videos of experimental sessions. An example
of the mouse tracking in the Morris water maze (MWM) is shown in (a), with the mouse
outlined in blue and the edge of the tank shown in red. From the video tracking, spatial
maps of maze activity may be generated, where a brighter green colour indicates more
time spent by mice at that location. Several relevant MWM metrics may be obtained. An
example of mouse tracking in the Barnes maze (BM) is shown in (b). The mouse is out-
lined in the blue, its head and tail are identified in red, and the BM apparatus is outlined
in green. Like with the MWM, spatial maps of mouse activity and relevant BM metrics may
be obtained. An example of mouse tracking in the elevated plus maze (EPM) is shown in
the (c). The mouse is outlined in blue, and the edges of the EPM are shown in green. The
regions of the EPM are labelled in red, with the “OA” labels corresponding to the open
arms, the “CA” labels corresponding to the closed arms, and the red square correspond-
ing to the centre region. The mouse was considered to be completely within a region of the
maze if the centroid of the mouse segmentation was in the region.
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mice that were trained to find the target platform in Quadrant 2 at 12 months of age were
then trained to find the target platform in Quadrant 4 at 15 months of age.
4.2.3.2 Barnes Maze
Although studies investigating the effect of Vitamin D on spatial memory and learning
have mostly employed the MWM [22, 23, 24, 25], the Barnes maze (BM) task was used in the
present study as an alternative method for assessment of spatial memory and learning. The
BM offers an advantage over the MWM, since differences in speed, anxiety, and locomotor
ability are automatically controlled for [31]. The BM consisted of a white, circular platform
(92 cm in diameter), elevated 105 cm above the floor (San Diego Instruments, San Diego,
CA, USA). The platform had 20 equally spaced holes that were 5 cm in diameter, with
7.5 cm between holes. A false box or a target box made of black-coloured plastic could be
placed underneath any of the holes. The BM testing room was lit with fluorescent lighting
located on the ceiling, and a single visual cue was placed on three of the four walls. The
distal visual cues were a circle, square, and triangle printed in black ink on a white sheet of
paper [32]. Also on the ceiling was an overhead webcam that recorded all mouse activity.
Mice were evaluated over a five-day testing period. For the first four days, mice were
trained to find the target box. Each training day consisted of four trials. Trials began with
the mouse being placed inside a start tube (20 cm in diameter). When the start tube was
removed, the mouse could roam freely and the video recording was started. A beeping
alarm from a digital timer was used during the trial as a mild aversive stimulus. Trials
were stopped when the mouse found the target box and climbed completely inside or if
the maximum trial time of 180 seconds was reached. If the mouse did not find the target
during the trial, the experimenter gently guided the mouse to the hole containing the tar-
get box with his hand. The base of the tail was then gently pulled in the direction away
from the target hole, which encouraged the mouse to move towards the target hole and
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climb into the target box. Once the mouse was in the target box, whether by its own voli-
tion or with help from the experimenter, it remained in the box for 1 minute before it was
returned to its home cage. Trials were conducted in a spaced fashion, wherein the first trial
of all mice being tested were completed before the second trial of the first mouse began.
Between trials, the maze, the target box, and the false boxes were cleaned with a 10% alco-
hol solution to remove odours and the maze was rotated 90 degrees to prevent mice from
using intra-maze cues. After four training days were completed, a 90 second probe trial
was conducted on the fifth day to assess reference memory. The probe trial was conducted
in the same way as the training trials, except that the target box was replaced with a false
box and trials were not stopped early for any reason. Videos of the training and probe tri-
als were analyzed using in-house software written in Python, which used OpenCV 3.4.3
libraries to automatically segment the Barnes maze apparatus, identify the hole locations,
and track the mouse head, tail, and centre of mass (Figure 4.2b). Each hole zone was de-
fined as the hole plus 1 cm around the hole, and a mouse was considered to have entered a
hole zone if the head was in the zone. Metrics including the latency time to find the target
hole (primary latency), the time spent at false holes before finding the target (primary er-
ror time), average proximity to the target hole, and the time spent at the target hole (target
time) were measured by the software. The software also generated spatial maps of mouse
activity (Figure 4.2b) for the probe trials, which were used to compare probe trial activity
in the BM between groups and between time points.
Since mice were tested in the Barnes maze at 6 months, 9 months, 12 months, and 15
months of age, the location of the target box was changed for each time point to minimize
longitudinal learning effects. Specifically, at 6 months of age, mice were randomized to be
trained at either target hole 1, 6, 11, or 16 without consideration for diet group membership.
Mice that were trained to find target hole 1 at 6 months of age were then trained to find
target hole 6 at 9 months of age, target hole 11 at 12 months of age, and then target hole
16 at 15 months of age. Similarly, mice that were trained to find target hole 6 at 6 months
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of age were then trained to find target hole 11 at 9 months of age, and so on. This target
assignment scheme was also used for mice randomized to target hole 11 and 16 at 6 months
of age.
4.2.3.3 Confounding Variables of Spatial Learning and Memory
Some variables that could confound a mouse’s performance in the BM and MWM were
measured. Weight was measured, since it could be a confounding variable for the MWM
as a mouse’s buoyancy depends on its weight. A mouse’s physical ability and motivation to
complete a maze (i.e. anxiety-like behaviour) was also assessed, since these could confound
a mouse’s performance in the BM and MWM. Physical ability was assessed by measuring
neuromuscular function and grip strength with the wire hang test, while anxiety-like be-
haviour was assessed using the elevated plus maze (EPM).
4.2.3.3.1 Wire Hang
Neuromuscular function and grip strength were measured using a wire hang test. A stan-
dard wire cage top was used as the experiment apparatus. The edges of the wire cage were
taped off, preventing the mice from reaching the edges and climbing onto the other side
when inverted. To perform the experiment, a mouse was gently placed on the wire cage
top. The wire cage top was then gently shaken to induce the mice to grip onto the appa-
ratus. Next, the cage top was inverted and suspended 40 cm above a large tub cage filled
with bedding. The total time that the mouse was able to hang inverted was measured. Each
mouse performed 5 trials of the wire hang experiment. The longest and shortest wire hang
times were removed and the remaining 3 times were averaged.
4.2.3.3.2 Elevated Plus Maze
Anxiety-like behaviour was assessed using the EPM (Med Associates Inc., Fairfax, VT,
USA). The maze consisted of four arms that were 34.9 cm long and 6.07 cm wide. Two
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of the arms were closed with walls that were 19.13 cm tall, while the other two arms were
open arms without walls. The centre of the maze was a square region with sides that were
6.1 cm in length. Experiments began with the animals being placed at the centre. The an-
imals were then allowed to roam freely for 10 minutes. Activity was recorded with a we-
bcam placed directly above the maze. The video recorded by the webcam was analyzed
using in-house software written in Python. Using the OpenCV 3.4.3 libraries, the analysis
software automatically segmented the open and closed arm regions of the maze, identified
the mouse outline, and tracked the mouse location (Figure 4.2c). A mouse was considered
to be completely within a region of the maze if the centroid of the mouse segmentation
was in the region. The total amount of time spent in open arm regions (open arm time) is
considered a valid index of anxiety [33] and was recorded.
4.2.4 Magnetic Resonance Imaging and Ventricle Volume
Ventricle volume, a valid metric of neuronal loss and AD progression in humans [34], was
measured in the mice using MRI. MRI data were acquired from a subset of mice receiving
either the control diet or VitD- diet. 8 mice receiving the control diet were scanned at 6
months of age, with follow-up scans of the same mice performed at 9 months, 12 months,
and 15 months of age. For mice receiving the VitD- diet, 8 were scanned at 6 months, 24
were scanned at 9 months, 8 were scanned at 12 months, and 8 were scanned at 15 months.
Where possible, the same mice were followed longitudinally.
Mice were scanned in a Varian 9.4 Tesla small-bore MRI scanner (Palo Alto, CA, USA)
at the Centre for Functional and Metabolic Mapping, Robarts Research Institute using an
Agilent Millipede MP30 radio-frequency (RF) coil (Santa Clara, CA, USA). High-resolution
3D anatomical images (Figure 4.3a) were acquired using the TrueFISP (fast imaging with
steady state precession) sequence [35] with the following parameters: TR/TE=7/3.5 ms,
flip angle=70◦, FOV=19.2 × 19.2 × 14.4 mm3, matrix=128 × 128 × 96, resolution=150 ×
150× 150 µm3, coronal slice orientation, reception bandwidth=32051 Hz (250 Hz/pixel),
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6 averages. TrueFISP images have excellent tissue/CSF contrast that facilitates ventricle
segmentation.
To segment the ventricles, voxels in the image were classified as either tissue or CSF.
This segmentation was performed using in-house software written in Python using the Ni-
Babel v2.1.0 libraries [36] and VTK 8.0.1 libraries [37]. First, a pulse-coupled neural network
(PCNN) [38] was used for brain extraction (Figure 4.3b). Then, an estimated distribution of
image voxel intensities was obtained from the brain extracted image using Gaussian ker-
nel density estimation. Voxels with intensities below the 93.5th percentile were considered
tissue, while voxels with intensities above the 93.5th percentile were considered to be CSF
(Figure 4.3c). With only the CSF voxels, a discrete marching cubes algorithm was used to
generate closed isosurfaces of all CSF volumes. Surfaces that corresponded to the lateral
and 3rd ventricles were manually selected (Figure 4.3d). The volume enclosed by these
surfaces were calculated and recorded as the estimated ventricle volume.
4.2.5 Magnetic Resonance Spectroscopy
4.2.5.1 Acquisition
Proton magnetic resonance spectroscopy (1H-MRS) data were acquired in all mice during
the same MRI session used to acquire the images to assess ventricle volume. In vivo 1H-
MRS data were acquired using a localization by adiabatic selective refocusing (LASER)
sequence [39] from a 2× 6× 3 mm3 voxel encompassing both hippocampi (Figure 4.4a).
The spectroscopy voxel was manually positioned using anatomical landmarks on 2D fast-
spin echo (2D-FSE) anatomical images (TR/TE=4000/10 ms; FOV=19.2× 19.2 mm2, TE=10
ms, matrix=128× 128, slice thickness=0.5 mm). Both water suppressed and water unsup-
pressed data were acquired with the following parameters: TR=3250 ms, TE=18.9 ms, band-
width=6000 Hz, averages=128 for water unsuppressed data, and averages=8 for the water
unsuppressed data. The adiabatic full passage pulse used (AFP) was a hyperbolic secant
169
Chapter 4. Chronic VitD deficiency in adult APP/PS1 mice
FIGURE 4.3: An example of a high-resolution (150× 150× 150 µm3) TrueFISP image with
excellent tissue/cerebrospinal fluid (CSF) contrast for ventricle segmentation is shown in
(a). A pulse-coupled neural network was first used to segment the brain from the sur-
rounding structures (b). Then, an estimated distribution of image voxel intensities was
obtained from the brain extracted image using Gaussian kernel density estimation with
voxels having intensities below the 93.5th percentile being considered tissue, and voxels
having intensities above the 93.5th percentile being considered CSF. The identified CSF
voxels are labelled with yellow and shown in (c). Next, a discrete marching cubes algo-
rithm was used to generate closed isosurfaces of all CSF volumes. Finally, surfaces that
corresponded to the lateral and 3rd ventricles were manually selected (d), and the total
enclosed volume was recorded as the ventricle volume. Ventricle volume is plotted with
respect to age in (d). Standard errors are shown. Ventricle volume showed no significant
effect of age, diet, or age-by-diet interaction indicating that ventricle volume did not sig-
nificantly change with age and did not differ significantly between mice on a control diet
and mice on a vitamin D deficient (VitD-) diet.
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FIGURE 4.4: An example of a brain extracted 2D fast-spin echo (2D-FSE) anatomical image
is shown in (a). The 2× 6× 3 mm3 spectroscopy voxel encompassing both hippocampi
is labelled in green. Voxels that are cerebrospinal fluid (CSF), identified using the same
segmentation method as described for ventricle segmentation, are shown in yellow. This
enabled the calculation of the fraction of the spectroscopy voxel that was tissue and the
fraction that was CSF. An example of post-processed 1H-MRS spectra acquired from the
hippocampal region is shown in (b). The fitted prior knowledge template is also shown,
along with the individual metabolite components. Longitudinal measurements of NAA,
creatine (Cr), lactate (Lac), and taurine concentrations are plotted in (c), (d), and (e), re-
spectively. Data were analyzed using linear mixed models (see text for details) and the
estimated marginal means are shown with standard errors. Statistically significant Sidak-
corrected post-hoc comparisons (p < 0.05: *, p < 0.01: **) are indicated with asterisks.
Differences between time points are shown with red brackets for the control diet group
and blue brackets for the vitamin D deficient diet group. Between group differences are
indicated with asterisks only.
(HS2) pulse with a time-bandwidth product of 15. Water suppression was achieved using
the VAPOR (variable pulse power and optimized relaxation delays) scheme that preceded
the LASER sequence. A metabolite-suppressed macromolecule only spectrum was also ac-
quired using a single inversion recovery technique interleaved with the LASER acquisition
of the full (macromolecule + metabolite) spectrum. At each time point, the scanning session
always occurred after all behavioural studies were complete to ensure that anaesthesia did
not affect the behavioural measurements (Figure 4.1b).
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4.2.5.2 Post-Processing
The 1H-MRS data were first lineshape and eddy current corrected using combined QUAL-
ITY deconvolution and eddy current correction (QUECC) [40] with 400 QUALITY points
[41]. Residual water in the water suppressed spectrum was removed by subtracting peaks
between 4.2 ppm and 5.7 ppm identified by a Hankel singular value decomposition
(HSVD) fitting routine that required no prior knowledge. HSVD fitting was also used to
generate a noiseless model of acquired macromolecule spectra, which was subtracted from
the water suppressed full spectrum to obtain a metabolite-only spectrum.
Metabolite-only spectra were then fitted with prior knowledge templates (Figure 4.4b)
using a Levenberg-Marquardt minimization algorithm [42]. Water unsuppressed spectra
were fitted with a prior knowledge template containing a single Lorentzian at 4.7 ppm to
obtain the amplitude of the water signal. For the water suppressed spectra, an echo-time
specific, simulated 9.4 T LASER prior knowledge template generated using density matrix
simulations was used. Simulations were performed using Python code written in-house
that utilized the PyGAMMA library of the VeSPA (Versatile Simulation, Pulses and Analy-
sis) software suite [43]. Metabolites included in this prior knowledge template included N-
acetyl aspartate (NAA), aspartate (Asp), lactate (Lac), alanine (Ala), glutamate (Glu), glu-
tamine (Gln), glutathione (GSH), creatine (Cr), taurine, choline (Cho), glycerophosphoryl-
choline (GroPCho), phosphorylcholine (PCho), scyllo-inositol (Scyllo), myo-inositol (Myo),
glucose (Glc), and glycine (Gly). To reduce the number of variables to be fitted, parameters
describing the lineshapes of the metabolites were constrained within the prior knowledge
template. Within metabolites, peak amplitudes, shifts, and phases were fixed relative to
one another. Relative peak amplitudes were not fixed between metabolites, since these are
expected to vary across mice. Relative peak positions and phases between some metabo-
lites were fixed. The positions and phases of low-amplitude metabolites were linked to the
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Reference
Metabolite
Linked Metabolites Comments
Shift Phase
NAA Asp Asp, Glc, Gly, Lac,
Ala, Scyllo, Myo
• Shifts for Cr were not
fixed relative to any
reference metabolite.
• A separate linewidth
parameter was defined
for Glu, Gln, and GSH.
A single linewidth pa-
rameter was defined
for all other metabo-
lites.
• A single delay param-
eter was defined for all
metabolites.
Lac Ala
Glu Gln, GSH, GABA Gln, GSH, GABA
Tau Cho, Scyllo, Myo,
Glc, Gly
Cr, Cho
TABLE 4.1: A summary of relationships between metabolite parameters in the prior knowl-
edge template [44]. Peak positions (shifts) and phases of low-amplitude metabolites were
linked to the shifts and phases of higher-amplitude metabolites. Within metabolites, peak
amplitudes, shifts, and phases were fixed relative to one another. The following metabo-
lites were included in the prior knowledge template used to fit 1H-MRS data: NAA, Asp,
Lac, Ala, Glu, Gln, GSH, Cr, Tau, Cho, GroPCho, PCho, Scyllo, Myo, Glc, and Gly.
positions and phases of high-amplitude metabolites such as NAA, Tau, and Glu. A sum-
mary of the parameter constraints are provided in Table 4.1.
4.2.5.3 Metabolite Quantification
Hippocampal metabolite concentrations were obtained as previously described [45] using
the fitted and corrected amplitudes of the metabolite signal and the water signal. Correc-
tions for the relaxation rates of metabolites in tissue and CSF incorporated T1 and T2 values
obtained from literature (Table 4.2) as well as tissue and CSF fractions obtained from the
2D-FSE anatomical images. The same T1 and T2 values were used for both the white mat-
ter (WM) and grey matter (GM) tissue compartments, as these compartments could not be
separated within the 2D-FSE anatomical images. However, the cerebrospinal fluid (CSF)
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compartment could be separated from the overall tissue compartment using the same seg-
mentation method as described above for the 3D TrueFISP volumes (Figure 4.4a). This
enabled the calculation of the GM, WM and CSF partial volume within the spectroscopy
voxel.
4.2.6 Statistical Analyses
4.2.6.1 Analysis of Longitudinal Data
Longitudinal changes in serum 25(OH)D level, behavioural metrics, ventricle volume mea-
surements, and metabolite levels were analyzed using linear mixed models with the age of
the mouse, the mouse’s diet (control diet or VitD- diet), and the age-by-diet interaction as
fixed effects. Repeated observations on the same mice were accounted for using an unstruc-
tured covariance matrix term, and maximum likelihood estimation was used to produce
the statistical models. If any fixed effects were significant, post-hoc tests of simple main
effects and comparisons of covariate-adjusted estimated marginal means were performed
to identify statistically significant differences between time points and between groups. A
Sidak correction [51] was applied to control for multiple comparisons.
For the BM and MWM metrics, the mouse’s wire hang time, weight, mean speed during
the trial, and open arm time in the EPM were used as covariates in the statistical models.
Since successful completion of the BM task requires the mouse to make a choice between a
false box and the target box, a wrong choice involves the same motor ability as the correct
choice. Thus, differences in motor ability are inherently controlled for in the BM’s design.
As a result, reduced models with only the mouse’s open arm time in the EPM as a covariate
were used to analyze the BM data. All statistical analyses were performed using the mixed
command in IBM SPSS Statistics version 25 (IBM, Armonk, NY, USA).
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Metabolite
T1 [s] T2[ms]
Tissue CSF Reference Tissue CSF Reference
NAA 1.6740 [46] 321 [47]
Ala 1.3701a 161a
GABA 1.3701a 161a
Asp 1.3701a 161a
Cho, GroP-
Cho, PCho
1.3484 445
Cr 1.6792 104
Glc 1.3701 161
Glu 1.4975 70
Gln 1.4975b 56
GSH 1.3701a 161a
Gly 1.3701a 161a
Myo 1.3701 161
Scyllo 1.3701a 161a
Lac 1.3701a 161a
Taurine 2.3289 162
Water 2.0567 4.2867 [46, 48] 44 111.3 [48, 47]
a T1 and T2 values of metabolites which were not available in literature were as-
sumed to be similar to that of Myo [49, 50].
b The T1 value of Gln was assumed to be similar to Glu because the Glx (Glu + Gln)
was measured in [46].
TABLE 4.2: A summary of the metabolite-specific T1 and T2 values used for relaxation
correction of the fitted metabolite signals. T1 and T2 values are obtained directly from the
literature.
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4.2.6.2 Analysis of Spatial Maps of Mouse Activity
A permutation testing method typically used to compare surface dose maps for radio-
therapy [52] was used to compare spatial maps of probe trial activity in the BM and MWM
between groups and between time points. Briefly, the method calculates a test statistic from
the activity maps that summarizes the overall difference in maze activity between groups.
Then the method randomly permutes the group labels to generate a null distribution, from
which an adjusted p value threshold for statistical significance is calculated. Finally, regions
where pixel-wise comparisons meet this threshold are considered significantly different.
Permutation testing gives strong control over false positives, whereas directly comparing
activity between groups at each pixel of the map does not. To reduce the amount of compu-
tation needed, activity maps were resampled to 10% of the original image resolution before
applying the method.
4.3 Results
4.3.1 Vitamin D Status
The linear mixed model for serum 25(OH)D levels (Figure 4.5) showed a significant effect
of age (F(3, 36) = 95.366, p < 0.001), diet (F(1, 36) = 321.941, p < 0.001), and age-by-diet
interaction (F(3, 36) = 85.994, p < 0.001). Post-hoc univariate tests showed that VitD levels
decreased with age in both the control (significant effect of age: F(3, 35) = 6.065, p < 0.01)
and VitD- diet groups (significant effect of age: F(3, 42) = 253.769, p < 0.001). Mice on
the control diet had higher serum 25(OH)D levels than mice on the VitD- diet at 9 months
(significant effect of diet: F(1, 55) = 240.726, p < 0.001), 12 months (significant effect
of diet: F(1, 31) = 537.911, p < 0.001), and 15 months of age (significant effect of diet:
F(1, 28) = 37.996, p < 0.001).
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FIGURE 4.5: Serum 25(OH)D levels as measured by radioimmunoassay were analyzed us-
ing linear mixed models. The estimated marginal means with standard errors are shown.
Statistically significant Sidak-corrected post-hoc comparisons (p < 0.05: *, p < 0.01: **,
p < 0.001: ***) are indicated with the asterisks. Differences between time points are shown
with red brackets for the control diet group and blue brackets for the vitamin D deficient
(VitD-) diet group. Between group differences are indicated with asterisks only. VitD lev-
els decreased with age in both the control diet and VitD- diet mice, with control diet mice
having higher serum 25(OH)D levels than mice on the VitD- diet at 9 months, 12 months,
and 15 months of age.
177
Chapter 4. Chronic VitD deficiency in adult APP/PS1 mice
4.3.2 Morris Water Maze
4.3.2.1 Training Phase
At 12 months of age, analysis of primary latency (Figure 4.6a) showed a significant effect
of training day (F(3, 27) = 10.616, p < 0.001). Univariate post-hoc tests showed that there
was a decrease in the time to find the platform with training day in mice receiving both
the control diet (F(3, 27) = 8.590, p < 0.001) and the VitD- diet (F(3, 27) = 3.152, p <
0.05). Primary latency over the training days were not different between groups as there
was no significant effect of diet (F(1, 30) = 0.204, p = 0.665) or age-by-diet interaction
(F(1, 26) = 0.741, p = 0.537). Analysis of primary path length (Figure 4.6b) showed similar
results, with a significant effect of training day (F(3, 27) = 10.184, p < 0.001). Univariate
post-hoc tests revealed a significant decrease in distance travelled to find the target with
training day in both control diet mice (F(3, 27) = 7.866, p < 0.01) and VitD- diet mice
(F(3, 27) = 3.253, p < 0.05), but no significant differences between groups (diet effect:
F(1, 30) = 0.688, p = 0.413; age-by-diet effect: F(3, 26) = 0.549, p = 0.653). In line with
these results, average proximity to target during training trials (Figure 4.6c) decreased with
time as there was a significant effect of training day (F(3, 25) = 6.118, p < 0.01). Post-
hoc tests of average proximity to target revealed that mice on the VitD- diet were further
away from the target on average during day 4 of training than mice on the control diet
(F(1, 33) = 8.424, p < 0.01). Together, these results suggests that mice on both diets were
able to learn the MWM task at 12 months of age.
At 15 months of age, there was no significant effect of training day, diet, or day-by-diet
interaction in the analyses of primary latency and primary path length. Analysis of the
average proximity to target during training trials revealed a significant effect of training
day (Figure 4.6c; F(3, 24) = 3.654, p < 0.05), but post-hoc tests showed no differences
between training days or between groups. This indicates that mice did not improve in
maze performance with training. However, performance in MWM as measured by primary
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latency, primary path length, and proximity to target was better on Day 1 of training at 15
months of age compared to Day 1 of training at 12 months of age, indicating that mice had
retained the MWM task rules from testing at 12 months of age.
4.3.2.2 Probe Trial
Analyses of the MWM probe trial showed significant effects of age for the primary latency
(Figure 4.6d; F(1, 36) = 13.383, p < 0.01) and average proximity to the target platform
location (Figure 4.6e; F(1, 36) = 11.294, p < 0.01) metrics. A significant effect of age was
also found when analyzing the time spent in the quadrant of the maze containing the lo-
cation of the target platform (Figure 4.6f; F(1, 36) = 7.195, p < 0.05). Post-hoc univariate
analyses of these metrics showed a significant effect of age only for mice on the VitD- diet.
For these mice, primary latency decreased with age (F(1, 34) = 12.646, p < 0.01), average
proximity to target decreased with age (F(1, 34) = 17.676, p < 0.001), and target quadrant
time increased with age (F(1, 34) = 10.335, p < 0.01). Together, this indicates that the per-
formance in the probe trial of VitD- diet mice, but not control diet mice, improved from 12
months of age to 15 months of age.
Significant age-by-diet interactions were found for the average proximity to target met-
ric (F(1, 25) = 8.090, p < 0.01) and target quadrant time metric (F(1, 25) = 4.278, p <
0.05). Post-hoc analyses showed that 12 month old VitD- mice were, on average, further
away from the location of the target than 12 month old control diet mice (F(1, 31) =
7.096, p < 0.05) during the probe trial. This indicates that VitD- mice had worse recall
of the platform location than control diet mice at 12 months of age. However, no regional
differences between control diet mice and VitD- mice were detected on the spatial maps
of MWM activity at 12 months of age. At 15 months of age, post-hoc analyses of primary
latency showed that VitD- diet mice found the target location faster than mice on the con-
trol diet (F(1, 28) = 5.347, p < 0.05). However, no regional differences were detected on
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FIGURE 4.6: The performance of APPSwe/PS1∆E9 mice in the Morris water maze (MWM)
is shown in blue for mice on the control diet and in red for mice on the Vitamin D defi-
cient (VitD-) diet. Metrics obtained from both the training (a–c) and the probe (d–f) trials
were analyzed using linear mixed models with wire hang time, weight, mean speed in the
MWM, and open arm time in the elevated plus maze as covariates. The covariate-adjusted
estimated marginal means with standard errors are shown. Statistically significant Sidak-
corrected post-hoc comparisons (p < 0.05: *, p < 0.01: **, p < 0.001: ***) are indicated
with the asterisks. Differences between time points are shown with red brackets for the
control diet group and blue brackets for the VitD- diet group. Between group differences
are indicated with asterisks only. For clarity, only between group differences are shown
for the training data. Metrics measuring spatial learning included primary latency (a) and
primary error time (b), which both decreased with training day at 12, but not 15 months
of age. Average proximity to the target platform (c) decreased with training day at 12 and
15 months of age, but 12 month old VitD- diet mice were further away from the target
than control diet mice on day 4 of training. Probe trial metrics measuring spatial memory
included primary latency (d), time spent in the quadrant containing the target location (e),
and average proximity to the target location (f), which all indicated improvement with age
for VitD- diet mice, but not for control diet mice. Compared to control diet mice, VitD- diet
mice performed worse on the proximity to target metric at 12 months of age (f), but better
on the primary latency metric at 15 months of age (d).
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spatial maps of MWM activity. There were also no regional differences detected on spatial
maps of MWM activity between time points.
4.3.3 Barnes Maze
4.3.3.1 Training Phase
Linear mixed model analyses revealed a significant effect of training day for the latency
time to find the target hole (primary latency; Figure 4.7a) and the time spent at false holes
before finding the target (primary error time; Figure 4.7b) at 6 months (primary latency:
F(3, 56) = 126.643, p < 0.001; primary error time: F(3, 56) = 96.571, p < 0.001), 9 months
(primary latency: F(3, 55) = 36.431, p < 0.001; primary error time: F(3, 55) = 32.043, p <
0.001), 12 months (primary latency: F(3, 26) = 9.244, p < 0.001; primary error time:
F(3, 26) = 10.007, p < 0.001), and 15 months (primary latency: F(3, 24) = 4.834, p < 0.01;
primary error time: F(3, 24) = 5.547, p < 0.01). Similarly, analyses of average proxim-
ity to target (Figure 4.7c) also revealed a significant effect of training day at 6 months
(F(3, 56) = 52.204, p < 0.001), 9 months (F(3, 55) = 21.316, p < 0.001), 12 months
(F(3, 26) = 12.403, p < 0.001), and 15 months (F(3, 24) = 3.865, p < 0.05) of age. To-
gether, this indicates that mice were able to learn the BM task at all ages.
Though no significant diet and day-by-diet effects were detected any time point, post-
hoc univariate tests showed some group differences. At 12 months of age, VitD- diet
mice had lower primary latency on day 2 of training than control diet mice (Figure 4.7a;
F(1, 26) = 4.424, p < 0.05), indicating that VitD- diet mice may have learned the task faster
than control diet mice. At 15 months of age, VitD- diet mice had higher primary error time
than control diet mice (Figure 4.7b; F(1, 24) = 4.643, p < 0.05) on day 1 of training at 15
months of age, indicating that control diet mice may be remembering the BM task rules
from previous testing at 12 months of age, while VitD- diet mice were not.
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FIGURE 4.7: The performance of APPSwe/PS1∆E9 mice in the Barnes maze (BM) is shown
in blue for mice on the control diet and in red for mice on the Vitamin D deficient (VitD-)
diet. Metrics obtained from both the training (a–c) and the probe (d) trials were analyzed
using linear mixed models with open arm time in the elevated plus maze as a covariate.
The covariate-adjusted estimated marginal means with standard errors are shown. Statisti-
cally significant Sidak-corrected post-hoc comparisons (p < 0.05: *, p < 0.01: **, p < 0.001:
***) are indicated with the asterisks. Differences between time points are shown with red
brackets for the control diet group and blue brackets for the VitD- diet group. Between
group differences are indicated with asterisks only. For clarity, only between group dif-
ferences are shown for the training data. Metrics measuring spatial learning included the
latency to find the target hole (a), the time spent at false holes before finding the target
(b), and the average proximity to the target (c), which all decreased with training day at
every time point, indicating mice were able to learn the BM task. Metrics measuring spa-
tial learning in the probe trial (d) included target visit time, primary latency, and average
proximity to the target. These metrics worsened with age for the control mice, but not the
VitD- diet mice. Compared to control diet mice, VitD- diet mice spent more time at the
target hole at 12 and 15 months of age. They also remained closer to the target hole during
the probe trial at 9 and 12 months of age.
182
4.3. Results
4.3.3.2 Probe Trial
Analyses of the BM probe trial (Figure 4.7d) revealed a significant effect of age for the target
visit time (F(3, 34) = 4.652, p < 0.01), with post-hoc univariate analyses showing that as
mice on the control diet grew older, target visit time decreased (F(3, 27) = 3.633, p < 0.05).
In line with these results, a significant effect of age for primary latency was also observed
(F(3, 36) = 3.666, p < 0.05), with post-hoc univariate analyses showing that primary la-
tency for control mice increased with age. No worsening of BM performance with age was
seen in VitD- diet mice. This is corroborated further by the regional differences in BM activ-
ity of control diet mice between time points (Figure 4.8). Permutation testing revealed that
mice on the control diet spent less time at the target hole when they were 12 or 15 months
of age than at 6 months of age. The BM activity for VitD- mice differed when comparing
activity at 9 months vs. 15 months of age, but this difference occurred at a false hole. No
other regional differences in BM activity across time points were observed in the VitD- diet
mice.
There was also a significant effect of diet for the target visit time metric (F(3, 34) =
10.454, p < 0.01), with post-hoc analyses showing that control diet mice spent less time
at the target than VitD- diet mice at 12 months of age (F(1, 26) = 12.869, p < 0.01) and
15 months of age (F(1, 25) = 5.069, p < 0.05). For the average proximity to target metric,
there was a significant age-by-diet effect (F(3, 30) = 3.350, p < 0.05), with post-hoc tests
showing that control diet mice were further away from the target hole on average than
control diet mice at both 9 months of age (F(1, 55) = 5.124, p < 0.05) and 12 months of age
(F(1, 27) = 5.685, p < 0.05). Together, this indicates that control diet mice may have worse
recall of the target hole location than VitD- mice at 9, 12, and 15 months of age. However,
no regional differences of BM activity between groups were detected on spatial activity
maps at any time point.
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FIGURE 4.8: Average maps of probe trial activity in the Barnes maze (BM) are shown for
APPSwe/PS1∆E9 mice on the control diet at 6 months, 9 months, 12 months, and 15 months
of age (a). A brighter green colour on the map indicates more time spent by mice in that
location, while the arrow indicates the location of the target hole. Maps were compared
between time points using a permutation testing method that has strong control over false
positives (see text for details). The results of these comparisons are shown in (b) and (c).
Only areas that differ in activity at a significance level of p < 0.05 are shown. Permutation
testing revealed that 6 month old control diet mice spent an average of 5 seconds more at
the target hole than 12 month old (b) and 15 month old (c) control diet mice.
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4.3.4 Confounding Variables of Spatial Learning and Memory
4.3.4.1 Weight and Wire Hang Time
Analysis of weight change over time revealed a significant effect of age (F(3, 35) =
14.725, p < 0.001), diet (F(1, 46) = 7.236, p < 0.05), and age-by-diet interaction
(F(3, 35) = 3.185, p < 0.05). Post-hoc univariate analyses revealed an increase in weight
with age for both the control diet mice (F(3, 32) = 6.701, p < 0.01) and the VitD- diet
mice (F(3, 44) = 12.822, p < 0.001). Post-hoc analyses also showed that VitD- mice
were heavier than control mice at 6 months (F(1, 56) = 5.079, p < 0.05), 9 months
(F(1, 53) = 6.055, p < 0.05), and 12 months of age (F(1, 40) = 14.007, p < 0.01).
Analysis of wire hang time revealed a significant effect of age (F(3, 37) = 15.931, p <
0.001). There was also a significant effect of weight on the wire hang time (F(1, 103) =
18.803, p < 0.001). Post-hoc analyses (adjusted for weight) revealed a decrease in wire
hang time with age for both the control diet mice (F(3, 28) = 7.289, p < 0.01) and VitD- diet
mice (F(3, 46) = 11.872, p < 0.001). No diet and age-by-diet main effects were detected,
and no between group differences were detected in post-hoc analyses at any time point.
Between-group and across-time differences in weight and wire hang time justified their
inclusion as covariates when analyzing MWM data.
4.3.4.2 Open Arm Time in the EPM
Analysis of the total amount of time spent in open arm regions revealed a significant effect
of age (F(3, 27) = 13.561, p < 0.001), but no significant effects of diet or age-by-diet in-
teraction. Post-hoc analyses showed that the time spent in open arm regions decreased
with age for both control diet mice (F(3, 24) = 3.476, p < 0.05) and VitD- diet mice
(F(3, 36), p < 0.001), indicating that anxiety levels increased with age for all mice. There
were no differences between groups at any time point. Changes of anxiety levels over time
justified the inclusion of open arm time as covariates in the analysis of MWM and BM data.
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4.3.5 Ventricle Volume
Analyses of ventricle volume (Figure 4.3e) showed no significant effect of age, diet, or age-
by-diet interaction. This indicates that mice on a control diet had the same ventricle volume
as mice on the VitD- diet and that ventricle volume remained stable across time.
4.3.6 Magnetic Resonance Spectroscopy
Analysis of NAA concentration in the hippocampus as measured by 1H-MRS (Figure 4.4c)
revealed a significant effect of age (F(3, 22) = 9.164, p < 0.001) and diet (F(1, 31) =
5.693, p < 0.05). Post-hoc univariate analyses revealed that NAA concentration decreased
with age for both control diet mice (F(3, 10) = 6.868, p < 0.01) and the VitD- diet
mice (F(3, 18) = 3.777, p < 0.05). Post-hoc analyses also showed that 12 month old
control diet mice had higher NAA concentrations than 12 month old VitD- diet mice
(F(1, 14) = 5.537, p < 0.05). At 12 months of age, higher NAA concentrations were as-
sociated with lower average proximity to the target platform location in the MWM probe
trial (Figure 4.9a; two-tailed Pearson correlation: r = −0.6127, p < 0.05).
A significant effect of age (F(3, 23) = 4.274, p < 0.05) and age-by-diet interaction
(F(3, 23) = 3.134, p < 0.05) was observed for the Cr concentration (Figure 4.4d). Post-hoc
analyses revealed that 12 month old control diet mice had higher Cr concentrations than
12 month old VitD- diet mice (F(1, 14) = 13.684, p < 0.01). Like for NAA, higher Cr con-
centrations were associated with lower average proximity to the target platform location in
the MWM probe trial (Figure 4.9b; two-tailed Pearson correlation: r = −0.6148, p < 0.05).
In the analysis of Lac concentration (Figure 4.4e), there was a significant effect of age
(F(3, 20) = 7.528, p < 0.01) and age-by-diet interaction (F(3, 20) = 3.918, p < 0.05).
Post-hoc analyses showed that Lac concentration decreased with age for control diet
mice (F(3, 13) = 4.123, p < 0.01), while it increased with age for the VitD- diet mice
(F(3, 20) = 5.867, p < 0.001). Post-hoc analyses also revealed that mice in the VitD- diet
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group had lower Lac concentrations at baseline (6 months of age) than mice in the control
diet group (F(1, 16) = 6.305, p < 0.05). By 12 months of age, VitD- diet mice had higher
Lac concentrations than control diet mice (F(1, 14) = 5.443, p < 0.05). The increase in Lac
concentration over time was correlated with BM probe trial performance over time for the
VitD- diet mice. Specifically, a greater increase in Lac concentration from 12 months to 15
months of age was associated with a smaller increase in primary latency (Figure 4.9c; two-
tailed Pearson correlation: r = −0.9043, p < 0.05). In other words, a greater increase in
lactate was associated with less worsening in BM probe trial performance.
For taurine concentration (Figure 4.4f), a significant age-by-diet interaction was ob-
served (F(3, 12) = 6.616, p < 0.01). Post-hoc univariate analyses showed a significant
age effect for VitD- diet mice only (F(3, 16) = 5.619, p < 0.01), indicating that taurine
concentration changed with age for these mice. Indeed, 12 month old VitD- diet mice had
lower taurine levels than 9 month old (p < 0.05) and 15 month old VitD- mice (p < 0.05).
4.4 Discussion
The goal of this study was to thoroughly evaluate the role of chronic VitD deficiency in
AD using adult APPSwe/PS1∆E9 mice. Since mice on the VitD- diet had significantly lower
serum 25(OH)D levels than mice on the control diet at 9 months, 12 months, and 15 months
of age (Figure 4.5), chronic VitD deficiency was successfully established in this transgenic
model. This resulted in neurochemical changes detected using 1H-MRS, such as decreased
hippocampal NAA and Cr concentrations as well as increased Lac and taurine concen-
trations. Chronic VitD deficiency also appeared to result in better spatial memory perfor-
mance as measured on the BM and MWM. These results are discussed in more detail below.
In the present study, chronic VitD deficiency did not appear to result in differences
of ventricle size (Figure 4.3) as measured by MRI, a valid metric of neuronal loss and AD
progression in humans [34]. This result is not surprising, as APPSwe/PS1∆E9 mice typically
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FIGURE 4.9: The correlation between NAA concentration in the hippocampus of 12 month
old APPSwe/PS1∆E9 mice as measured by 1H-MRS and average proximity to the tar-
get platform location in the MWM probe trial is shown in (a). Increased NAA concen-
trations were associated with lower average proximity (two-tailed Pearson correlation:
r = −0.6127, p < 0.05). Creatine concentration in the hippocampus of 12 month old mice
were also associated with lower average proximity in the MWM probe trial (two-tailed
Pearson correlation: r = −0.6148, p < 0.05), as shown in (b). The 12 to 15 month change in
primary latency in the BM probe trial of APPSwe/PS1∆E9 mice on the Vitamin D deficient
(VitD-) diet is plotted against the 12 to 15 month change in hippocampal lactate (Lac) con-
centration as measured by 1H-MRS in (c). A greater increase in Lac concentration from 12
to 15 months of age was associated with a smaller increase in primary latency (two-tailed
Pearson correlation: r = −0.9043, p < 0.05).
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only exhibit modest neuronal loss [53] with no statistically significant total brain volume
or shape change from 6 months to 13 months of age [54].
On the other hand, neurochemical changes in the brain were detected using 1H-MRS
(Figure 4.4). Decreases in hippocampal NAA and Cr (Figure 4.4c, d) with age were ob-
served in APPSwe/PS1∆E9 mice on both the control and VitD- diets and. At 12 months of
age, lower NAA and Cr concentrations were associated with lower spatial memory recall
in the mice as measured by the MWM probe trial (Figure 4.9a, b). This result is consis-
tent with measurements of NAA and Cr concentrations in humans, both of which decrease
with AD progression and are associated with a decline in global cognitive function [55,
56]. VitD deficiency appears to accelerate this decline, since VitD- diet mice had lower hip-
pocampal NAA and Cr concentrations than control diet mice at 12 months of age. But,
by 15 months of age, hippocampal NAA and Cr levels of control diet mice had declined
to that of VitD- mice. Since NAA synthesis in the brain requires acetyl-coenzyme A lev-
els that exceed neuronal metabolic requirements [57] and Cr is essential for brain energy
homeostasis [58], decreasing NAA and Cr concentrations could reflect an increasing brain
energy deficit, a view supported by reduced brain glucose uptake in AD as measured by
FDG-PET [59, 60]. This reduction in glucose uptake could be offset by lactate, an important
source of energy in the brain [61, 62, 63]. Interestingly, the present study shows that VitD
deficiency increases the level of lactate in the brain (Figure 4.4e). APPSwe/PS1∆E9 mice on
a VitD- diet showed increasing hippocampal lactate concentrations with age, while mice
on a control diet showed decreasing lactate concentrations. At 12 months of age, VitD- diet
mice had increased levels of lactate compared to control diet mice. In addition to being
an energy source, lactate is also a signalling molecule in the brain that activates neuro-
protective mechanisms, promotes increased blood flow and fuel delivery, and is important
for long term memory formation [64]. The attenuated decline in spatial memory as mea-
sured by BM probe trial performance (Figure 4.9c) in VitD- diet mice in the present study
supports the notion that increasing lactate concentrations over time may help preserve
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memory function.
Increased lactate in the brain is likely a result of increased astrocyte metabolism, since
astrocyte metabolism is primarily via aerobic glycolysis, producing lactate to sustain neu-
ronal activity [65]. Thus, it is possible that VitD deficiency is increasing astrocyte activation
in the mice, resulting in increased lactate levels. Though we are not aware of any stud-
ies that have directly shown the effect of VitD deficiency on astrocytes, VitD administra-
tion has been shown to suppress astrocyte activation in vivo [66]. Suppression of astrocyte
activation is likely detrimental, as studies using transgenic mouse models that allow for
conditional ablation of reactive astrocytes have shown that astrocyte activation is essential
for restricting inflammation, limiting neuronal injury, and preserving neuronal function in
central nervous system injury and disease [67, 68].
In the context of AD, it has been shown that nerve cells resistant to Aβ toxicity have
increased markers of aerobic glycolysis [69], and overexpression of these markers confer
resistance to Aβ [70]. Further, reactive astrocytosis in conjunction with improved memory
function has been observed in response to taurine administration in APP/PS1 mice [71].
In the present study, taurine levels remained stable for APPSwe/PS1∆E9 mice on the con-
trol diet, but increased from 12 months of age to 15 months of age in mice on the VitD-
diet. In addition, decreased NAA, decreased Cr, and increased lactate (as observed in
APPSwe/PS1∆E9 mice on the VitD- diet) have been demonstrated to be associated with
high macrophage and glial density [72, 73]. Microglial activity has a protective role in AD,
including phagocytosing Aβ and clearing Aβ aggregates from the brain [74]. Together, the
neurochemical changes observed suggest that VitD deficiency could be conferring some
neuroprotection in AD.
The behavioural results of the present study supports this interpretation. Though
APPSwe/PS1∆E9 mice on both the control diet and VitD- diet exhibited spatial learning
with few differences (Figure 4.6a-c and Figure 4.7a-c), stark differences in spatial memory
function were observed in the BM and MWM probe trials. In the MWM probe trials, VitD
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deficient APPSwe/PS1∆E9 mice were further away from the target platform location that
mice on the control diet at 12 months of age (Figure 4.6f), but performance improved from
12 months to 15 months of age (Figure 4.6d-f), with VitD- diet mice finding the target lo-
cation faster than control diet mice at 15 months of age (Figure 4.6d). In contrast, mice on
the control diet did not display improvement in MWM probe trial performance. In the BM
probe trials, VitD deficient APPSwe/PS1∆E9 mice spent more time at the target hole at 12
and 15 months of age and were closer to the target hole during the probe trial at 9 and 12
months of age compared to control diet mice (Figure 4.7d). Analysis of overall BM activity
showed that control diet mice spent less time at the target hole when they were 12 or 15
months of age than at 6 months of age (Figure 4.8), suggesting worsening BM probe trial
performance. In contrast, no differences between time-points in BM activity at the target
hole were observed in the VitD- diet mice. Improvement in probe trial performance with
age and better performance in the MWM at 15 months of age coupled with better probe
trial performance by APPSwe/PS1∆E9 mice on a VitD- diet at 9 months, 12 months, and 15
months in the BM suggests that chronic VitD deficiency helped to preserve spatial memory
function.
To our knowledge, this is the first study evaluating VitD deficiency over the course of
9 months in an APP/PS1 mouse model of AD. One other study compared a low VitD diet
(500 IU/kg VitD3 in the feed) to a control diet (1000 IU/kg VitD3 in the feed) and a high
VitD diet (1000 IU/kg VitD3 in the feed + 1000 IU intramuscular injection every 2 weeks)
in quercetin-supplemented APP/PS1 mice from 3 months of age to 8 months of age [75].
Interestingly, they also found that mice on the low VitD diet had the best spatial memory
performance as measured by the MWM maze, though it is unclear whether their observed
effect was due to a VitD deficiency alone, or due to an interaction between quercetin and
VitD status. Another study used a rat model of AD, where AD was induced via intracere-
broventricular injection of Aβ1-42 [22]. In that study, AD rats given a diet devoid of VitD for
2 months performed worse in the MWM maze than rats given a normal diet with sufficient
191
Chapter 4. Chronic VitD deficiency in adult APP/PS1 mice
VitD. This is consistent with our observation that APPSwe/PS1∆E9 mice on a VitD- diet
perform worse in the MWM than mice on a control diet after 6 months of VitD deficiency.
However, after 9 months of VitD deficiency, we found that APPSwe/PS1∆E9 mice on a VitD-
diet actually performed better in the MWM. Thus, VitD deficiency may be detrimental in
the short term, but beneficial in the long term. More literature is available regarding VitD
supplementation than VitD deprivation in mouse models of AD, with most studies finding
that VitD supplementation confers a benefit [26, 76, 77, 78]. VitD supplementation was not
performed in the current study and the results presented herein do not refute or corrobo-
rate the benefits of VitD supplementation in AD. It is entirely plausible that both chronic
VitD supplementation and chronic VitD deprivation confer benefit in AD.
Though the current study did not look at ex vivo histology, indirect measurement of in
vivo biological processes were assessed using 1H-MRS. To our knowledge, this was the first
study to demonstrate longitudinal changes of in vivo brain metabolite levels due to VitD
deficiency in a mouse model of AD. Many studies have looked at longitudinal changes in
APP/PS1 mice on a standard, nutritionally sufficient diet, with the most consistent changes
reported being decreases in NAA and Glu levels relative to creatine [79, 80, 81, 82] as well
as increases in Myo relative to creatine [80, 81]. However, in our mice, no effect of age was
observed for the Glu or Myo concentration. Instead, an effect of age was observed for the
Cr concentration, suggesting that some of the previously reported changes could have been
driven by a change in Cr concentration rather than true changes in NAA, Glu or Myo.
The lack of ex vivo histology is a limitation of the current study. A reactive astrocytosis
process was inferred from measurements made using 1H-MRS, but this should be verified
using histology. However, since a longitudinal design was used, ex vivo histology would
have required sacrificing a proportion of the mice at each time point, significantly increas-
ing the cost and reducing the statistical power of the study. Another point of caution with
regards to 1H-MRS measurements in the current study was the use of literature values of
metabolite T1 and T2 in tissue (Table 4.2) to calculate metabolite concentrations. There is a
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possibility that these T1 and T2 values may not be appropriate, as they were measured in
wild-type mice and rats [46, 48, 47] and could be different in APPSwe/PS1∆E9 mice.
The lack of measurements made in wild-type mice was another limitation of the current
study. Comparing measurements made in VitD deficient APPSwe/PS1∆E9 mice to VitD
deficient wild-type mice would have allowed us to determine whether the effect of VitD
deficiency is specific to AD or not. However, because the specific question being addressed
in this study is how VitD deficiency affects the AD process, APPSwe/PS1∆E9 mice on a
control diet served as a sufficient control group.
The fact that an APPSwe/PS1∆E9 mouse model of AD was studied is very important to
consider when interpreting the results of this study. This is because the APPSwe/PS1∆E9
mouse is considered a mild model of Aβ toxicity. This model displays only modest neu-
ronal loss [53], and only abundant Aβ accumulation by 9 months of age [83], without devel-
opment of tau pathology [84]. Thus, AD pathology in APP/PS1 mice is probably consistent
with prodromal or mild AD and the results of this study may not apply in moderate or se-
vere AD. In other words, VitD deficiency may only be beneficial early on in the AD process,
but may either have no effect or be detrimental in later stages of AD. Additional studies are
needed in more aggressive models of AD to clarify the role of VitD deficiency in moderate
to severe AD.
4.5 Conclusion
This longitudinal study thoroughly evaluated the role of chronic VitD deficiency in AD.
VitD deficiency was successfully established in adult transgenic APPSwe/PS1∆E9 af-
ter 3 months on a VitD deficient diet and was maintained for 12 months. Relative to
APPSwe/PS1∆E9 mice on a nutritionally sufficient control diet, VitD deficiency did not
change ventricle volume, an MRI marker of neuronal loss. However, VitD deficiency did
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result in decreased NAA and Cr concentration as compared to control diet mice and in-
creased Lac and taurine concentration with age, which is consistent with astrocytosis and
gliosis. Increased Lac in VitD deficient mice was associated with attenuated decline in
spatial memory performance as measured on the BM probe trial. Overall, VitD deficient
mice performed better or improved on measures of spatial memory than control diet mice.
Together, our observations in VitD deficient APPSwe/PS1∆E9 mice suggest that VitD de-
ficiency may improve memory by upregulating beneficial reactive astrocytosis in the pro-
dromal stages of AD. Further studies are needed to determine the impact of VitD deficiency
and supplementation in patients with mild AD.
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Summary and Future Work
5.1 Summary
The purpose of this thesis was to study the metabolic and structural changes of specific
brain regions as a consequence of Alzheimer’s disease (AD) alone and under conditions
of AD and Vitamin D deprivation. The scientific investigations that were conducted are
summarized in this section.
5.1.1 Reduced hippocampal glutamate and posterior cingulate NAA in MCI
and AD is associated with episodic memory performance and white mat-
ter integrity in the cingulum
Chapter 2 described a cross-sectional study where brain metabolism and microstructure
were evaluated by proton magnetic resonance spectroscopy (1H-MRS) and diffusion ten-
sor imaging (DTI) in the limbic system of eight individuals with mild cognitive impair-
ment (MCI), nine with Alzheimer’s disease (AD), and sixteen elderly controls (NEC). Com-
pared to NEC, posterior cingulate N-acetyl aspartate (NAA) concentrations were reduced
in MCI and AD. Differences in diffusion metrics of white-matter microstructure were also
observed in the region of the cingulum that corresponds anatomically to the posterior cin-
gulate cortex (PCC). Individuals with AD had lower fractional anisotropy (FA) and higher
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RD than NECs or individuals with MCI – a pattern consistent with demylenation. Lower
posterior cingulate NAA concentrations were correlated with more demylenation (lower
FA, greater RD and T1) and with worse scores on on the Craft Story 21 Recall (CSR) and
Benson Complex Figure Copy (BCFC) tests of episodic memory, the type of memory sup-
ported by the limbic system. Together, this suggested that NAA deficit in the PCC of peo-
ple with AD could indicate a demyelinating process in the region that manifests as poorer
memory performance.
Reduced left hippocampal glutamate concentrations were also found in MCI and AD
compared to NECs. In the region of the cingulum that corresponds anatomically to the
hippocampus, individuals with AD had greater radial diffusivity (RD), axial diffusivity
(AxD) and T1 values – a pattern consistent with tissue atrophy. RD and AxD values in this
region also correlated with hippocampal glutamate levels. Lower hippocamapal glutamate
levels were associated with more tissue atrophy (greater RD, lower AxD) and with worse
scores on the CSR and BCFC tests on episodic memory. These results suggested that lower
hippocampal glutamate concentration could indicate impaired neuro-energetics or a loss
of glutamatergic neurons, ultimately manifesting as poorer episodic memory performance.
Overall, the results of this study show that metabolite concentrations measured using
1H-MRS may provide valuable insight into the underlying metabolic and microstructural
processes of episodic memory impairment and increase the confidence of a clinical diag-
nosis of MCI or AD.
5.1.2 Optimized in vivo glutamate measurement using long-echo-time semi-
LASER at 7 T
NAA is one of the strongest signals present in a 1H-MRS spectrum and can be reliably
measured in the brain with a variety of acquisition parameters. On the other hand, gluta-
mate is harder to measure because it is a strongly J-coupled spin system and its resonances
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overlaps with the resonances of macromolecules, glutamine, and GABA. Therefore, the
selection of acquisition parameters are important.
In Chapter 2, glutamate was measured using acquisition parameters that were not op-
timized. In order to improve and facilitate the measurement of glutamate in future studies,
an experiment to find the optimal echo time (TE) for the measurement of glutamate con-
centration using 1H-MRS at 7 T was performed. This experiment was presented in Chapter
3.
Time-domain simulations were performed to model the TE dependence of glutamate
signal energy, a measure of glutamate signal strength. These simulations were verified
against in vivo measurements made in the sensorimotor cortex of five human participants
and in vitro measurements made in a mixed-metabolite phantom containing glutamate,
glutamine, and GABA. Simulations showed a local maximum of glutamate signal energy
at TE = 107 ms. Consistent with this, in vitro measurements produced a maximal signal
energy for glutamate at TE = 100 ms. In vivo measurements showed that TE = 105 ms pro-
duced the greatest glutamate signal energy, while also resulting in the smallest inter-subject
glutamate-to-creatine ratio (Glu/Cr) coefficient of variation. In other words, TE = 105 ms
provides the greatest statistical power to measure in vivo differences in Glu/Cr between
groups. Together, these results indicate that TE = 105 ms is optimum for in vivo glutamate
measurement at 7 T with semi-LASER.
5.1.3 Chronic Vitamin D deficiency in adult APP/PS1 mice: Effect on memory
performance and brain metabolite levels
Having established in Chapter 2 that 1H-MRS could be used to provide insight into the
underlying metabolic and structural processes of episodic memory impairment in AD, the
same approach was applied to study the effects of Vitamin D (VitD) deficiency in a mouse
model of AD in Chapter 4. VitD can protect against the effects of calcium dysregulation and
oxidative stress, and VitD deficiency is thought to exacerbate AD progression. However,
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literature on VitD deficiency in AD remains inconsistent. Thus, the objective of the study
was to use 1H-MRS, shown in Chapter 2 to provide insight into the underlying metabolic
and structural processes of episodic memory impairment of AD, to help clarify the role of
chronic VitD deficiency in AD.
The effects of Vitamin D (VitD) deficiency were studied longitudinally in a transgenic
mouse model of AD (APPSwe/PS1∆E9). Mice were fed either a VitD deficiency diet (< 1
IU/kg VitD3) or a nutritionally sufficient control diet (1000 IU/kg VitD3) from 6 months
to 15 months of age. Comprehensive evaluation of the resulting longitudinal neurochemi-
cal, anatomical, and memory changes in the brain were assessed using 1H-MRS, high res-
olution MRI, and two independent spatial memory tasks, respectively. The spatial tasks
used were the Barnes maze (BM) and Morris water maze (MWM). Longitudinal serum
25(OH)D levels were also measured using radioimmunoassay. Measurements were made
at 6 months, 9 months, 12 months, and 15 months of age.
Mice on the VitD deficient diet had significantly lower serum 25(OH)D levels than mice
on the control diet at 9 months, 12 months, and 15 months of age, showing that chronic
VitD deficiency was successfully established. Neurochemical changes detected included
decreased NAA and Cr concentrations and increasing lactate and taurine concentrations
in mice on the VitD deficient diet. This pattern of change is consistent with a reactive as-
trocytosis process. Interestingly, VitD deficiency appeared to result in better performance
or improvement in performance in the BM and MWM. Overall, the observations made in
VitD deficient APPSwe/PS1∆E9 mice suggest that VitD deficiency may improve memory
by upregulating beneficial reactive astrocytosis in the prodromal stages of AD.
5.2 Conclusions
The aim of this thesis was to study the metabolic and structural changes in the brain as
a result of Alzheimer’s disease. Using 1H-MRS at 7 T, both decreased NAA in the PCC
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and decreased glutamate in the hippocampus were detected in individuals with MCI and
AD compared to NECs and were associated with changes in diffusion metrics consistent
with atrophy and demylenation processes. Importantly, reduced NAA and glutamate con-
centrations were observed in both MCI and AD compared to NECs, whereas differences
in diffusion metrics were only observed in AD subjects compared to NECs. This suggests
that changes in brain metabolite concentrations may precede structural changes. This con-
clusion is supported by the results presented in Chapter 4, which measured metabolite
changes longitudinally in APPSwe/PS∆E9 mice. In these mice, NAA concentrations de-
creased with time, a result consistent with the observation of decreased NAA concentra-
tions in the PCC of individuals with MCI and AD made in Chapter 2, but ventricle volume
(a metric of neuronal loss) remained stable with time. Since APPSwe/PS∆E9 mice are con-
sidered a model of mild AD, the results may suggest that NAA concentrations decrease in
the early, mild stages of AD before neuronal loss occurs in the more severe stages.
In human participants, brain metabolite concentrations measured using 1H-MRS were
associated with decreased episodic memory performance as measured using neuropsy-
chological testing (Chapter 2). Similarly, in transgenic AD mice, brain metabolite concen-
trations were associated with decreased spatial memory performance, a proxy measure of
episodic memory in rodents (Chapter 4). These results suggest that brain metabolite con-
centrations could indicate biological changes that underlie early symptoms of AD. Since
the progression of AD is a continuum, progressing from an asymptomatic phase to MCI
and to AD, measuring such biological changes could help clinicians stage individuals prior
to symptom onset.
To measure these metabolite changes effectively, particularly with difficult-to-measure
metabolites of interest such as glutamate, optimal acquisition parameters should be used.
In Chapter 3, a long TE of 105 ms was determined to be optimal for human in vivo measure-
ment of glutamate using 1H-MRS at 7 T. Advantages of using this TE includes decreased
power deposition by allowing lower maximum RF pulse amplitudes in conjunction with
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longer RF pulses and decreased macromolecule contributions, eliminating the requirement
for acquisition of separate macromolecule or macromolecule fitting techniques, which add
additional scan time or bias the glutamate measurement. In comparison to previous stud-
ies, this TE yielded comparable glutamate-to-creatine ratios, but with a smaller coefficient
of variation. Use of this TE for future studies of glutamate concentration in AD should
provide more precision and statistical power.
5.3 Future Work
5.3.1 The Clinical Utility of Brain Metabolite Concentrations
The studies performed as part of this thesis suggested that brain metabolite concentra-
tions could indicate biological changes that underlie early symptoms of AD and could be
predictive of structural changes that occur later on in the disease process. Though the lon-
gitudinal measurements of transgenic AD mice in Chapter 4 showed that metabolite con-
centrations change over time in AD, only a cross-sectional study was performed in humans
(Chapter 2). A comprehensive longitudinal study that tracks brain metabolite concentra-
tions using high-field 1H-MRS with optimized acquisition parameters, measures of brain
structure, and measures of cognitive impairment in a large cohort of older individuals as
they progress from the asymptomatic phase to MCI and to AD would be needed to defini-
tively determine the prognostic value of 1H-MRS and its value in helping clinicians stage
individuals along the AD continuum.
Single-voxel 1H-MRS in the hippocampus and PCC was used in this thesis to study
NAA and glutamate concentrations. Though these regions are known to be involved early
in the pathological progression of AD, it would be valuable to assess the distribution of
NAA and glutamate across the whole brain. Techniques such as magnetic resonance spec-
troscopic imaging (MRSI) using acquisition parameters optimized for NAA and glutamate
measurement could be used to perform such a measurement. The value of assessing the
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distribution of metabolites is to identify areas of the brain that would be useful for differ-
entiating AD from other dementias that have different neuropathology, progression, and
prognosis. Knowing the best brain areas to make the measurement would be necessary if
1H-MRS is to be used as a tool to help make a clinical diagnosis of AD.
5.3.2 Optimized Acquisition of Brain Metabolite Signals
Chapter 3 in this thesis showed that measurement of the glutamate signal could benefit
from an optimized TE. The next step would be to use this optimized TE in a 1H-MRS study.
Since the TE was determined for 7 T semi-LASER 1H-MRS specifically, it would also be
useful to determine the optimal TE for glutamate acquisition at other commonly used field
strengths, such as 1.5 T, 3 T or 9.4 T, and with other commonly used sequences. The same
approach described in this thesis could also be used to determine the optimal TEs for the
measurement of other metabolites using 1H-MRS. This work could set the foundation for
an acquisition method where multiple different TEs are used, enabling the optimal mea-
surement of a panel of metabolites.
5.3.3 The Role of Vitamin D in Alzheimer’s Disease
Finally, Chapter 4 in this thesis comprehensively evaluated the effect of VitD deficiency
in APPSwe/PS1∆E9 mice. The changes measured using 1H-MRS suggested that the spa-
tial memory performance associated with VitD deficiency was due to a reactive astrocy-
tosis process. However, this needs to be confirmed with future studies that includes both
1H-MRS measurements and brain histology in VitD deficient APPSwe/PS1∆E9 mice. One
approach would be to expose different cohorts of APPSwe/PS1∆E9 mice to different dura-
tions of VitD deficiency, measuring their metabolite levels using 1H-MRS, sacrificing them
immediately after their scanning session, and analzying their brains for astrocyte markers
such as glial fibrillary acidic protein (GFAP).
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Studies of VitD deficiency should also be performed in rodent models of AD pathology
that are more aggressive than APPSwe/PS1∆E9, such as mice that express 5 familial AD
genes (5xFAD mice). This is necessary to evaluate the role of VitD deficiency in moderate
to severe AD. It is possible that VitD deficiency is beneficial in mild AD, as was suggested
by the results of Chapter 4, but is detrimental in moderate to severe AD.
A natural next step after concretely establishing the role of VitD deficiency in various
stages of AD would be to assess whether VitD supplementation could be beneficial. If there
is a potential benefit, it would also be important to determine at which point along the AD
continuum that VitD supplementation is beneficial. Considering the findings of Chapter
4 that VitD deficiency may beneficial rather than detrimental in the early stages of AD, it
could be that VitD supplementation is only beneficial at later stages of AD.
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A
Physics of Magnetization and The
Equilibrium Magnetization
A.1 Magnetization
The physical phenomenon of nuclear magnetic resonance arises from the quantum me-
chanical properties of the protons and neutrons that make up atomic nuclei. As shown in
Figure A.1a, protons are composed of three quarks. Quarks are elementary particles with
fundamental properties of charge and spin. The charges of the quarks produce a net charge
of +e for the proton. The spin of a quark is 1/2 and the spins of an up quark and a down
quark cancel. In a proton, the combination of quarks produces a net spin of 1/2. Neutrons
are also composed of three quarks, combining to produce a net spin of 1/2 and a net charge
of 0 (Figure A.1b).
Since nuclei are made up of combinations of protons and neutrons, nuclei can also
have the property of spin. However, not all nuclei have spin; nuclei with an even number
of protons and an even number of neutrons have a spin of 0. This is because there is a
strong tendency for protons to pair with another proton and a neutron to pair with another
neutron. The spins of the quarks cancel in proton-proton and neutron-neutron pairs, pro-
ducing a net spin of 0. It is only nuclei with an odd number of protons or an odd number
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FIGURE A.1: Protons and neutrons are each made of three quarks. (a) A proton has two
up quarks and one down quarks, a net charge of +e, and a net spin of 1/2. (b) A neutron
has two down quarks and one up quark, with a net charge of 0 and a net spin of 1/2.
of neutrons that have a non-zero spin. Only nuclei with non-zero spin can undergo nuclear
magnetic resonance.
Associated with nuclear spin, I, is the property of spin angular momentum, ~L, which
is a vector quantity. Due to Heisenberg’s uncertainty principle, the exact direction of ~L is
unknown. However, the component of~L in any direction, i, can be measured,
Li = h̄Ii Ii ∈ {−I,−(I − 1) · · · I − 1, I} (A.1)
Ii can take on 2I − 1 values, which is equal to the number of spin states of the nucleus. The
magnitude of~L is also known and is given by its eigenvalue:
∣∣∣~L∣∣∣ = √I(I − 1) (A.2)
Nuclei with angular momentum and charge will also have an associated magnetic mo-
ment that can be observed empirically. Analytically, this magnetic moment is given by:
~µ =
gq
2m
~L
~µ = γ~L (A.3)
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where q is nuclear charge, m is nuclear mass,~L is the spin angular momentum and g is the
g-factor, a proportionality constant that relates the observed magnetic-moment to the in-
trinsic spin angular momentum. γ = gq2m is the gyromagnetic ratio unique to each nucleus.
If the nuclei are then placed in a magnetic field, ~B0, they will acquire potential energy,
U, defined by:
U = −~µ · ~B0 (A.4)
U = γ~L · ~B0 (by Equation (A.3))
Since ~L is quantized, U is also quantized, and a nuclei may only occupy 2I − 1 different
energy states. The probability that a nucleus is found in a particular energy state, ε, is
governed by the Bolztmann distribution:
P(ε) =
e−Uε/kT
∑ε e−Uε/kT
(A.5)
where Uε is the energy of state ε, k is the Boltzmann constant, and T is the temperature.
In proton magnetic resonance imaging and spectroscopy, the nucleus of interest is 1H,
and the magnetic field is oriented along the z-axis (i.e. ~B0 = B0ẑ). A 1H nucleus is made
up of a single proton, and therefore has spin I = 1/2 and two spin states: |+〉 and |−〉.
The probability that a 1H nucleus is in an energy state where µz is aligned with ~B0 may
be derived from Equation (A.1), (A.3) – (A.5), and the fact that kT  |U| at physiological
temperatures:
P
(
ε~µ‖~B0
)
=
µzB0
kT
=
γh̄B0
2kT
(A.6)
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This probability may then be used to determine the net magnetic moment of an ensemble
of 1H nuclei, ~M0, also called the equilibrium magnetization:
~M0 = proton density · size of µz · probability of 1H nuclei with ~µ ‖ ẑ
= ρ0 · µz ·
µzB0
kT
ẑ
~M0 = ρ0
γ2h̄2B0
4kT
ẑ (A.7)
Since ~M0 is macroscopic, its behaviour may be described without quantum mechanics. In
the magnetic field, ~B0, ~M0 will experience a torque given by the following cross-product:
~τ = ~M0 × ~B0 =
d
dt
~J (A.8)
At each instant in time, the torque causes a change in the angular momentum of the system,
~J, in the direction of the torque. Since ~M0 ‖ ~J, the ~M0 also changes in the direction of
~τ, resulting in the clockwise precession of the magnetization around ~B0 (Figure A.2). The
angular frequency of this precession is the Larmor frequency, ω0, which is given by:
ω0 = γB0 (A.9)
A.2 Measuring Magnetization
In an MR scanner, the magnetization is measured using a receive coil. There is a time-
varying magnetic field associated with the precessing magnetization, which produces mag-
netic flux through the receive coil. This flux generates an electromotive force (em f ) in the
coil, producing a voltage signal that can be recorded. Using Ampère’s Law, the definition
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FIGURE A.2: Torque, ~τ, exerted by the magnetic field, ~B0, on the magnetization, ~M0,
changes the angular momentum,~J, in the direction of~τ. Since ~M0 ‖ ~J, the ~M0 also changes
in the direction of ~τ, resulting in clockwise precession about ~B0.
of magnetic vector potential, and Faraday’s Law, the em f induced in the coil may derived:
em f =
−d
dt
Φ(t)
=
−d
dt
∫∫∫
~M0(~r, t) · ~Breceive(~r) dV (A.10)
where ~Breceive is the sensitivity profile of the receive coil. Coils used for MR imaging are
typically designed such that the sensitivity profile is optimized to detect magnetization
perpendicular to the direction of ~B0. Thus, ~M0 must be manipulated such that a component
of ~M0 lies within the x̂, ŷ-plane.
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Quantum Mechanical Calculations for
the Simulation of Metabolite Spin
Systems
B.1 Overview
A mostly classical treatment of the physics of magnetic resonance and 1H-MRS were given
in Sections 1.3 and 1.4 of this thesis. However, J-coupling behaviour for strongly coupled
metabolite spin systems could not be adequately described using classical mechanics. In
this case, quantum mechanical calculations are needed. These calculations can also be used
to produce simulated metabolite spectra that can be part of a prior knowledge template
used to analyse in vivo data. A brief description of the quantum mechanical calculations
needed for these purposes are given in this Appendix.
B.2 Describing the State of a System
In quantum mechanics, the state of a quantum mechanical system, such as a single nuclear
spin or a particle, is given by its wave function, ψ(~r, t). This is analogous to the classical
concept of a trajectory and contains all possible information about the particle. The wave
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function is interpreted as the probability amplitudes of the particle’s presence:
dP(~r, t) = C |ψ(~r, t) |2 d3~r (B.1)
Associated with the wave function is an element of a linear vector space, F, called
Hilbert space. This element, |ψ〉, is called a “ket” and can be expressed in terms of the
basis functions of Hilbert space | fi〉:
|ψ〉 =
n
∑
i=1
ψi | fi〉 ∈ F (B.2)
A more compact representation of this expression is simply a vector of the coefficients ψi:
~ψ =

ψ1
ψ2
...
ψn

(B.3)
As discussed in Section A.1, the spin-1/2 1H nucleus has two spin states. Expressed in
the notation of quantum mechanics, these two states are as follows:
|ψ〉 = |+〉 =
1
0
 (B.4)
|ψ〉 = |−〉 =
0
1
 (B.5)
The ket representation of a the system state also has a dual representation called a “bra,”
〈ψ|, which is defined as follows for a spin-1/2 system:
〈ψ| =
[
a∗ b∗
]
(B.6)
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where |ψ〉 =
a
b
 and ∗ represents the conjugate.
B.3 Describing Measurable Quantities
Every measurable quantity in a quantum mechanical system is described using an opera-
tor. An operator generates one ket from another:
Ĥ |ψ〉 = |ζ〉 (B.7)
If |ζ〉 = λ |ψ〉, then |ψ〉 is called the eigenket of the operator Ĥ, and λ is the eigenvalue of
the operator Ĥ.
Operators also have a matrix representation and can generate one vector representation
of a ket from another:
H~ψ = ~ζ (B.8)
The eigenvalues of the operator Ĥ is equal to the eigenvalues of the operator matrix
H. These eigenvalues are the only possible values that the quantity can take when it is
measured, and each eigenvalue has an associated probability of measurement. The state of
the system after a measurement is the eigenket associated with the measured eigenvalue.
In the case of a 1H nucleus, one of the measurable quantities is its angular momentum
along the z-direction, Lz. In quantum mechanics notation, this quantity is represented using
the operator L̂z, which has the associated matrix:
Lz =
h̄/2 0
0 −h̄/2
 (B.9)
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This matrix has eigenvalues h̄/2 and−h̄/2, which are the only two possible values of angu-
lar momentum that can be measured. Associated with these eigenvalues are the eigenkets
|+〉 = [1 0]T and |−〉 = [0 1]T, which are the two possible system states of a 1H nucleus
(Equation (B.5)).
B.4 Time Evolution of a System State
The time-evolution of the state of a quantum mechanical system is given by Schrödinger’s
equation:
δ
δt
|ψ〉 = −jĤ(t) |ψ(t)〉 (B.10)
where |ψ(t)〉 is the ket representing the system state, and Ĥ(t) is the operator representing
the energy of the system.
B.5 Describing a Statistical Ensemble of Quantum Mechanical
Systems
In 1H-MRS, it is not a single 1H nucleus that is being observed, but rather an ensemble
of nuclei. In this case, wave function representations and Schroödinger’s equation (B.10)
are not very useful, because the exact wave function of every single spin being observed is
rarely known. Thus, an ensemble of nuclei must be described statistically.
This can be done using a density operator, σ̂. σ̂ has the associated matrix σ, which is
defined as follows:
σ =
N
∑
j=1
pj
∣∣ψj〉 〈ψj∣∣ (B.11)
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where pj is the probability of a system being in state
∣∣ψj〉. The density matrix can then
help us to take the ensemble average of a measurable quantity. For example, the ensemble
average of a measurable quantity A is given by:
¯〈A〉 = Tr {σA}
=
N
∑
j=1
pj
〈
ψj
∣∣A ∣∣ψj〉 (B.12)
where Tr is the matrix trace operation. In this equation,
〈
ψj
∣∣A ∣∣ψj〉 is the quantum mechan-
ical average of A. In other words, this is the expected value of A if the system is in state∣∣ψj〉. Since pj is the probability of the system being in state ∣∣ψj〉, Equation (B.12) is simply
a statistical average of expected measured values.
B.6 Time Evolution of a Statistical Ensemble of Quantum Me-
chanical Systems
The time-evolution of a statistical ensemble of quantum mechanical systems is described
using the Liouville-von Neumann equation:
δ
δt
σ̂ = −j
[
Ĥ, σ̂
]
(B.13)
In this equation, the square brackets represent the commutator operation: [A, B] = AB−
BA. The operator Ĥ is called the Hamiltonian and represents the energy of the ensemble.
In 1H-MRS, the Hamiltonian is the sum of different Hamiltonians associated with dif-
ferent physical interactions:
Ĥ = Ĥ1 + Ĥ2 + Ĥ3 + Ĥ4 + Ĥ5 + · · ·
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where Ĥ1 is associated the interaction of nuclear spins with the main magnetic field ~B0, Ĥ2
is associated with the spin-spin interaction, Ĥ3 is associated with the J-coupling between
spins, Ĥ4 is associated with the chemical shift phenomenon, and Ĥ5 is associated with the
interaction of nuclear spins withthe ~B1 field. Other Hamiltonians associated with other
processes could also be part of the sum.
If it can be assumed that the Hamiltonian, Ĥ, does not change with time, the solution
to the Liouville-von Neumann equation in terms of the operator matrices is:
σ(t) = e−jHt/h̄σ(0)ejHt/h̄ (B.14)
This is the key equation used to simulate metabolite spin-systems and generate parameter
values to produce a constrained prior knowledge template for 1H-MRS analysis.
B.7 General Procedure for Metabolite Spin-System Simulations
Having established the required mathematics for metabolite spin-system simulations, the
general procedure to implement such a simulation can be laid out. Before calculations can
begin, a few items need to be defined first:
1. Given a metabolite whose 1H have specific chemical shielding and J-coupling con-
stants, define a static Hamiltonian for the system:
Ĥ = ĤCS + ĤJ
where ĤCS is the chemical shielding Hamiltonian, and ĤJ is the scalar coupling
Hamiltonian.
2. Define the RF pulse waveforms using RF pulse files from the MRI scanner.
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3. Define the RF pulse sequence using the pulse sequence timings available from the
MRI scanner.
4. Define a density matrix for the metabolite spin-system.
Relaxation effects can typically be ignored to simplify the simulations, since a classi-
cal treatment of relaxation effects can be applied to the simulation results using known
metabolite T2 values.
Once these items are defined, the density matrix of the metabolite spin-system may be
evolved in time under the defined RF pulse sequence using Equation (B.14). During the
periods of time in the pulse sequence where no RF pulse is being applied, Ĥ = ĤCS + ĤJ
is simply substituted into Equation (B.14) to evolve σ(t). During the periods of time in
the pulse sequence where an RF pulse is being applied, a static Hamiltonian is defined
to describe the interactions of the 1H nuclei with the ~B1 field at each time-step of the RF
pulse. The Hamiltonians are substituted into the Equation (B.14) to evolve σ(t) under the
applied RF pulse.
The resulting density matrix after the pulse sequence is complete can be used to gen-
erate expectation values for measurable quantities of interest using Equation (B.12). These
quantities can include the metabolite amplitudes, shifts, and phases that result from the
application of the pulse sequence. Metabolite amplitudes, shifts, and phases can then be
used to generate the metabolite signal models that are included in a prior knowledge tem-
plate and to constrain the prior knowledge template itself. In the case of a metabolite with
strong J-coupling, where the peak splitting behaviour does not follow Pascal’s triangle, the
calculated metabolite amplitudes, shifts, and phases can be used to describe and visualize
the splitting behaviour.
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C
Absolute Metabolite Quantification
Using an Internal Water Reference
Absolute metabolite concentrations of a metabolite can be calculated by using an internal
water reference. This internal water reference is the unsuppressed water signal collected
at the same time as the water-suppressed spectra. Instead of using a ratio of each metabo-
lite signal over the signal of a reference metabolite (e.g. creatine), a ratio over the signal of
water is used. This is advantageous because the water signal from brain tissue is consis-
tent between individuals, whereas a reference in vivo metabolite signal can vary between
individuals because its concentration varies.
Using an internal reference to determine metabolite concentration can be written as
follows:
[M] =
Ŝm
ŜW
[W] (C.1)
where
[M] = concentration of the metabolite
[W] = concentration of pure water = 55.14 M
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ŜW = corrected water signal
Ŝm = corrected metabolite signal
As Equation (C.1) shows, the measured water signal is mapped to the known con-
centration of pure water, This mapping is then used to determine what concentration the
measured metabolite signal represents. The measured water and metabolite signals are not
used directly; they are first corrected for a variety of factors. 1
C.1 Corrections for T1 and T2 Relaxation
The most important of these corrections is the correction for T1 and T2 relaxation. The
objective of the T1 and T2 relaxation correction is to determine what the measured signal
would be if there was no relaxation. Relaxation of the transverse magnetization is described
by the following equation:
Mxy = M0
(
1− e−TR/T1
) (
e−TE/T2
)
(C.2)
where Mxy is the measured signal, and M0 is the signal before T1 and T2 relaxation begins.
Equation (C.2) describes relaxation in a single tissue compartment. However, in the
context of in-vivo brain metabolite quantification, the GM, WM, and CSF compartments
must be considered:
Mxy = M0,GM
(
1− e−TR/T1,GM
) (
e−TE/T2,GM
)
+ M0,WM
(
1− e−TR/T1,WM
) (
e−TE/T2,WM
)
(C.3)
+ M0,CSF
(
1− e−TR/T1,CSF
) (
e−TE/T2,CSF
)
1It is important to note that spectroscopic voxel volume is not considered in the present discussion, as it
is assumed the unsuppressed water signal and the water-suppressed spectra are measured using the same
spectroscopic voxel. If this is not the case, voxel volume would have to be considered.
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M0,GM, M0,WM, and M0,CSF may be expressed in terms of M0. Considering only the GM
compartment for the moment,
M0,GM = fGMαGM M0
where fGM is the volume fraction of GM in the spectroscopic voxel, and αGM is the relative
proton density in GM.
To explain why M0,GM = fGMαGM M0, it is important to remember that M0 is propor-
tional to the total number of protons in the spectroscopic voxel. Since proton density is
the number of protons in a volume, multiplying the volume fraction by the relative proton
density allows us to determine the fraction of the total number of protons contributed by
the GM. This fraction can then be used to properly attribute the proportion of M0 to GM.
Using the same reasoning,
M0,GM = fWMαWM M0
M0,CSF = fCSFαCSF M0
where fWM is the volume fraction of WM in the spectroscopic voxel, fCSF is the volume
fraction of CSF in the spectroscopic voxel, αWM is the relative proton density in WM, and
αCSF is the relative proton density in CSF.
Thus, Equation (C.3) may be rewritten as:
Mxy = fGMαGM M0
(
1− e−TR/T1,GM
) (
e−TE/T2,GM
)
+ fWMαWM M0
(
1− e−TR/T1,WM
) (
e−TE/T2,WM
)
(C.4)
+ fCSFαCSF M0
(
1− e−TR/T1,CSF
) (
e−TE/T2,CSF
)
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Since the objective of the T1 and T2 relaxation correction is to determine the signal with-
out T1 or T2 relaxation, applying a correction for T1 and T2 is the same as solving for M0.
Solving (C.4) for M0 results in:
M0 =
Mxy
fGMαGMRGM + fWMαWMRWM + fCSFαCSFRCSF
(C.5)
where
RGM =
(
1− e−TR/T1,GM
) (
e−TE/T2,GM
)
RWM =
(
1− e−TR/T1,WM
) (
e−TE/T2,WM
)
RCSF =
(
1− e−TR/T1,CSF
) (
e−TE/T2,CSF
)
C.1.1 T1 and T2 Correction for the Measured Water Signal (SW)
Equation (C.5) may be applied directly to correct the measured water signal for T1 and T2
relaxation:
ŜW =
SW
fGMαWGMR
W
GM + fWMα
W
WMR
W
WM + fCSFα
W
CSFR
W
CSF
(C.6)
where
αWGM = 0.82 = the relative proton density of water in GM as compared to that of pure water
αWWM = 0.73 = the relative proton density of water in WM as compared to that of pure water
αWCSF = 1.00 = the relative proton density of water in CSF as compared to that of pure water
and RWGM, R
W
WM, and R
W
CSF are the corresponding relaxation terms of Equation (C.5) using
the tissue specific T1 and T2 relaxation rates of water. SW = AW , the amplitude of the fitted
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and Gain/Scaling Factors (G)
water peak.
C.1.2 T1 and T2 Correction for the Measured Metabolite Signal (Sm)
Unlike the measured water signal, Equation (C.5) cannot be directly applied to correct the
measured metabolite signal because of a couple of reasons. First, it is assumed that the CSF
contribution to the metabolite signal is negligible because there are little to no metabolites
in the CSF. No part of the metabolite signal should be attributed to the CSF compartment
and any metabolite signal should be equally attributed to the WM and GM compartment.
Secondly, the relative proton density in GM, WM, and CSF for metabolites are not known.
Because of this, αGM, αWM, and αCSF are assumed to be 1.00 for metabolites. The equation
to correct the measured metabolite signal for T1 and T2 is then:
Ŝm =
Sm
fGM
fGM+ fWM
RmGM +
fWM
fGM+ fWM
RmWM
(C.7)
where RmGM and R
m
WM are the corresponding relaxation terms of Equation (C.5) using the
tissue specific T1 and T2 relaxation rates of metabolite m. Sm = ∑Kk A
m
k , the sum of the
amplitudes of the metabolite as determined by the fitted prior-knowledge model.
C.2 Corrections for Number of Averages (Navg), Number of MRS-
visible 1H Nuclei (ρ), and Gain/Scaling Factors (G)
In addition to corrections for T1 and T2 relaxation, the following corrections are applied to
the measured water and metabolite signals:
1. A correction for the number of averages used to acquire the water signal
2. A correction for the number of MRS-visible 1H nuclei in the water molecule
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3. Corrections for any gain and scaling factors applied by the scanner and during post-
processing
These corrections are applied as follows:
ŜW =
SW
NWavg ρW GW
(C.8)
Ŝm =
Sm
Nmavg ρm Gm
(C.9)
C.3 Summary of Corrections for the Measured Water Signal
Combining Equations (C.6) and (C.8), the final equation for the corrected water signal is:
ŜW =
AW
NWavg ρW GW
(
fGMαWGMR
W
GM + fWMα
W
WMR
W
WM + fCSFα
W
CSFR
W
CSF
) (C.10)
C.4 Summary of Corrections for the Measured Metabolite Signal
Combining Equations (C.7) and (C.9), the final equation for the corrected metabolite signal
is:
Ŝm =
∑Kk A
m
k
Nmavg ρm Gm
(
fGM
fGM+ fWM
RmGM +
fWM
fGM+ fWM
RmWM
) (C.11)
C.5 Metabolite Quantification Equations
C.5.1 Voxel Concentration
The equation to calculate the concentration of a metabolite with respect to the entire of the
spectroscopic voxel volume is obtained by substituting Equations (C.10) and (C.11) into
230
C.5. Metabolite Quantification Equations
Equation (C.1):
[M]voxel =
 ∑Kk Amk
Nmavg ρm Gm
(
fGM
fGM+ fWM
RmGM +
fWM
fGM+ fWM
RmWM
)

×
(
AW
NWavg ρW GW
(
fGMαWGMR
W
GM + fWMα
W
WMR
W
WM + fCSFα
W
CSFR
W
CSF
))−1
× 55.14 M
(C.12)
Equation (C.12) may be simplified into:
[M]voxel =
(
∑Kk A
m
k
AW
)
︸ ︷︷ ︸
ratio of
measured signals
×
 fGMαWGMRWGM + fWMαWWMRWWM + fCSFαWCSFRWCSF
fGM
fGM+ fWM
RmGM +
fWM
fGM+ fWM
RmWM

︸ ︷︷ ︸
relaxation correction
×
(
NWavg
Nmavg
× ρ
W
ρm
× G
W
Gm
)
︸ ︷︷ ︸
correction for number of averages,
number of nuclei, and gain
× (55.14 M)︸ ︷︷ ︸
concentration
of pure water
(C.13)
C.5.2 Tissue Concentration
With Equation (C.13), a metabolite concentration with respect to the entire volume of the
spectroscopic voxel was found. To determine the concentration of the metabolite in brain
tissue alone, the dilution equation can be applied:
ctissueVtissue = cvoxelVvoxel
ctissue = cvoxel
Vvoxel
Vtissue
ctissue = cvoxel
1
fGM + fWM
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Thus, the metabolite concentration in brain tissue is:
[M]tissue =
(
∑Kk A
m
k
AW
)
︸ ︷︷ ︸
ratio of
measured signals
×
 fGMαWGMRWGM + fWMαWWMRWWM + fCSFαWCSFRWCSF
fGM
fGM+ fWM
RmGM +
fWM
fGM+ fWM
RmWM

︸ ︷︷ ︸
relaxation correction
×
(
NWavg
Nmavg
× ρ
W
ρm
× G
W
Gm
)
︸ ︷︷ ︸
correction for number of averages,
number of nuclei, and gain
× (55.14 M)︸ ︷︷ ︸
concentration
of pure water
×
(
1
fGM + fWM
)
︸ ︷︷ ︸
dilution volume
correction
(C.14)
Equation (C.14) can be simplified by multiplying the dilution volume correction
through the relaxation correction term for the metabolite signal:
[M]tissue =
(
∑Kk A
m
k
AW
)
×
(
fGMαWGMR
W
GM + fWMα
W
WMR
W
WM + fCSFα
W
CSFR
W
CSF
fGMRmGM + fWMR
m
WM
)
×
(
NWavg
Nmavg
× ρ
W
ρm
× G
W
Gm
)
× (55.14 M) (C.15)
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Simulated, echo-time-specific 7 T semi-LASER and 9.4 T LASER prior knowledge tem-
plates were used to fit the post-processed spectra. These prior knowledge templates were
generated with Prior Information Templates (PINTS) software tool written by Dickson
Wong. PINTS is part of the MRS Analysis, Generation, and In vivo Quantification (MAGIQ)
software suite also written by Dickson Wong. The full code for the MAGIQ software
suite is available on the Centre for Functional and Metabolic Mapping’s Gitlab Server
(https://git.cfmm.robarts.ca/bartha-lab/MAGIQ). It will be publicly available as open-
source software in the future.
The code relies on the PyGAMMA library of the VeSPA software suite (https://scion.
duhs.duke.edu/vespa/gamma/wiki/PyGamma) to model the spectra. Using the PyGAMMA
library directly instead of using the VeSPA Suite graphical user interface allowed the exact
replication of RF pulse shapes form the scanner, the running of calibration experiments for
the RF pulses, and the looping over multiple metabolites and echo-times within a single
Python program.
Below is a flowchart that provides a high-level description of how the simulated prior
knowledge templates were generated.
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Also included below is the code for the MetaboliteSimulation class used to define
a simulation for each metabolite. This code and the annotations should be sufficient for
a reader to understand how to set up a simulation, define a pulse sequence, and obtain
simulation results using PyGAMMA.
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Import system
libraries.import sys
import os
import datetime
5 import time
import glob
import platform
from PyQt5 import QtCore , QtGui , QtWidgets , uic
import subprocess as subproc
10 import multiprocessing as mp
from collections import defaultdict
from itertools import groupby
Import math
libraries.15 import scipy as sp
import scipy.signal as spsg
import numpy as np
import math
from pyfftw.interfaces import scipy_fftpack as fftw
20
Import
PyGAMMA
for metabolite
simulations.
import pygamma as pg
Import custom
data classes.
25 from dataclasses import *
Define the
simulation class.
class MetaboliteSimulation(QtCore.QObject):
30 postToConsole = QtCore.pyqtSignal(str)
outputResults = QtCore.pyqtSignal(object)
finished = QtCore.pyqtSignal(int)
def __init__(self , thread_num , insysfile ,
↪→ sim_experiment):
35
QtCore.QObject.__init__(self)
self.thread_num = thread_num
self.insysfile = insysfile
40 self.sim_experiment = sim_experiment
def simulate(self):
self.postToConsole.emit(’ | Simulating ...
↪→ ’ + self.insysfile)
45 metab_name = self.insysfile.replace(’.sys’,’’
↪→ )
Retrieve the
appropriate
spin-system
definition
according to
field strength.
if self.sim_experiment.b0 == 123.3:
self.insysfile = ’pints/metabolites /3T_’
↪→ + self.insysfile
50 elif self.sim_experiment.b0 == 297.2:
self.insysfile = ’pints/metabolites /7T_’
↪→ + self.insysfile
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elif self.sim_experiment.b0 == 400.2:
self.insysfile = ’pints/metabolites /9.4
↪→ T_’ + self.insysfile
55Define the semi-
LASER pulse
sequence.
if self.sim_experiment.name == "semi -LASER":
Load in the
current spin-
system.
spin_system = pg.spin_system ()
spin_system.read(self.insysfile)
60 for i in range(spin_system.spins()):
spin_system.PPM(i, spin_system.PPM(
↪→ i) - self.sim_experiment.
↪→ RF_OFFSET)
Specify the
echo-time-
dependent
parameters to be
used to define
delays between
RF pulses.
TE = self.sim_experiment.TE
65 TE1 = float((TE * 0.31) / 1000.0)
TE3 = float((TE * 0.31) / 1000.0)
TE2 = float(TE /1000.0 - TE1 - TE3)
TE_fill = TE /1000.0 - TE1 - TE2 - TE3
70
Build a
90-degree
excitation pulse
from a Siemens
*.pta file.
inpulse90file = self.sim_experiment.
↪→ inpulse90file
A_90 = self.sim_experiment.A_90
PULSE_90_LENGTH = self.sim_experiment.
↪→ PULSE_90_LENGTH
gyratio = self.sim_experiment.getGyratio
↪→ ()
75
pulse90 = Pulse(inpulse90file ,
↪→ PULSE_90_LENGTH)
n_old = np.linspace(0, PULSE_90_LENGTH ,
↪→ 255)
n_new = np.linspace(0, PULSE_90_LENGTH ,
↪→ 256)
80
waveform_real = sp.interpolate.
↪→ InterpolatedUnivariateSpline(
↪→ n_old , np.real(pulse90.waveform)*
↪→ A_90)(n_new)
waveform_imag = sp.interpolate.
↪→ InterpolatedUnivariateSpline(
↪→ n_old , np.imag(pulse90.waveform)*
↪→ A_90)(n_new)
pulse90.waveform = waveform_real + 1j*(
↪→ waveform_imag)
85 ampl_arr = np.abs(pulse90.waveform)*
↪→ gyratio
phas_arr = np.unwrap(np.angle(pulse90.
↪→ waveform))*180.0/ math.pi
pulse = pg.row_vector(len(pulse90.
↪→ waveform))
ptime = pg.row_vector(len(pulse90.
↪→ waveform))
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90 for j, val in enumerate(zip(ampl_arr ,
↪→ phas_arr)):
pulse.put(pg.complex(val[0],val [1])
↪→ , j)
ptime.put(pg.complex(pulse90.
↪→ pulsestep ,0), j)
pulse_dur_90 = pulse.size() * pulse90.
↪→ pulsestep
95 peak_to_end_90 = pulse_dur_90 - (209 +
↪→ self.sim_experiment.fudge_factor)
↪→ * pulse90.pulsestep
pwf_90 = pg.PulWaveform(pulse , ptime , "
↪→ 90 excite")
pulc_90 = pg.PulComposite(pwf_90 ,
↪→ spin_system , self.sim_experiment.
↪→ obs_iso)
Define the
propagator for
the 90-degree
pulse.
100 Ureal90 = pulc_90.GetUsum (-1)
Build a AFP
pulse from a
Siemens *.pta
file.
inpulse180file = self.sim_experiment.
↪→ inpulse180file
A_180 = self.sim_experiment.A_180
105 PULSE_180_LENGTH = self.sim_experiment.
↪→ PULSE_180_LENGTH
gyratio = self.sim_experiment.getGyratio
↪→ ()
pulse180 = Pulse(inpulse180file ,
↪→ PULSE_180_LENGTH)
110 n_old = np.linspace(0, PULSE_180_LENGTH ,
↪→ 511)
n_new = np.linspace(0, PULSE_180_LENGTH ,
↪→ 512)
waveform_real = sp.interpolate.
↪→ InterpolatedUnivariateSpline(
↪→ n_old , np.real(pulse180.waveform)
↪→ *A_180)(n_new)
waveform_imag = sp.interpolate.
↪→ InterpolatedUnivariateSpline(
↪→ n_old , np.imag(pulse180.waveform)
↪→ *A_180)(n_new)
115 pulse180.waveform = waveform_real + 1j*(
↪→ waveform_imag)
ampl_arr = np.abs(pulse180.waveform)*
↪→ gyratio
phas_arr = np.unwrap(np.angle(pulse180.
↪→ waveform))*180.0/ math.pi
freq_arr = np.gradient(phas_arr)
120
pulse = pg.row_vector(len(pulse180.
↪→ waveform))
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ptime = pg.row_vector(len(pulse180.
↪→ waveform))
for j, val in enumerate(zip(ampl_arr ,
↪→ phas_arr)):
pulse.put(pg.complex(val[0],val [1])
↪→ , j)
125 ptime.put(pg.complex(n_new [1],0), j
↪→ )
pulse_dur_180 = pulse.size() * pulse180.
↪→ pulsestep
pwf_180 = pg.PulWaveform(pulse , ptime , "
↪→ 180 afp")
pulc_180 = pg.PulComposite(pwf_180 ,
↪→ spin_system , self.sim_experiment.
↪→ obs_iso)
130
Define the
propagator for
the AFP pulse.
Ureal180 = pulc_180.GetUsum (-1)
Initialize the
Hamiltonian
and density
operator matrix
for the current
spin system.
135 H = pg.Hcs(spin_system) + pg.HJ(
↪→ spin_system)
D = pg.Fm(spin_system , self.
↪→ sim_experiment.obs_iso)
ac = pg.acquire1D(pg.gen_op(D), H, self.
↪→ sim_experiment.dwell_time)
ACQ = ac
140Define the
delays between
RF pulses using
echo-time-
dependent
parameters.
delay1 = TE1 /2.0 + TE_fill /8.0
↪→ -
↪→ pulse_dur_180 /2.0 -
↪→ peak_to_end_90
delay2 = TE1 /2.0 + TE_fill /8.0 + TE2 /4.0
↪→ + TE_fill /8.0 - pulse_dur_180
delay3 = TE2 /4.0 + TE_fill /8.0 + TE2 /4.0
↪→ + TE_fill /8.0 - pulse_dur_180
delay4 = TE2 /4.0 + TE_fill /8.0 + TE3 /2.0
↪→ + TE_fill /8.0 - pulse_dur_180
145 delay5 = TE3 /2.0 + TE_fill /8.0
↪→ -
↪→ pulse_dur_180 /2.0
Define the
propagators
for each delay
period.
Udelay1 = pg.prop(H, delay1)
Udelay2 = pg.prop(H, delay2)
150 Udelay3 = pg.prop(H, delay3)
Udelay4 = pg.prop(H, delay4)
Udelay5 = pg.prop(H, delay5)
Apply RF pulse
propagators
and delay
propagators in
the appropriate
sequence to
“run the semi-
LASER pulse
sequence.”
155 sigma0 = pg.sigma_eq(spin_system) #
↪→ init
sigma1 = Ureal90.evolve(sigma0)
↪→ # apply 90-degree pulse
sigma0 = pg.evolve(sigma1 , Udelay1)
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sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP1
sigma0 = pg.evolve(sigma1 , Udelay2)
160 sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP2
sigma0 = pg.evolve(sigma1 , Udelay3)
sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP3
sigma0 = pg.evolve(sigma1 , Udelay4)
sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP4
165 sigma0 = pg.evolve(sigma1 , Udelay5)
Define the
LASER pulse
sequence.
elif self.sim_experiment.name == "LASER":
Load in the
current spin-
system.
170 spin_system = pg.spin_system ()
spin_system.read(self.insysfile)
for i in range(spin_system.spins()):
spin_system.PPM(i, spin_system.PPM(
↪→ i) - self.sim_experiment.
↪→ RF_OFFSET)
175 Build the AHP
pulse.inpulse90file = self.sim_experiment.
↪→ inpulse90file
A_90 = self.sim_experiment.A_90
PULSE_90_LENGTH = self.sim_experiment.
↪→ PULSE_90_LENGTH
gyratio = self.sim_experiment.getGyratio
↪→ ()
180
pulse90 = Pulse(inpulse90file ,
↪→ PULSE_90_LENGTH , ’varian ’)
n_new = np.linspace(0, PULSE_90_LENGTH ,
↪→ 256)
185 waveform_real = np.real(pulse90.waveform
↪→ )*A_90
waveform_imag = np.imag(pulse90.waveform
↪→ )*A_90
pulse90.waveform = waveform_real + 1j*(
↪→ waveform_imag)
ampl_arr = np.abs(pulse90.waveform)*
↪→ gyratio
190 phas_arr = np.unwrap(np.angle(pulse90.
↪→ waveform))*180.0/ math.pi
pulse = pg.row_vector(len(pulse90.
↪→ waveform))
ptime = pg.row_vector(len(pulse90.
↪→ waveform))
for j, val in enumerate(zip(ampl_arr ,
↪→ phas_arr)):
195 pulse.put(pg.complex(val[0],val [1])
↪→ , j)
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ptime.put(pg.complex(pulse90.
↪→ pulsestep ,0), j)
pulse_dur_90 = pulse.size() * pulse90.
↪→ pulsestep
pwf_90 = pg.PulWaveform(pulse , ptime , "
↪→ 90 excite")
200 pulc_90 = pg.PulComposite(pwf_90 ,
↪→ spin_system , self.sim_experiment.
↪→ obs_iso)
Define the
propagator for
the AHP pulse.
Ureal90 = pulc_90.GetUsum (-1)
205
Build the AFP
pulse.
inpulse180file = self.sim_experiment.
↪→ inpulse180file
A_180 = self.sim_experiment.A_180
PULSE_180_LENGTH = self.sim_experiment.
↪→ PULSE_180_LENGTH
gyratio = self.sim_experiment.getGyratio
↪→ ()
210
pulse180 = Pulse(inpulse180file ,
↪→ PULSE_180_LENGTH , ’varian ’)
n_new = np.linspace(0, PULSE_180_LENGTH ,
↪→ 512)
215 waveform_real = np.real(pulse180.
↪→ waveform)*A_180
waveform_imag = np.imag(pulse180.
↪→ waveform)*A_180
pulse180.waveform = waveform_real + 1j*(
↪→ waveform_imag)
ampl_arr = np.abs(pulse180.waveform)*
↪→ gyratio
220 phas_arr = np.unwrap(np.angle(pulse180.
↪→ waveform))*180.0/ math.pi
freq_arr = np.gradient(phas_arr)
pulse = pg.row_vector(len(pulse180.
↪→ waveform))
ptime = pg.row_vector(len(pulse180.
↪→ waveform))
225 for j, val in enumerate(zip(ampl_arr ,
↪→ phas_arr)):
pulse.put(pg.complex(val[0],val [1])
↪→ , j)
ptime.put(pg.complex(n_new [1],0), j
↪→ )
pulse_dur_180 = pulse.size() * pulse180.
↪→ pulsestep
230 pwf_180 = pg.PulWaveform(pulse , ptime , "
↪→ 180 afp")
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pulc_180 = pg.PulComposite(pwf_180 ,
↪→ spin_system , self.sim_experiment.
↪→ obs_iso)
Define the
propagator for
the AFP pulse.
Ureal180 = pulc_180.GetUsum (-1)
235
Calculate the
pulse timings.
ROF1 = 100E-6 #sec
ROF2 = 10E-6 #sec
TCRUSH1 = 0.0008 #sec
240 TCRUSH2 = 0.0008 #sec
ss_grad_rfDelayFront = 0#TCRUSH1 - ROF1
ss_grad_rfDelayBack = 0#TCRUSH2 - ROF2
ro_grad_atDelayFront = 0
245 ro_grad_atDelayBack = 0
TE = self.sim_experiment.TE / 1000.
ipd = (TE - pulse_dur_90 \
- 6*( ss_grad_rfDelayFront +
↪→ pulse_dur_180 +
↪→ ss_grad_rfDelayBack)
↪→ \
250 - ro_grad_atDelayFront) / 12
Define the
delays between
RF pulses.
delay1 = ipd + ss_grad_rfDelayFront
delay2 = ss_grad_rfDelayBack + 2*ipd +
↪→ ss_grad_rfDelayFront
255 delay3 = ss_grad_rfDelayBack + 2*ipd +
↪→ ss_grad_rfDelayFront
delay4 = ss_grad_rfDelayBack + 2*ipd +
↪→ ss_grad_rfDelayFront
delay5 = ss_grad_rfDelayBack + 2*ipd +
↪→ ss_grad_rfDelayFront
delay6 = ss_grad_rfDelayBack + 2*ipd +
↪→ ss_grad_rfDelayFront
delay7 = ss_grad_rfDelayBack + ipd +
↪→ ro_grad_atDelayFront
260
Initialize the
Hamiltonian
and density
operator matrix
for the current
spin system.
H = pg.Hcs(spin_system) + pg.HJ(
↪→ spin_system)
D = pg.Fm(spin_system , self.
↪→ sim_experiment.obs_iso)
ac = pg.acquire1D(pg.gen_op(D), H, self.
↪→ sim_experiment.dwell_time)
265 ACQ = ac
Define the
propagators
for each delay
period.
Udelay1 = pg.prop(H, delay1)
Udelay2 = pg.prop(H, delay2)
270 Udelay3 = pg.prop(H, delay3)
Udelay4 = pg.prop(H, delay4)
Udelay5 = pg.prop(H, delay5)
Udelay6 = pg.prop(H, delay6)
Udelay7 = pg.prop(H, delay7)
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275
Apply RF pulse
propagators
and delay
propagators in
the appropriate
sequence to
“run the LASER
pulse sequence”.
sigma0 = pg.sigma_eq(spin_system) #
↪→ init
sigma1 = Ureal90.evolve(sigma0)
↪→ # apply 90-degree pulse
sigma0 = pg.evolve(sigma1 , Udelay1)
280 sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP1
sigma0 = pg.evolve(sigma1 , Udelay2)
sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP2
sigma0 = pg.evolve(sigma1 , Udelay3)
sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP3
285 sigma0 = pg.evolve(sigma1 , Udelay4)
sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP4
sigma0 = pg.evolve(sigma1 , Udelay5)
sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP5
sigma0 = pg.evolve(sigma1 , Udelay6)
290 sigma1 = Ureal180.evolve(sigma0) #
↪→ apply AFP6
sigma0 = pg.evolve(sigma1 , Udelay7)
Extract lines
from the
transition table.
mx = pg.TTable1D(ACQ.table(sigma0))
295
Using a binning
procedure to
correct for
degenerate
splittings and
other processes
based on peak
shifts and
phases.
# BINNING
# Note: Metabolite Peak Normalization and
↪→ Blending
300 # The transition tables calculated by the
↪→ GAMMA density matrix simulations
↪→ frequently contain a
# large number of transitions caused by
↪→ degenerate splittings and other
↪→ processes. At the
# conclusion of each simulation run a routine
↪→ is called to extract lines from the
↪→ transition table.
# These lines are then normalized using a
↪→ closed form calculation based on the
↪→ number of spins.
# To reduce the number of lines required for
↪→ display , multiple lines are blended by
↪→ binning them
305 # together based on their PPM locations and
↪→ phases. The following parameters are
↪→ used to
# customize these procedures:
# Peak Search Range -- Low/High (PPM): the
↪→ range in PPM that is searched for
↪→ lines from the
# metabolite simulation.
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310
# Peak Blending Tolerance (PPM and Degrees):
↪→ the width of the bins (+/- in PPM and
↪→ +/- in
# PhaseDegrees) that are used to blend the
↪→ lines in the simulation. Lines that
↪→ are included in the
# same bin are summed using complex addition
↪→ based on Amplitude and Phase.
315 b0 = self.sim_experiment.b0
obs_iso = self.sim_experiment.obs_iso
tolppm = self.sim_experiment.tolppm
tolpha = self.sim_experiment.tolpha
ppmlo = self.sim_experiment.ppmlo
320 ppmhi = self.sim_experiment.ppmhi
rf_off = self.sim_experiment.RF_OFFSET
field = b0
nspins = spin_system.spins()
325
nlines = mx.size()
tmp = pg.Isotope(obs_iso)
obs_qn = tmp.qn()
330
qnscale = 1.0
for i in range(nspins):
qnscale *= 2* spin_system.qn(i)+1
qnscale = qnscale / (2.0 * (2.0* obs_qn +1))
335
freqs = []
outf = []
outa = []
outp = []
340 nbin = 0
found = False
PI = 3.14159265358979323846
RAD2DEG = 180.0/ PI
345
indx = mx.Sort(0,-1,0)
for i in range(nlines):
freqs.append(-1 * mx.Fr(indx[i]) /(2.0* PI
↪→ *field))
350
for i in range(nlines):
freq = freqs[i]
if (freq > ppmlo) and (freq < ppmhi):
val = mx.I(indx[i])
355 tmpa = np.sqrt(val.real()**2 + val.
↪→ imag()**2) / qnscale
tmpp = -RAD2DEG * np.angle(val.real
↪→ ()+1j*val.imag())
if nbin == 0:
outf.append(freq)
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360 outa.append(tmpa)
outp.append(tmpp)
nbin += 1
else:
for k in range(nbin):
365 if (freq >= outf[k]-tolppm)
↪→ and (freq <= outf[k]+
↪→ tolppm):
if (tmpp >= outp[k]-
↪→ tolpha) and (tmpp
↪→ <= outp[k]+ tolpha)
↪→ :
ampsum = outa[k]+
↪→ tmpa
outf[k] = (outa[k]*
↪→ outf[k] +
↪→ tmpa*freq)/
↪→ ampsum
outp[k] = (outa[k]*
↪→ outp[k] +
↪→ tmpa*tmpp)/
↪→ ampsum
370 outa[k] += tmpa;
found = True
if not found:
outf.append(freq)
outa.append(tmpa)
375 outp.append(tmpp)
nbin += 1
found = False
for i, item in enumerate(outf):
380 outf[i] = item + rf_off
outp[i] = outp[i] - 90.0
Create a new
metabolite
object using
simulated shifts,
amplitudes, and
phases.
metab = Metabolite ()
385 metab.name = metab_name
metab.var = 0.0
for i in range(sp.size(outf)):
if outf[i] <= 5:
390 metab.ppm.append(outf[i])
metab.area.append(outa[i])
metab.phase.append (-1.0* outp[i])
insysfile = self.insysfile.replace(’pints/
↪→ metabolites /3T_’, ’’)
395 insysfile = self.insysfile.replace(’pints/
↪→ metabolites /7T_’, ’’)
insysfile = self.insysfile.replace(’pints/
↪→ metabolites /9.4T_’,’’)
Apply default
scaling factors
and T2 values.
These values
are not set in
stone; they may
be changed by
other programs
in the MAGIQ
software suite.
if insysfile == ’alanine.sys’: #
400 metab.A_m = 0.078
metab.T2 = (87E-3)
elif insysfile == ’aspartate.sys’:
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metab.A_m = 0.117
metab.T2 = (87E-3)
405 elif insysfile == ’choline_1 -CH2_2 -CH2.sys’:
↪→ #
metab.A_m = 0.165
metab.T2 = (87E-3)
elif insysfile == ’choline_N(CH3)3_a.sys’ or
↪→ insysfile == ’choline_N(CH3)3_b.sys’:
↪→ #
metab.A_m = 0.165
410 metab.T2 = (121E-3)
elif insysfile == ’creatine_N(CH3).sys’:
metab.A_m = 0.296
metab.T2 = (90E-3)
elif insysfile == ’creatine_X.sys’:
415 metab.A_m = 0.296
metab.T2 = (81E-3)
elif insysfile == ’d-glucose -alpha.sys’: #
metab.A_m = 0.049
metab.T2 = (87E-3)
420 elif insysfile == ’d-glucose -beta.sys’: #
metab.A_m = 0.049
metab.T2 = (87E-3)
elif insysfile == ’eth.sys’: #
metab.A_m = 0.320
425 metab.T2 = (87E-3)
elif insysfile == ’gaba.sys’: #
metab.A_m = 0.155
metab.T2 = (82E-3)
elif insysfile == ’glutamate.sys’:
430 metab.A_m = 0.898
metab.T2 = (88E-3)
elif insysfile == ’glutamine.sys’:
metab.A_m = 0.427
metab.T2 = (87E-3)
435 elif insysfile == ’glutathione_cysteine.sys’:
metab.A_m = 0.194
metab.T2 = (87E-3)
elif insysfile == ’glutathione_glutamate.sys’
↪→ :
metab.A_m = 0.194
440 metab.T2 = (87E-3)
elif insysfile == ’glutathione_glycine.sys’:
metab.A_m = 0.194
metab.T2 = (87E-3)
elif insysfile == ’glycine.sys’:
445 metab.A_m = 0.068
metab.T2 = (87E-3)
elif insysfile == ’gpc_7 -CH2_8 -CH2.sys’: #
metab.A_m = 0.097
metab.T2 = (87E-3)
450 elif insysfile == ’gpc_glycerol.sys’: #
metab.A_m = 0.097
metab.T2 = (87E-3)
elif insysfile == ’gpc_N(CH3)3_a.sys’: #
metab.A_m = 0.097
455 metab.T2 = (121E-3)
elif insysfile == ’gpc_N(CH3)3_b.sys’: #
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metab.A_m = 0.097
metab.T2 = (121E-3)
elif insysfile == ’lactate.sys’: #
460 metab.A_m = 0.039
metab.T2 = (87E-3)
elif insysfile == ’myoinositol.sys’:
metab.A_m = 0.578
metab.T2 = (87E-3)
465 elif insysfile == ’naa_acetyl.sys’:
metab.A_m = 1.000
metab.T2 = (130E-3)
elif insysfile == ’naa_aspartate.sys’:
metab.A_m = 1.000
470 metab.T2 = (69E-3)
elif insysfile == ’naag_acetyl.sys’:
metab.A_m = 0.160
metab.T2 = (130E-3)
elif insysfile == ’naag_aspartyl.sys’:
475 metab.A_m = 0.160
metab.T2 = (87E-3)
elif insysfile == ’naag_glutamate.sys’:
metab.A_m = 0.160
metab.T2 = (87E-3)
480 elif insysfile == ’pcho_N(CH3)3_a.sys’: #
metab.A_m = 0.058
metab.T2 = (121E-3)
elif insysfile == ’pcho_N(CH3)3_b.sys’: #
metab.A_m = 0.058
485 metab.T2 = (121E-3)
elif insysfile == ’pcho_X.sys’: #
metab.A_m = 0.058
metab.T2 = (87E-3)
elif insysfile == ’pcr_N(CH3).sys’:
490 metab.A_m = 0.422
metab.T2 = (90E-3)
elif insysfile == ’pcr_X.sys’:
metab.A_m = 0.422
metab.T2 = (81E-3)
495 elif insysfile == ’peth.sys’:
metab.A_m = 0.126
metab.T2 = (87E-3)
elif insysfile == ’scyllo -inositol.sys’:
metab.A_m = 0.044
500 metab.T2 = (87E-3)
elif insysfile == ’taurine.sys’:
metab.A_m = 0.117
metab.T2 = (85E-3)
elif insysfile == ’water.sys’:
505 metab.A_m = 1.000
metab.T2 = (43.60E-3)
# Send save data signal
self.outputResults.emit(metab)
510 self.postToConsole.emit(’ | Simulation
↪→ completed for ... ’ + self.insysfile)
self.finished.emit(self.thread_num)
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D.1 Spin System Definitions
The simulation code above loads in information about the spin system from an insysfile.
The insysfile is simply a text file that contains the peak shifts and J-coupling constants
for a particular metabolite formatted in a way that PyGAMMA expects. An example of an
insysfile is given below:
SysName (2) : gaba
NSpins (0) : 6
Iso (0) (2) : 1H
Iso (1) (2) : 1H
5 Iso (2) (2) : 1H
Iso (3) (2) : 1H
Iso (4) (2) : 1H
Iso (5) (2) : 1H
PPM (0) (1) : 2.2840
10 PPM (1) (1) : 2.2840
PPM (2) (1) : 1.8880
PPM (3) (1) : 1.8880
PPM (4) (1) : 3.0130
PPM (5) (1) : 3.0130
15 J(0,1) (1) : -15.938
J(0,2) (1) : 7.678
J(0,3) (1) : 6.980
J(0,4) (1) : 0.0
J(0,5) (1) : 0.0
20 J(1,2) (1) : 6.980
J(1,3) (1) : 7.678
J(1,4) (1) : 0.0
J(1,5) (1) : 0.0
J(2,3) (1) : -15.000
25 J(2,4) (1) : 8.510
J(2,5) (1) : 6.503
J(3,4) (1) : 6.503
J(3,5) (1) : 8.510
J(4,5) (1) : -14.062
30 Omega (1) : 297.2
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D.2 RF Pulse Definitions
The simulation code above builds the RF pulses used in the semi-LASER sequence from
Siemens *.pta files. These *.pta files are included below.
D.2.1 90-degree Excitation Pulse
PULSENAME: P10.P10NORM
COMMENT: Asymmetric amplitude modulated RF pulse - BW = 6.77/ length , gamma*B1 power
↪→ for 1ms 90deg = 1.67 kHz , asym factor = 0.23
REFGRAD: 3.105550000
MINSLICE: 1.000000000
5 MAXSLICE: 400.000000000
AMPINT: 38.391006745
POWERINT: 35.910179272
ABSINT: 57.869012713
10 0.001955034 0.000000000 ; (0)
0.001955034 0.000000000 ; (1)
0.002932551 0.000000000 ; (2)
0.002932551 0.000000000 ; (3)
0.002932551 0.000000000 ; (4)
15 0.003910068 0.000000000 ; (5)
0.003910068 0.000000000 ; (6)
0.004887586 0.000000000 ; (7)
0.004887586 0.000000000 ; (8)
0.004887586 0.000000000 ; (9)
20 0.005865103 0.000000000 ; (10)
0.005865103 0.000000000 ; (11)
0.006842620 0.000000000 ; (12)
0.006842620 0.000000000 ; (13)
0.006842620 0.000000000 ; (14)
25 0.007820137 0.000000000 ; (15)
0.007820137 0.000000000 ; (16)
0.007820137 0.000000000 ; (17)
0.007820137 0.000000000 ; (18)
0.008797654 0.000000000 ; (19)
30 0.008797654 0.000000000 ; (20)
0.008797654 0.000000000 ; (21)
0.008797654 0.000000000 ; (22)
0.008797654 0.000000000 ; (23)
0.008797654 0.000000000 ; (24)
35 0.008797654 0.000000000 ; (25)
0.008797654 0.000000000 ; (26)
0.007820137 0.000000000 ; (27)
0.007820137 0.000000000 ; (28)
0.007820137 0.000000000 ; (29)
40 0.006842620 0.000000000 ; (30)
0.006842620 0.000000000 ; (31)
0.005865103 0.000000000 ; (32)
0.004887586 0.000000000 ; (33)
0.004887586 0.000000000 ; (34)
45 0.003910068 0.000000000 ; (35)
248
D.2. RF Pulse Definitions
0.002932551 0.000000000 ; (36)
0.001955034 0.000000000 ; (37)
0.000977517 0.000000000 ; (38)
0.000000000 3.141592741 ; (39)
50 0.001955034 3.141592741 ; (40)
0.002932551 3.141592741 ; (41)
0.003910068 3.141592741 ; (42)
0.005865103 3.141592741 ; (43)
0.006842620 3.141592741 ; (44)
55 0.008797654 3.141592741 ; (45)
0.009775171 3.141592741 ; (46)
0.011730205 3.141592741 ; (47)
0.013685239 3.141592741 ; (48)
0.014662757 3.141592741 ; (49)
60 0.016617792 3.141592741 ; (50)
0.018572824 3.141592741 ; (51)
0.020527858 3.141592741 ; (52)
0.021505376 3.141592741 ; (53)
0.023460411 3.141592741 ; (54)
65 0.024437929 3.141592741 ; (55)
0.026392963 3.141592741 ; (56)
0.028347995 3.141592741 ; (57)
0.029325513 3.141592741 ; (58)
0.030303029 3.141592741 ; (59)
70 0.031280547 3.141592741 ; (60)
0.033235583 3.141592741 ; (61)
0.033235583 3.141592741 ; (62)
0.034213100 3.141592741 ; (63)
0.035190616 3.141592741 ; (64)
75 0.035190616 3.141592741 ; (65)
0.036168132 3.141592741 ; (66)
0.036168132 3.141592741 ; (67)
0.035190616 3.141592741 ; (68)
0.035190616 3.141592741 ; (69)
80 0.034213100 3.141592741 ; (70)
0.033235583 3.141592741 ; (71)
0.032258064 3.141592741 ; (72)
0.031280547 3.141592741 ; (73)
0.029325513 3.141592741 ; (74)
85 0.027370479 3.141592741 ; (75)
0.025415445 3.141592741 ; (76)
0.022482892 3.141592741 ; (77)
0.019550342 3.141592741 ; (78)
0.016617792 3.141592741 ; (79)
90 0.013685239 3.141592741 ; (80)
0.009775171 3.141592741 ; (81)
0.005865103 3.141592741 ; (82)
0.001955034 3.141592741 ; (83)
0.001955034 0.000000000 ; (84)
95 0.006842620 0.000000000 ; (85)
0.011730205 0.000000000 ; (86)
0.016617792 0.000000000 ; (87)
0.021505376 0.000000000 ; (88)
0.026392963 0.000000000 ; (89)
100 0.031280547 0.000000000 ; (90)
0.037145648 0.000000000 ; (91)
0.043010753 0.000000000 ; (92)
0.047898337 0.000000000 ; (93)
0.053763442 0.000000000 ; (94)
105 0.059628543 0.000000000 ; (95)
0.064516127 0.000000000 ; (96)
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0.070381232 0.000000000 ; (97)
0.075268820 0.000000000 ; (98)
0.080156401 0.000000000 ; (99)
110 0.085043989 0.000000000 ; (100)
0.089931577 0.000000000 ; (101)
0.094819158 0.000000000 ; (102)
0.098729230 0.000000000 ; (103)
0.102639295 0.000000000 ; (104)
115 0.105571851 0.000000000 ; (105)
0.108504400 0.000000000 ; (106)
0.110459432 0.000000000 ; (107)
0.112414464 0.000000000 ; (108)
0.114369504 0.000000000 ; (109)
120 0.115347020 0.000000000 ; (110)
0.115347020 0.000000000 ; (111)
0.115347020 0.000000000 ; (112)
0.113391981 0.000000000 ; (113)
0.112414464 0.000000000 ; (114)
125 0.109481916 0.000000000 ; (115)
0.106549367 0.000000000 ; (116)
0.102639295 0.000000000 ; (117)
0.097751714 0.000000000 ; (118)
0.092864126 0.000000000 ; (119)
130 0.086021505 0.000000000 ; (120)
0.079178885 0.000000000 ; (121)
0.071358748 0.000000000 ; (122)
0.062561095 0.000000000 ; (123)
0.053763442 0.000000000 ; (124)
135 0.043988269 0.000000000 ; (125)
0.033235583 0.000000000 ; (126)
0.021505376 0.000000000 ; (127)
0.009775171 0.000000000 ; (128)
0.002932551 3.141592741 ; (129)
140 0.016617792 3.141592741 ; (130)
0.030303029 3.141592741 ; (131)
0.043988269 3.141592741 ; (132)
0.058651026 3.141592741 ; (133)
0.073313780 3.141592741 ; (134)
145 0.087976538 3.141592741 ; (135)
0.103616811 3.141592741 ; (136)
0.119257085 3.141592741 ; (137)
0.133919850 3.141592741 ; (138)
0.149560124 3.141592741 ; (139)
150 0.165200397 3.141592741 ; (140)
0.179863155 3.141592741 ; (141)
0.194525898 3.141592741 ; (142)
0.208211139 3.141592741 ; (143)
0.221896380 3.141592741 ; (144)
155 0.235581622 3.141592741 ; (145)
0.247311831 3.141592741 ; (146)
0.259042025 3.141592741 ; (147)
0.269794732 3.141592741 ; (148)
0.279569894 3.141592741 ; (149)
160 0.287390023 3.141592741 ; (150)
0.295210153 3.141592741 ; (151)
0.301075280 3.141592741 ; (152)
0.305962861 3.141592741 ; (153)
0.308895409 3.141592741 ; (154)
165 0.310850441 3.141592741 ; (155)
0.310850441 3.141592741 ; (156)
0.308895409 3.141592741 ; (157)
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0.305962861 3.141592741 ; (158)
0.301075280 3.141592741 ; (159)
170 0.294232637 3.141592741 ; (160)
0.285434991 3.141592741 ; (161)
0.274682313 3.141592741 ; (162)
0.262952089 3.141592741 ; (163)
0.248289347 3.141592741 ; (164)
175 0.231671557 3.141592741 ; (165)
0.214076251 3.141592741 ; (166)
0.193548381 3.141592741 ; (167)
0.172043011 3.141592741 ; (168)
0.148582593 3.141592741 ; (169)
180 0.123167157 3.141592741 ; (170)
0.095796674 3.141592741 ; (171)
0.067448683 3.141592741 ; (172)
0.037145648 3.141592741 ; (173)
0.004887586 3.141592741 ; (174)
185 0.027370479 0.000000000 ; (175)
0.062561095 0.000000000 ; (176)
0.097751714 0.000000000 ; (177)
0.134897366 0.000000000 ; (178)
0.172043011 0.000000000 ; (179)
190 0.210166171 0.000000000 ; (180)
0.249266863 0.000000000 ; (181)
0.289345056 0.000000000 ; (182)
0.328445762 0.000000000 ; (183)
0.368523955 0.000000000 ; (184)
195 0.408602148 0.000000000 ; (185)
0.448680341 0.000000000 ; (186)
0.488758564 0.000000000 ; (187)
0.527859211 0.000000000 ; (188)
0.565982401 0.000000000 ; (189)
200 0.604105592 0.000000000 ; (190)
0.640273690 0.000000000 ; (191)
0.676441848 0.000000000 ; (192)
0.710654914 0.000000000 ; (193)
0.743890524 0.000000000 ; (194)
205 0.775171041 0.000000000 ; (195)
0.805474102 0.000000000 ; (196)
0.833822072 0.000000000 ; (197)
0.859237552 0.000000000 ; (198)
0.883675456 0.000000000 ; (199)
210 0.906158388 0.000000000 ; (200)
0.925708711 0.000000000 ; (201)
0.943304002 0.000000000 ; (202)
0.958944261 0.000000000 ; (203)
0.971652031 0.000000000 ; (204)
215 0.982404709 0.000000000 ; (205)
0.990224838 0.000000000 ; (206)
0.996089935 0.000000000 ; (207)
0.999022484 0.000000000 ; (208)
1.000000000 0.000000000 ; (209)
220 0.998044968 0.000000000 ; (210)
0.994134903 0.000000000 ; (211)
0.987292290 0.000000000 ; (212)
0.978494644 0.000000000 ; (213)
0.966764390 0.000000000 ; (214)
225 0.953079164 0.000000000 ; (215)
0.937438905 0.000000000 ; (216)
0.919843614 0.000000000 ; (217)
0.900293231 0.000000000 ; (218)
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0.877810359 0.000000000 ; (219)
230 0.855327487 0.000000000 ; (220)
0.829912007 0.000000000 ; (221)
0.803519070 0.000000000 ; (222)
0.775171041 0.000000000 ; (223)
0.745845556 0.000000000 ; (224)
235 0.715542495 0.000000000 ; (225)
0.684261978 0.000000000 ; (226)
0.652003884 0.000000000 ; (227)
0.619745851 0.000000000 ; (228)
0.586510241 0.000000000 ; (229)
240 0.552297175 0.000000000 ; (230)
0.518084049 0.000000000 ; (231)
0.483870953 0.000000000 ; (232)
0.449657857 0.000000000 ; (233)
0.416422278 0.000000000 ; (234)
245 0.395894438 0.000000000 ; (235)
0.374389052 0.000000000 ; (236)
0.352883667 0.000000000 ; (237)
0.331378311 0.000000000 ; (238)
0.308895409 0.000000000 ; (239)
250 0.287390023 0.000000000 ; (240)
0.264907122 0.000000000 ; (241)
0.243401766 0.000000000 ; (242)
0.220918864 0.000000000 ; (243)
0.199413493 0.000000000 ; (244)
255 0.177908108 0.000000000 ; (245)
0.157380253 0.000000000 ; (246)
0.136852399 0.000000000 ; (247)
0.117302053 0.000000000 ; (248)
0.097751714 0.000000000 ; (249)
260 0.080156401 0.000000000 ; (250)
0.062561095 0.000000000 ; (251)
0.044965789 0.000000000 ; (252)
0.029325513 0.000000000 ; (253)
0.013685239 0.000000000 ; (254)
265 0.000000000 0.000000000 ; (255)
D.2.2 Adiabatic Full Passage Pulse
PULSENAME: HS4_R25.HS4_R25
COMMENT: HS4.0 adiabatic inversion pulse using sech/tanh mod: R=25.0
REFGRAD: 11.468075000
MINSLICE: 1.000000000
5 MAXSLICE: 400.000000000
AMPINT: 56.670000000
POWERINT: 324.724113587
ABSINT: 360.759644176
10 0.010000000 1.421587586 ; (0)
0.010861272 1.268189430 ; (1)
0.011785276 1.114791512 ; (2)
0.012775575 0.961393595 ; (3)
0.013835855 0.807995856 ; (4)
15 0.014969926 0.654598236 ; (5)
0.016181717 0.501200855 ; (6)
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0.017475275 0.347803652 ; (7)
0.018854763 0.194406718 ; (8)
0.020324456 0.041010056 ; (9)
20 0.021888735 -0.112386264 ; (10)
0.023552084 -0.265782207 ; (11)
0.025319088 -0.419177681 ; (12)
0.027194424 -0.572572649 ; (13)
0.029182851 -0.725966990 ; (14)
25 0.031289212 -0.879360616 ; (15)
0.033518419 -1.032753468 ; (16)
0.035875447 -1.186145425 ; (17)
0.038365327 -1.339536309 ; (18)
0.040993132 -1.492925882 ; (19)
30 0.043763965 -1.646314144 ; (20)
0.046682969 -1.799700856 ; (21)
0.049755275 -1.953085661 ; (22)
0.052986033 -2.106468439 ; (23)
0.056380369 -2.259848833 ; (24)
35 0.059943378 -2.413226843 ; (25)
0.063680120 -2.566601515 ; (26)
0.067595594 -2.719972849 ; (27)
0.071694717 -2.873340607 ; (28)
0.075982340 -3.026703835 ; (29)
40 0.080463171 3.103123188 ; (30)
0.085141823 2.949770212 ; (31)
0.090022750 2.796423435 ; (32)
0.095110238 2.643083334 ; (33)
0.100408405 2.489751101 ; (34)
45 0.105921157 2.336427212 ; (35)
0.111652173 2.183112860 ; (36)
0.117604889 2.029809237 ; (37)
0.123782486 1.876517415 ; (38)
0.130187824 1.723238587 ; (39)
50 0.136823505 1.569974303 ; (40)
0.143691748 1.416725993 ; (41)
0.150794446 1.263495326 ; (42)
0.158133104 1.110284209 ; (43)
0.165708825 0.957094550 ; (44)
55 0.173522308 0.803928554 ; (45)
0.181573823 0.650788486 ; (46)
0.189863116 0.497676849 ; (47)
0.198389530 0.344596386 ; (48)
0.207151875 0.191549957 ; (49)
60 0.216148421 0.038540728 ; (50)
0.225376934 -0.114427961 ; (51)
0.234834641 -0.267352521 ; (52)
0.244518176 -0.420229077 ; (53)
0.254423618 -0.573053539 ; (54)
65 0.264546484 -0.725821495 ; (55)
0.274881661 -0.878528297 ; (56)
0.285423487 -1.031169057 ; (57)
0.296165675 -1.183738351 ; (58)
0.307101339 -1.336230636 ; (59)
70 0.318223029 -1.488640070 ; (60)
0.329522729 -1.640960455 ; (61)
0.340991765 -1.793185115 ; (62)
0.352621049 -1.945307255 ; (63)
0.364400774 -2.097319365 ; (64)
75 0.376320750 -2.249214172 ; (65)
0.388370246 -2.400983572 ; (66)
0.400538027 -2.552618980 ; (67)
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0.412812442 -2.704112053 ; (68)
0.425181478 -2.855453491 ; (69)
80 0.437632650 -3.006633997 ; (70)
0.450153232 3.125541687 ; (71)
0.462730169 2.974713087 ; (72)
0.475350171 2.824075937 ; (73)
0.487999707 2.673640966 ; (74)
85 0.500665188 2.523419619 ; (75)
0.513332844 2.373423100 ; (76)
0.525988936 2.223663330 ; (77)
0.538619637 2.074152708 ; (78)
0.551211178 1.924903512 ; (79)
90 0.563750029 1.775928378 ; (80)
0.576222718 1.627240181 ; (81)
0.588615954 1.478852391 ; (82)
0.600916803 1.330778241 ; (83)
0.613112628 1.183031440 ; (84)
95 0.625191092 1.035625815 ; (85)
0.637140274 0.888575256 ; (86)
0.648948789 0.741894066 ; (87)
0.660605609 0.595596373 ; (88)
0.672100246 0.449696600 ; (89)
100 0.683422863 0.304209113 ; (90)
0.694564164 0.159148410 ; (91)
0.705515265 0.014528991 ; (92)
0.716268241 -0.129634649 ; (93)
0.726815522 -0.273328006 ; (94)
105 0.737150252 -0.416536659 ; (95)
0.747266412 -0.559246242 ; (96)
0.757158399 -0.701442420 ; (97)
0.766821384 -0.843110979 ; (98)
0.776251197 -0.984237909 ; (99)
110 0.785444319 -1.124809384 ; (100)
0.794397891 -1.264811397 ; (101)
0.803109705 -1.404230714 ; (102)
0.811578035 -1.543053746 ; (103)
0.819801927 -1.681267381 ; (104)
115 0.827780843 -1.818858624 ; (105)
0.835514963 -1.955815077 ; (106)
0.843004882 -2.092123985 ; (107)
0.850251675 -2.227773428 ; (108)
0.857257009 -2.362751484 ; (109)
120 0.864022851 -2.497046471 ; (110)
0.870551765 -2.630647182 ; (111)
0.876846611 -2.763542652 ; (112)
0.882910550 -2.895721912 ; (113)
0.888747096 -3.027174950 ; (114)
125 0.894360244 3.125293970 ; (115)
0.899753988 2.995323896 ; (116)
0.904932737 2.866109371 ; (117)
0.909901023 2.737659693 ; (118)
0.914663732 2.609983921 ; (119)
130 0.919225752 2.483090162 ; (120)
0.923592091 2.356986761 ; (121)
0.927767992 2.231681824 ; (122)
0.931758761 2.107182980 ; (123)
0.935569704 1.983497024 ; (124)
135 0.939206243 1.860631466 ; (125)
0.942673802 1.738592982 ; (126)
0.945977807 1.617387772 ; (127)
0.949123740 1.497022152 ; (128)
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0.952116907 1.377501965 ; (129)
140 0.954962790 1.258832932 ; (130)
0.957666695 1.141020417 ; (131)
0.960233867 1.024069428 ; (132)
0.962669551 0.907984972 ; (133)
0.964978814 0.792771637 ; (134)
145 0.967166781 0.678433836 ; (135)
0.969238281 0.564975858 ; (136)
0.971198201 0.452401668 ; (137)
0.973051310 0.340714991 ; (138)
0.974802196 0.229919478 ; (139)
150 0.976455271 0.120018527 ; (140)
0.978015065 0.011015344 ; (141)
0.979485750 -0.097087011 ; (142)
0.980871379 -0.204285666 ; (143)
0.982176125 -0.310577899 ; (144)
155 0.983403683 -0.415961146 ; (145)
0.984557927 -0.520432949 ; (146)
0.985642433 -0.623991072 ; (147)
0.986660659 -0.726633430 ; (148)
0.987616003 -0.828357875 ; (149)
160 0.988511682 -0.929162562 ; (150)
0.989350855 -1.029045701 ; (151)
0.990136445 -1.128005624 ; (152)
0.990871370 -1.226040840 ; (153)
0.991558373 -1.323149800 ; (154)
165 0.992200136 -1.419331074 ; (155)
0.992799103 -1.514583468 ; (156)
0.993357718 -1.608905792 ; (157)
0.993878305 -1.702296853 ; (158)
0.994363010 -1.794755697 ; (159)
170 0.994814038 -1.886281252 ; (160)
0.995233357 -1.976872563 ; (161)
0.995622814 -2.066528797 ; (162)
0.995984256 -2.155249357 ; (163)
0.996319413 -2.243033409 ; (164)
175 0.996629953 -2.329880238 ; (165)
0.996917367 -2.415789127 ; (166)
0.997183144 -2.500759602 ; (167)
0.997428775 -2.584791183 ; (168)
0.997655451 -2.667883396 ; (169)
180 0.997864485 -2.750035524 ; (170)
0.998057127 -2.831247091 ; (171)
0.998234332 -2.911518097 ; (172)
0.998397291 -2.990848064 ; (173)
0.998546958 -3.069236517 ; (174)
185 0.998684287 3.136502266 ; (175)
0.998810112 3.059997559 ; (176)
0.998925269 2.984435320 ; (177)
0.999030590 2.909815550 ; (178)
0.999126792 2.836138487 ; (179)
190 0.999214530 2.763404369 ; (180)
0.999294460 2.691613436 ; (181)
0.999367177 2.620765924 ; (182)
0.999433279 2.550861835 ; (183)
0.999493241 2.481901169 ; (184)
195 0.999547601 2.413884401 ; (185)
0.999596775 2.346811533 ; (186)
0.999641180 2.280682325 ; (187)
0.999681294 2.215497255 ; (188)
0.999717414 2.151256561 ; (189)
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200 0.999749899 2.087959766 ; (190)
0.999779046 2.025607347 ; (191)
0.999805212 1.964199066 ; (192)
0.999828637 1.903735280 ; (193)
0.999849498 1.844215989 ; (194)
205 0.999868155 1.785641074 ; (195)
0.999884725 1.728010654 ; (196)
0.999899447 1.671324849 ; (197)
0.999912500 1.615583539 ; (198)
0.999924064 1.560786843 ; (199)
210 0.999934256 1.506934762 ; (200)
0.999943256 1.454027414 ; (201)
0.999951124 1.402064681 ; (202)
0.999958038 1.351046562 ; (203)
0.999964058 1.300973177 ; (204)
215 0.999969304 1.251844525 ; (205)
0.999973893 1.203660607 ; (206)
0.999977887 1.156421423 ; (207)
0.999981284 1.110126972 ; (208)
0.999984264 1.064777255 ; (209)
220 0.999986827 1.020372272 ; (210)
0.999988973 0.976912141 ; (211)
0.999990821 0.934396684 ; (212)
0.999992371 0.892826021 ; (213)
0.999993742 0.852200150 ; (214)
225 0.999994874 0.812519014 ; (215)
0.999995828 0.773782670 ; (216)
0.999996603 0.735991120 ; (217)
0.999997258 0.699144363 ; (218)
0.999997795 0.663242400 ; (219)
230 0.999998212 0.628285170 ; (220)
0.999998569 0.594272733 ; (221)
0.999998868 0.561205149 ; (222)
0.999999166 0.529082298 ; (223)
0.999999344 0.497904211 ; (224)
235 0.999999464 0.467670947 ; (225)
0.999999583 0.438382477 ; (226)
0.999999702 0.410038769 ; (227)
0.999999762 0.382639885 ; (228)
0.999999821 0.356185764 ; (229)
240 0.999999881 0.330676436 ; (230)
0.999999940 0.306111902 ; (231)
0.999999940 0.282492161 ; (232)
0.999999940 0.259817213 ; (233)
0.999999940 0.238087043 ; (234)
245 1.000000000 0.217301667 ; (235)
1.000000000 0.197461069 ; (236)
1.000000000 0.178565279 ; (237)
1.000000000 0.160614267 ; (238)
1.000000000 0.143608049 ; (239)
250 1.000000000 0.127546623 ; (240)
1.000000000 0.112429991 ; (241)
1.000000000 0.098258145 ; (242)
1.000000000 0.085031085 ; (243)
1.000000000 0.072748818 ; (244)
255 1.000000000 0.061411340 ; (245)
1.000000000 0.051018652 ; (246)
1.000000000 0.041570753 ; (247)
1.000000000 0.033067644 ; (248)
1.000000000 0.025509326 ; (249)
260 1.000000000 0.018895797 ; (250)
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1.000000000 0.013227058 ; (251)
1.000000000 0.008503108 ; (252)
1.000000000 0.004723949 ; (253)
1.000000000 0.001889580 ; (254)
265 1.000000000 0.000000000 ; (255)
1.000000000 0.000000000 ; (256)
1.000000000 0.001889580 ; (257)
1.000000000 0.004723949 ; (258)
1.000000000 0.008503108 ; (259)
270 1.000000000 0.013227058 ; (260)
1.000000000 0.018895797 ; (261)
1.000000000 0.025509326 ; (262)
1.000000000 0.033067644 ; (263)
1.000000000 0.041570753 ; (264)
275 1.000000000 0.051018652 ; (265)
1.000000000 0.061411340 ; (266)
1.000000000 0.072748818 ; (267)
1.000000000 0.085031085 ; (268)
1.000000000 0.098258145 ; (269)
280 1.000000000 0.112429991 ; (270)
1.000000000 0.127546623 ; (271)
1.000000000 0.143608049 ; (272)
1.000000000 0.160614267 ; (273)
1.000000000 0.178565279 ; (274)
285 1.000000000 0.197461069 ; (275)
1.000000000 0.217301667 ; (276)
0.999999940 0.238087043 ; (277)
0.999999940 0.259817213 ; (278)
0.999999940 0.282492161 ; (279)
290 0.999999940 0.306111902 ; (280)
0.999999881 0.330676436 ; (281)
0.999999821 0.356185764 ; (282)
0.999999762 0.382639885 ; (283)
0.999999702 0.410038769 ; (284)
295 0.999999583 0.438382477 ; (285)
0.999999464 0.467670947 ; (286)
0.999999344 0.497904211 ; (287)
0.999999166 0.529082298 ; (288)
0.999998868 0.561205149 ; (289)
300 0.999998569 0.594272733 ; (290)
0.999998212 0.628285170 ; (291)
0.999997795 0.663242400 ; (292)
0.999997258 0.699144363 ; (293)
0.999996603 0.735991120 ; (294)
305 0.999995828 0.773782670 ; (295)
0.999994874 0.812519014 ; (296)
0.999993742 0.852200150 ; (297)
0.999992371 0.892826021 ; (298)
0.999990821 0.934396684 ; (299)
310 0.999988973 0.976912141 ; (300)
0.999986827 1.020372272 ; (301)
0.999984264 1.064777255 ; (302)
0.999981284 1.110126972 ; (303)
0.999977887 1.156421423 ; (304)
315 0.999973893 1.203660607 ; (305)
0.999969304 1.251844525 ; (306)
0.999964058 1.300973177 ; (307)
0.999958038 1.351046562 ; (308)
0.999951124 1.402064681 ; (309)
320 0.999943256 1.454027414 ; (310)
0.999934256 1.506934762 ; (311)
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0.999924064 1.560786843 ; (312)
0.999912500 1.615583539 ; (313)
0.999899447 1.671324849 ; (314)
325 0.999884725 1.728010654 ; (315)
0.999868155 1.785641074 ; (316)
0.999849498 1.844215989 ; (317)
0.999828637 1.903735280 ; (318)
0.999805212 1.964199066 ; (319)
330 0.999779046 2.025607347 ; (320)
0.999749899 2.087959766 ; (321)
0.999717414 2.151256561 ; (322)
0.999681294 2.215497255 ; (323)
0.999641180 2.280682325 ; (324)
335 0.999596775 2.346811533 ; (325)
0.999547601 2.413884401 ; (326)
0.999493241 2.481901169 ; (327)
0.999433279 2.550861835 ; (328)
0.999367177 2.620765924 ; (329)
340 0.999294460 2.691613436 ; (330)
0.999214530 2.763404369 ; (331)
0.999126792 2.836138487 ; (332)
0.999030590 2.909815550 ; (333)
0.998925269 2.984435320 ; (334)
345 0.998810112 3.059997559 ; (335)
0.998684287 3.136502266 ; (336)
0.998546958 -3.069236517 ; (337)
0.998397291 -2.990848064 ; (338)
0.998234332 -2.911518097 ; (339)
350 0.998057127 -2.831247091 ; (340)
0.997864485 -2.750035524 ; (341)
0.997655451 -2.667883396 ; (342)
0.997428775 -2.584791183 ; (343)
0.997183144 -2.500759602 ; (344)
355 0.996917367 -2.415789127 ; (345)
0.996629953 -2.329880238 ; (346)
0.996319413 -2.243033409 ; (347)
0.995984256 -2.155249357 ; (348)
0.995622814 -2.066528797 ; (349)
360 0.995233357 -1.976872563 ; (350)
0.994814038 -1.886281252 ; (351)
0.994363010 -1.794755697 ; (352)
0.993878305 -1.702296853 ; (353)
0.993357718 -1.608905792 ; (354)
365 0.992799103 -1.514583468 ; (355)
0.992200136 -1.419331074 ; (356)
0.991558373 -1.323149800 ; (357)
0.990871370 -1.226040840 ; (358)
0.990136445 -1.128005624 ; (359)
370 0.989350855 -1.029045701 ; (360)
0.988511682 -0.929162562 ; (361)
0.987616003 -0.828357875 ; (362)
0.986660659 -0.726633430 ; (363)
0.985642433 -0.623991072 ; (364)
375 0.984557927 -0.520432949 ; (365)
0.983403683 -0.415961146 ; (366)
0.982176125 -0.310577899 ; (367)
0.980871379 -0.204285666 ; (368)
0.979485750 -0.097087011 ; (369)
380 0.978015065 0.011015344 ; (370)
0.976455271 0.120018527 ; (371)
0.974802196 0.229919478 ; (372)
258
D.2. RF Pulse Definitions
0.973051310 0.340714991 ; (373)
0.971198201 0.452401668 ; (374)
385 0.969238281 0.564975858 ; (375)
0.967166781 0.678433836 ; (376)
0.964978814 0.792771637 ; (377)
0.962669551 0.907984972 ; (378)
0.960233867 1.024069428 ; (379)
390 0.957666695 1.141020417 ; (380)
0.954962790 1.258832932 ; (381)
0.952116907 1.377501965 ; (382)
0.949123740 1.497022152 ; (383)
0.945977807 1.617387772 ; (384)
395 0.942673802 1.738592982 ; (385)
0.939206243 1.860631466 ; (386)
0.935569704 1.983497024 ; (387)
0.931758761 2.107182980 ; (388)
0.927767992 2.231681824 ; (389)
400 0.923592091 2.356986761 ; (390)
0.919225752 2.483090162 ; (391)
0.914663732 2.609983921 ; (392)
0.909901023 2.737659693 ; (393)
0.904932737 2.866109371 ; (394)
405 0.899753988 2.995323896 ; (395)
0.894360244 3.125293970 ; (396)
0.888747096 -3.027174950 ; (397)
0.882910550 -2.895721912 ; (398)
0.876846611 -2.763542652 ; (399)
410 0.870551765 -2.630647182 ; (400)
0.864022851 -2.497046471 ; (401)
0.857257009 -2.362751484 ; (402)
0.850251675 -2.227773428 ; (403)
0.843004882 -2.092123985 ; (404)
415 0.835514963 -1.955815077 ; (405)
0.827780843 -1.818858624 ; (406)
0.819801927 -1.681267381 ; (407)
0.811578035 -1.543053746 ; (408)
0.803109705 -1.404230714 ; (409)
420 0.794397891 -1.264811397 ; (410)
0.785444319 -1.124809384 ; (411)
0.776251197 -0.984237909 ; (412)
0.766821384 -0.843110979 ; (413)
0.757158399 -0.701442420 ; (414)
425 0.747266412 -0.559246242 ; (415)
0.737150252 -0.416536659 ; (416)
0.726815522 -0.273328006 ; (417)
0.716268241 -0.129634649 ; (418)
0.705515265 0.014528991 ; (419)
430 0.694564164 0.159148410 ; (420)
0.683422863 0.304209113 ; (421)
0.672100246 0.449696600 ; (422)
0.660605609 0.595596373 ; (423)
0.648948789 0.741894066 ; (424)
435 0.637140274 0.888575256 ; (425)
0.625191092 1.035625815 ; (426)
0.613112628 1.183031440 ; (427)
0.600916803 1.330778241 ; (428)
0.588615954 1.478852391 ; (429)
440 0.576222718 1.627240181 ; (430)
0.563750029 1.775928378 ; (431)
0.551211178 1.924903512 ; (432)
0.538619637 2.074152708 ; (433)
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0.525988936 2.223663330 ; (434)
445 0.513332844 2.373423100 ; (435)
0.500665188 2.523419619 ; (436)
0.487999707 2.673640966 ; (437)
0.475350171 2.824075937 ; (438)
0.462730169 2.974713087 ; (439)
450 0.450153232 3.125541687 ; (440)
0.437632650 -3.006633997 ; (441)
0.425181478 -2.855453491 ; (442)
0.412812442 -2.704112053 ; (443)
0.400538027 -2.552618980 ; (444)
455 0.388370246 -2.400983572 ; (445)
0.376320750 -2.249214172 ; (446)
0.364400774 -2.097319365 ; (447)
0.352621049 -1.945307255 ; (448)
0.340991765 -1.793185115 ; (449)
460 0.329522729 -1.640960455 ; (450)
0.318223029 -1.488640070 ; (451)
0.307101339 -1.336230636 ; (452)
0.296165675 -1.183738351 ; (453)
0.285423487 -1.031169057 ; (454)
465 0.274881661 -0.878528297 ; (455)
0.264546484 -0.725821495 ; (456)
0.254423618 -0.573053539 ; (457)
0.244518176 -0.420229077 ; (458)
0.234834641 -0.267352521 ; (459)
470 0.225376934 -0.114427961 ; (460)
0.216148421 0.038540728 ; (461)
0.207151875 0.191549957 ; (462)
0.198389530 0.344596386 ; (463)
0.189863116 0.497676849 ; (464)
475 0.181573823 0.650788486 ; (465)
0.173522308 0.803928554 ; (466)
0.165708825 0.957094550 ; (467)
0.158133104 1.110284209 ; (468)
0.150794446 1.263495326 ; (469)
480 0.143691748 1.416725993 ; (470)
0.136823505 1.569974303 ; (471)
0.130187824 1.723238587 ; (472)
0.123782486 1.876517415 ; (473)
0.117604889 2.029809237 ; (474)
485 0.111652173 2.183112860 ; (475)
0.105921157 2.336427212 ; (476)
0.100408405 2.489751101 ; (477)
0.095110238 2.643083334 ; (478)
0.090022750 2.796423435 ; (479)
490 0.085141823 2.949770212 ; (480)
0.080463171 3.103123188 ; (481)
0.075982340 -3.026703835 ; (482)
0.071694717 -2.873340607 ; (483)
0.067595594 -2.719972849 ; (484)
495 0.063680120 -2.566601515 ; (485)
0.059943378 -2.413226843 ; (486)
0.056380369 -2.259848833 ; (487)
0.052986033 -2.106468439 ; (488)
0.049755275 -1.953085661 ; (489)
500 0.046682969 -1.799700856 ; (490)
0.043763965 -1.646314144 ; (491)
0.040993132 -1.492925882 ; (492)
0.038365327 -1.339536309 ; (493)
0.035875447 -1.186145425 ; (494)
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505 0.033518419 -1.032753468 ; (495)
0.031289212 -0.879360616 ; (496)
0.029182851 -0.725966990 ; (497)
0.027194424 -0.572572649 ; (498)
0.025319088 -0.419177681 ; (499)
510 0.023552084 -0.265782207 ; (500)
0.021888735 -0.112386264 ; (501)
0.020324456 0.041010056 ; (502)
0.018854763 0.194406718 ; (503)
0.017475275 0.347803652 ; (504)
515 0.016181717 0.501200855 ; (505)
0.014969926 0.654598236 ; (506)
0.013835855 0.807995856 ; (507)
0.012775575 0.961393595 ; (508)
0.011785276 1.114791512 ; (509)
520 0.010861272 1.268189430 ; (510)
0.000000000 0.000000000 ; (511)
261
E
Research Ethics Approvals
Research ethics approvals for the studies presented in this thesis are provided on the fol-
lowing pages.
262
Appendix E. Research Ethics Approvals
263
From: eSiriusWebServer < >  
Sent: July-11-16 2:33 PM 
To:  
Cc: Account Generic 24 < >; Account Generic 24 < > 
Subject: eSirius Notification - Annual Protocol Renewal APPROVED by the AUS 2012-040::3 
  
 
2012-040::3: 
AUP Number: 2012-040 
AUP Title: The Interaction of Vitamin D and Memantine for Alzheimer Disease Treatment 
Yearly Renewal Date: 07/01/2016 
The YEARLY RENEWAL to Animal Use Protocol (AUP) 2012-040 has been approved, 
and will be approved for one year following the above review date. 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through the ACVS 
office. 
Health certificates will be required. 
REQUIREMENTS/COMMENTS 
Please ensure that individual(s) performing procedures on live animals, as described in this 
protocol, are familiar with the contents of this document. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with institutional 
safety standards and have received all necessary approvals. Please consult directly with 
your institutional safety officers. 
Submitted by: Kinchlea, Will D  
on behalf of the Animal Use Subcommittee 
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NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
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OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU. 
WILEY shall have the right to terminate this Agreement immediately upon breach of
this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND WHETHER
OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING ANY
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY PROVIDED
HEREIN. 
Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this Agreement
shall not be affected or impaired thereby. 
The failure of either party to enforce any term or condition of this Agreement shall not
constitute a waiver of either party's right to enforce each and every term and condition
of this Agreement. No breach under this agreement shall be deemed waived or
excused by either party unless such waiver or consent is in writing signed by the party
granting such waiver or consent. The waiver by or consent of a party to a breach of
any provision of this Agreement shall not operate or be construed as a waiver of or
consent to any other or subsequent breach by such other party. 
This Agreement may not be assigned (including by operation of law or otherwise) by
you without WILEY's prior written consent.
Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you and
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes
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all prior agreements and representations of the parties, oral or written. This Agreement
may not be amended except in writing signed by both parties. This Agreement shall be
binding upon and inure to the benefit of the parties' successors, legal representatives,
and authorized assigns. 
In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and conditions,
these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of (i)
the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment terms
and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules. Any
legal action, suit or proceeding arising out of or relating to these Terms and Conditions
or the breach thereof shall be instituted in a court of competent jurisdiction in New
York County in the State of New York in the United States of America and each party
hereby consents and submits to the personal jurisdiction of such court, waives any
objection to venue in such court and consents to service of process by registered or
certified mail, return receipt requested, at the last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and non-
Creative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html
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Other Terms and Conditions:
v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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Dickson Wong | Curriculum Vitae
MD/PhD Candidate in Medical Biophysics
Education
The University of Western Ontario London, ON
Doctor of Medicine (M.D.) 2018–present
Schulich School of Medicine and Dentistry
The University of Western Ontario London, ON
Doctor of Philosophy (Ph.D.), Medical Biophysics 2015–present
Advisor: Dr. Robert Bartha
McMaster University Hamilton, ON
Bachelor of Engineering (B.Eng.), GPA – 4.0 2011–2015
Electrical and Biomedical Engineering
The Royal Conservatory of Music Toronto, ON
Performance Associateship Diploma (ARCT), Honours 2009
Piano
Publications
2019 (In Preparation): “Chronic Vitamin D deficiency in adult APP/PS1 mice: Effect on memory performance and brain
metabolite levels”. Dickson Wong, Miranda Bellyou, Alex Li, Marco Prado, Olivier Beauchet, Cédric Annweiler,
Manuel Montero-Odasso, Robert Bartha. Journal of Neurochemistry.
2019 (In Preparation): “Observing metabolite changes in short versus long echo time functional magnetic resonance
spectroscopy at 7-Tesla”. Peter Jeon, Michael Mackinley, Kara Dempster, Dickson Wong, Lena Palaniyappan, Jean
Théberge. Magnetic Resonance in Medicine.
2019 (Submitted): “Glutamate and Dysconnection in the Salience Network: Neurochemical, Effective-connectivity, and
Computational Evidence in Schizophrenia”. Roberto Limongi, Peter Jeon, Michael Mackinley, Tushar Das, Kara
Dempster, Jean Theéberge, Robert Bartha, Dickson Wong, Lena Palaniyappan. Biological Psychiatry.
2019 (Accepted with Minor Revisions): “Relating Hippocampal Glutamate to Structural Changes and Cognitive
Performance in Alzheimer’s Disease: A 7T MRI Study”. Dickson Wong, Samir Atiya, Jennifer Fogarty, Manuel
Montero-Odasso, Stephen Pasternak, Chris Brymer, Michael Borrie, Robert Bartha. Journal of Alzheimer’s Disease
2019 (Submitted): “7T Magnetic Resonance Spectroscopy of the Hippocampus in Non-Lesional Temporal Lobe Epilepsy”.
John Adams, Simona Nikolova, Suzan Brown, Dickson Wong, Robert Bartha, Jorge G Burneo. Epilepsy Research.
2018: Optimized in vivo brain glutamate measurement using long-echo-time semi-LASER at 7T. Dickson Wong, Amy L.
Schranz, Robert Bartha. NMR in Biomedicine: 31:e4002. https://doi.org/10.1002/nbm.4002
2018: BIDS Extension Proposal 22 (BEP022): MRS (Magnetic Resonance Spectroscopy). Dickson Wong, Maryam
Mozaffari, Yiming Xiao, Jenny Chan. Brain Imaging Data Standard.
https://docs.google.com/document/d/1pWCb02YNv5W-UZZja24fZrdXLm4X7knXMiZI7E2z7mY/
2018: 1H MR spectroscopy of the motor cortex immediately following transcranial direct current stimulation at 7 Tesla.
Kayla Ryan, Krzysztof Wawrzyn, Joseph S. Gati, Blaine A. Chronik, Dickson Wong, Neil Duggal, Robert Bartha.
PLOS ONE 13(8): e0198053. https://doi.org/10.1371/journal.pone.0198053
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Presentations and Abstracts
2018 (Poster): “Relating Hippocampal Glutamate to Structural Changes and Cognitive Performance in Alzheimer’s Disease:
A 7T MRI Study”, Dickson Wong, Samir Atiya, Jennifer Fogarty, Manuel Montero-Odasso, Stephen Pasternak,
Chris Brymer, Michael Borrie, Robert Bartha, Alzheimer’s Association International Conference, July 22, 2018,
McCormick Place, Chicago, IL.
2018 (Presentation): “Relating Hippocampal Glutamate to Structural Changes and Cognitive Performance in Alzheimer’s
Disease: A 7T MRI Study”, Dickson Wong, Samir Atiya, Jennifer Fogarty, Manuel Montero-Odasso, Stephen
Pasternak, Chris Brymer, Michael Borrie, Robert Bartha, Imaging Network Ontario Symposium, March 28, 2018,
Chestnut Residence & Conference Centre, Toronto, ON.
2017 (Poster): “Vitamin D Supplementation May Protect Against Oxidative Stress in a Vitamin D Deficient Double-
TransgenicMouseModel of Alzheimer’sDisease”,DicksonWong, Miranda Bellyou, Olivier Beauchet,ManuelMontero-
Odasso, Cedric Annweiler, Robert Bartha, Alzheimer’s Association International Conference, July 17, 2017, ExCeL
London, London, UK.
2017 (Poster): “Combined Memantine and Vitamin D Treatment Provides the Same Cognitive Benefit As Memantine Alone
in a Chronically Vitamin D Deficient Double-Transgenic Mouse Model of Alzheimer’s Disease”, Dickson Wong, Miranda
Bellyou, Olivier Beauchet, Manuel Montero-Odasso, Cedric Annweiler, Robert Bartha, Alzheimer’s Association
International Conference, July 16, 2017, ExCeL London, London, UK.
2017 (Poster): “Vitamin D Supplementation May Protect Against Oxidative Stress in a Vitamin D Deficient Double-
TransgenicMouseModel of Alzheimer’sDisease”,DicksonWong, Miranda Bellyou, Olivier Beauchet,ManuelMontero-
Odasso, Cedric Annweiler, Robert Bartha, Alzheimer’s Imaging Consortium, July 15, 2017, ExCeL London, London,
UK.
2017 (E-Poster): “Optimal Echo Time for In-Vivo Glutamate Detection at 7T Using semi-LASER 1H-MRS”, Dickson
Wong, Amy Schranz, Robert Bartha, International Society for Magnetic Resonance in Medicine Annual Meeting,
April 22, 2017, Hawai’i Convention Center, Honolulu, HI.
2017 (Poster): “Memantine and Vitamin D Supplementation Improves Cognition in Chronically Vitamin D Deficient
APP/PS1 Mice”, Dickson Wong, Miranda Bellyou, Olivier Beauchet, Manuel Montero-Odasso, Cedric Annweiler,
Robert Bartha, London Health Research Day, March 28, 2017, London Convention Center, London, ON.
2017 (Poster): “Improved Glutamate Detection in the Brain at 7T Using Long Echo-Time 1H-MRS”, Dickson Wong,
Amy Schranz, Robert Bartha, Imaging Network of Ontario Symposium, March 15, 2017, Double Tree Hilton,
London, ON.
2016 (Poster): “Enabling Quantification of Ultra-High Field 1H-MRS of the Brain Using Simulated A Priori Knowledge”,
DicksonWong, Robert Bartha, LondonHealth Research Day, March 29, 2016, London Convention Centre, London,
ON.
2016 (Presentation): “Towards quantification of ultra-high field 1H-MR spectroscopy of the brain using simulated a priori
knowledge”, Dickson Wong, Robert Bartha, Medical Biophysics Graduate Seminar, March 3, 2016, The University
of Western Ontario, London, ON.
2016 (Presentation): “Magnetic Resonance Imaging in Early Alzheimer’s Disease”,DicksonWong, Clinician-Scientist
Trainee Symposium, Jan 4, 2016, The University of Western Ontario, London, ON.
2015 (Poster): “Imito-64: An Electrotactile Computer Interface for the Visually Impaired”, Dickson Wong, Dennis
Yazhemsky, Andrew Mahabal, Electrical and Computer Engineering Expo, April 7, 2015, McMaster University,
Hamilton, ON.
2014 (Presentation): “Evaluation of Intra-Fraction Prostate Motion during SBRT Treatment using Robotic Radiosurgery”,
Kundan Thind, Raimond Wong, Dickson Wong, Carrie Schultz, Tom Chow, RadioSurgery Society SRS/SBRT
Scientific Meeting, May 8, 2014, Hilton Minneapolis, Minneapolis, MN.
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2013 (Poster): “Applying Motion-Artifact Removal Techniques in an NIRS BCI: Effects on NIRS Signal Quality and BCI
Accuracy”, Dickson Wong, Sabine Weyand, Tom Chau, 7th Annual Ward Student Research Day, July 23, 2013,
Holland Bloorview Kids Rehabilitation Hospital, Toronto, ON.
2013 (Presentation): “Evaluation of PTV Margins for Lung SBRT on CyberKnife and Triology”, Lindsay Mathew,
Dickson Wong, Bill Edwards, Raimond Wong, Anand Swaminath, Marcin Wierzbicki, Tom Chow, RadioSurgery
Society SRS/SBRT Scientific Meeting, Feb 22, 2013, La Costa Resort, Carlsbad, CA.
2012 (Presentation): ”Intra-fractional Target Motion During CyberKnife Treatment For Brain Lesions”,DicksonWong,
William Edwards, Raimond Wong, Tom Chow, RadioSurgery Society SRS/SBRT Scientific Meeting, Feb 22-25,
2012, La Costa Resort, Carlsbad, CA.
Invited Lectures
2018 (Lecture): “Introduction to Reproducibility and Data Sharing”,DicksonWong, BrainhackWestern, May 3, 2018,
Western University, London, ON.
2017 (Lecture): “Magnetic Resonance Spectroscopy at 7 Tesla”, Dickson Wong, Centre for Functional and Metabolic
Mapping, March 18, 2017, Robarts Research Institute, London, ON.
2017 (Lecture): “Assessing the Combination of Vitamin D and Memantine for Alzheimer’s Disease Treatment with Ultra-
High Field MRI”,Dickson Wong, Centre for Functional and Metabolic Mapping Winter School, March 17, 2017,
Robarts Research Institute, London, ON.
2015 (Lecture): “Radios, Magnets and Alzheimer’s Disease: How magnetic resonance imaging is being used to look for
early signs of Alzheimer’s disease”, Dickson Wong, Retiring With Strong Minds, December 17th, 2015, Windermere
on the Mount, London, ON.
Academic Awards and Distinctions
J. B. Hargreaves/J. L. F. Hargreaves MD/PhD Award ($10,000; annually) London, ON
The University of Western Ontario 2018–Present
The Canadian Institutes of Health Research MD/PhD Studentship ($21,000; annually) London, ON
The University of Western Ontario 2015–Present
Course Award London, ON
Patient-Centred Clinical Methods Oct 2019
Awarded for exemplary performance in Patient-Centred Clinical Methods (Year 1)
Oral Presentation Award, 1st Place Toronto, ON
Imaging Network Ontario Symposium March 2018
Presentation: Relating Hippocampal Glutamate to Structural Changes and Cognitive Performance
in Alzheimer’s Disease: A 7T MRI Study
Oral Presentation Award London, ON
Robarts Research Retreat May 2017
Presentation: Memantine and Vitamin D Supplementation Improves Cognition in Chronically Vitamin D
Deficient APP/PS1 Mice
Educational Trainee Stipend ($600) Honolulu, HI
International Society for Magnetic Resonance in Medicine Annual Meeting & Exhibition Apr 2017
Frederick Banting and Charles Best Canada Graduate Scholarship ($17,500) London, ON
The University of Western Ontario May 2016
Project: The Combination of Vitamin D and Memantine for Alzheimer’s Disease Treatment
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Western Graduate Scholarships ($4,500; annually) London, ON
The University of Western Ontario 2015–2019
Alexander Graham Bell Canada Graduate Scholarships ($17,500), Declined Hamilton, ON
McMaster University May 2015
Project: Assessing Non-Linear Dynamic Behaviour of the Brain Using Combined EEG/fMRI
Dean’s Excellence Engineering Doctoral Award ($127,500), Declined Hamilton, ON
McMaster University 2015
Awarded to exceptional incoming PhD stduents
1st Place, Biomedical Engineering Design Project Category ($500) Hamilton, ON
Electrical and Computer Engineering Expo 2015
Project: Imito-64: An Electrotactile Display for the Visually Impaired
McMaster Chancellor’s Gold Medal Award Hamilton, ON
For the graduating undergraduate student who ranks highest in scholarship, leadership, and influence 2015
McMaster University
Undergraduate Awards for Scholarship Hamilton, ON
McMaster University 2011-2014
2014: The Kudsia Family Scholarship
2013-2015: The Provost’s Honour Roll Medal
2013: The Herbert A. Ricker Scholarship
2012: The Dr. Harry Lyman Hooker Scholarship
2011: The McMaster Honour Award, Level 3
2011-2015: Dean’s Honour Roll
2009: McMaster Engineering & Science Entrance Prize
Memberships
2015-present: Clinician Investigator Trainee Association of Canada (CITAC)
2015-present: Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment
(ISTAART) Student Member
2011-present: Golden Key International Honour Society Member
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